# REVIEW

**Open Access** 

# Comparative efficacy of robotic exoskeleton and conventional gait training in patients with spinal cord injury: a meta-analysis of randomized controlled trials



Shengye Liu<sup>1†</sup>, Fangyuan Chen<sup>2†</sup>, Jianqiao Yin<sup>3†</sup>, Guanqi Wang<sup>2</sup> and Liyu Yang<sup>1\*</sup>

# Abstract

**Objective** The purpose of this meta-analysis was to investigate the effects of Robotic exoskeleton gait training (REGT) on lower limb mobility, walking balance, functional scores and respiratory function in patients with spinal cord injury (SCI).

**Data sources** The PubMed, Embase, Cochrane Library databases were systematically searched from inception until December 24, 2024.

**Study selection** Eligible randomized controlled trials contained information on the population (SCI), intervention (REGT), and outcomes (walking speed and distance, walking balance, functional scores for SCI rehabilitation, respiratory function). Participants in the REGT intervention group were compared with those in conventional physical gait training (CPT) groups. Two independent researchers conducted the research, screened the articles, and assessed their eligibility.

**Data extraction** Two independent researchers extracted key information from each eligible study. The authors' names, year of publication, setting, total sample size, REGT, CPT training schedule, baseline/mean difference (MD), and 95% confidence interval (CI) were extracted using a standardized form, and the methodological quality was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system.

**Data synthesis** Of 595 studies identified, 15 randomized controlled trials (n = 579) were included for meta-analysis. Compared with conventional physical gait training (CPT), REGT showed no significant efficacy in walking speed (10-Meter Walk Test, WMD (95%CI) = -0.03 (-0.06, 0.00) m/s, P = 0.08) and walking distance, (6-Minute Walk Test, WMD (95% CI) = -1.83 (-14.48, 10.83) meters, P = 0.78). REGT showed statistically significant efficacy in walking stability (Timed Up and Go, WMD (95%CI) = 6.62 (0.35, 12.88) s, P = 0.04) and functional scores such as Walking Index for Spinal Cord Injury Version II (WMD (95%CI) = 2.17 (1.05, 3.29), P = 0.0001) and Lower Extremity Motor Score (WMD (95%CI) = 1.33 (0.58, 2.07), P = 0.0005). Additional Significant efficacy was also found in terms of respiratory function (forced expiratory volume in one second, WMD (95%CI) = 0.60 (0.05, 1.16) L, P = 0.03).

<sup>†</sup>Liu, Chen and Yin contributed equally to this work.

\*Correspondence: Liyu Yang yanglycmu@126.com Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

**Conclusions** This meta-analysis discovered the evidence that robotic exoskeleton gait training can improve the walking balance, strength of lower limbs, functional scores and respiratory function in the patients with spinal cord injury (SCI) compared to conventional gait training (CPT). No obvious evidence showed that REGT has more advantages than CPT in improving walking speed and distance. REGT combined with CPT are more recommended in the discovery of walking speed and distance of patients above 6 months after SCI.

Keywords Robotic exoskeleton gait training, Spinal cord injury, Meta-analysis, Gait rehabilitation

Spinal cord injury (SCI) is a devastating type of injury that impairs the movement, sensation, and bowel and bladder functions of patients due to damage to the spinal cord. The incidence rate of non-traumatic SCI is higher than that of traumatic spinal cord injury (TSCI) in developed countries, with an annual TSCI incidence rate of 9.3 per million population [1]. China is a high-prevalence country for SCI, with over 3 million SCI patients, and the number of new cases each year is as high as 90,000 [2]. Manifestation of chronic spinal cord injury includes Paraplegia, Tetraplegia, and Loss of sensation, muscle strength. After SCI, there are various secondary health issues such as cardiovascular complications, respiratory system complications, gastrointestinal and bladder dysfunction, muscle atrophy, obesity, osteoporosis, and pressure sores, which seriously affect the survival situation and quality of patients' life, and may consequently reduce their life expectancy [3-7].

In the aftermath of SCI, patients often have to face a challenging and lengthy rehabilitation process. The outcomes of rehabilitation for chronic SCI can vary depending on the severity and level of injury lesion, as well as the overall health and well-being of the individuals. However, it is important to note that the prognosis for recovery may be limited, and many individuals with chronic SCI experience long-term physical and cognitive impairments. Previous recommendations for SCI patients have included aerobic training, upper limb strength training, and lower limb flexibility training to maintain or improve motor abilities [8]. For individuals with cervical injuries affecting respiratory muscles, respiratory muscle training is suggested [9]. Advancements in neuroscientific technology have led to the emergence of various techniques, such as lower limb robotic exoskeletons [10], unloading training systems, muscle functional electrical stimulation, epidural electrical stimulation [11], brain-machine interfaces [12], and spinal cord neuromodulation techniques. These techniques are gradually transitioning from the laboratory to clinical settings with the aim of preserving active movement during the training for patients [13, 14]. The development of robotic exoskeletons, initially conceptualized decades ago, has gained significant momentum over the past 10-15 years, [15]. Based on assistance intensity, exoskeletons are classified as passive, powered, or active [16]. Device complexity and assistance capacity further depend on the number of actuated joints (e.g., ankle, knee, hip, or trunk), with multi-joint systems (e.g., knee-ankle-foot exoskeletons) addressing severe mobility deficits by supporting entire lower limbs [17, 18].

Robotic exoskeletons gait training (REGT) have become a popular and innovative solution for individuals with SCI to aid in their rehabilitation process. The first exoskeleton devices were invented in the 1960s [19]. Some well-known manufacturers of exoskeleton devices include Ekso Bionics, Cyberdyne, and Rex Bionics [20-22]. Robotic exoskeletons are wearable devices designed to assist patients with SCI in standing up and walking [23]. They can be controlled through a remote control or by using sensors and algorithms, allowing the exoskeleton to respond to the patient's movements [24, 25]. Many robotic exoskeletons also have adjustable joint angles [26], which can help prevent falls and provide better support during rehabilitation. The Lokomat system is an exoskeleton apparatus that includes a robotic exoskeleton device and a treadmill equipped with multiple sensors and electric drives [27]. Actuator-powered exoskeletons offer a new approach to improving rehabilitation outcomes for patients with SCI as walking assistance devices [28]. Through continuous lower limb weightbearing walking, REGT provides various sensory stimulations related to walking to the central nervous system, promoting the integration of different sensory inputs [29, 30]. This, in turn, enhances the function of the central pattern generator (CPG) in the spinal cord [31–33], strengthening the coordinated movement of agonist and antagonist muscles. Additionally, REGT promotes neuromuscular plasticity and facilitates the recovery of neural connectivity [34].

REGT has shown promising results in the field of rehabilitation for individuals with SCI. However, there is currently a lack of established guidelines or standardized practices for REGT in the treatment of SCI patients. Therefore, it is necessary to conduct a comprehensive assessment, both qualitative and quantitative, to evaluate the impact of REGT on patients with SCI, based on randomized controlled trials (RCTs). The objective of this meta-analysis is to systematically review and analyze the therapeutic efficacy of REGT in SCI patients, with the aim of supporting SCI treatment and providing reliable recommendations for clinical practice.

#### Methods

# Search strategy

In line with the PRISMA guidelines, the researchers conducted this study. This research protocol has been registered with the PROSPERO (CRD420251011718). A thorough exploration was performed on PubMed (1966-December 2024), Embase (1974-December 2024), and Cochrane Central Register of Controlled Trials (1991-December 2024) databases to identify pertinent literature pertaining to human studies published in the English language. The search strategy encompassed terms associated with spinal cord injury, exoskeletons, and the Lokomat. Specifically, we employed combinations of Medical Subject Headings (MeSH) terms and keywords, including "spinal cord injury," "exoskeleton," "Lokomat," and "robot-assisted." A comprehensive overview of the search strategy and the complete list of search terms can be found in Supplementary Tables S1-S3. We utilized the PICOS principle proposed by Cochrane, which encompasses the following components: population (spinal cord injury), intervention (exoskeleton, Lokomat, or robot-assisted gait training), comparison (conventional physical gait training), outcomes[Timed Up and Go (TUG) test, the Walking Index for Spinal Cord Injury Version II (WISCI-II), the Lower Extremity Motor Score (LEMS), as well as ground walking endurance such as the 6-Minute Walk Test (6 MWT) and the walking speed as the 10-Meter Walk Test (10 MWT), in addition to relevant respiratory function assessments] and study design (RCT). In addition, we conducted a manual search using references from the included studies to identify other potentially eligible studies, thereby enhancing the comprehensiveness of our search.

# Inclusion and exclusion criteria

Two evaluators independently assessed the titles, abstracts, and complete texts of the articles. Only those studies that fulfilled the predefined inclusion criteria were considered for inclusion in the meta-analysis. The inclusion criteria for research on the impact of robotic exoskeleton gait training on mobility in patients with SCI were as follows: (1) The studies needed to involve a robotic exoskeleton, which refers to a multi-joint orthotic device that is fueled by an external source and has the capability of moving at least two joints on each leg. (2) Moreover, the inclusion criteria encompassed adult patients aged 18 years and above. (3) The studies were peer-reviewed full-text publications or articles in press. (4) The design type of the patient grouping included in the study is RCT. Other study designs such as non

randomized controlled trials or pre-post studies or pilot studies were not included in this systematic review.

The following studies were not considered: (1) Studies involving a combination of robotic exoskeleton gait training with other treatments such as repetitive transcranial magnetic stimulation (rTMS); (2) Studies involving populations with multiple medical conditions (e.g., cerebral infarction and stroke) without distinct outcomes; (3) Studies with incomplete data; (4) Abstracts and conference summaries.

# Data items

Data from each study were extracted by two reviewers independently using a predefined form for data extraction. Disputes were settled through discussion and, if needed, with the assistance of a third investigator. The extracted data included various variables, such as the walking index for spinal cord injury (WISCI-II), the lower extremity motor score (LEMS), the 6-minutes walk test (6 MWT), the 10-minutes walk test (10 MWT), the Timed Up and Go (TUG), as well as respiratory function measures like forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peak expiratory flow (PEF). In addition, we included demographic, clinical, and treatment characteristics in the extracted data. Furthermore, details concerning the type of intervention and control regimen, as well as the evaluation method, were also incorporated. If any of these variables were unavailable in a study, our strategy involved reaching out to the authors through email.

# **Quality assessment**

The quality of the 15 studies included in this research was assessed by two reviewers, Fangyuan Chen and Jianqiao Yin, using the risk of bias (RoB) 1.0 evaluation framework developed by the Cochrane Collaboration. To determine bias, the reviewers examined random sequence generation, allocation concealment, blinding of participants and personnel, selective outcome assessment, incomplete outcome data, selective reporting, and other forms of bias.

The methodological quality of each selected trial was evaluated by obtaining scores from the PEDro website (www.pedro.org.au). In instances where information was unavailable, two researchers, Shengye Liu and Fangyuan Chen, conducted independent evaluations, with any disagreements resolved by the principal investigator, Liyu Yang. The PEDro scale is employed to assess the reliability and validity of randomized controlled trials (RCTs), utilizing a checklist comprising 11 evaluation items [35]. The PEDro score for each selected study serves as an indicator of methodological quality, categorized as follows: 9–10 indicates excellent quality, 6–8 indicates good

quality, 4–5 indicates fair quality, and scores below 4 indicate poor quality. Studies rated as good or excellent on the PEDro scale, with a sample size exceeding 50, are classified as providing level-1 evidence, whereas studies of lower quality, characterized by a fair or poor PEDro score and a sample size of 50 or fewer, are classified as providing level-2 evidence.

The level of evidence was classified using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) system, which categorizes evidence as high, moderate, low, or very low. Any disagreements were resolved through consensus reached via discussion. The assessment was conducted using the Rev-Man 5.3 software, which was provided by The Cochrane Collaboration located in London, United Kingdom.

#### Statistical analysis

A scientific investigation was undertaken to evaluate the efficacy of therapy in improving the walking ability of patients. To ascertain the outcome, multiple measures such as WISCI-II, LEMS, TUG, 6MWT, and 10 MWT were employed. The outcomes were presented as the weighted mean difference (WMD), while 95% confidence intervals (CIs) were calculated using the inverse variance technique, considering random effect weighting. To merge the data obtained from various studies, the change value for each outcome was pooled. The power of individual reports included in the present meta-analysis was accessed by GPower software v.3.1. To assess heterogeneity among the studies, the Cochran's Q test and the I<sup>2</sup> statistic were utilized. A significant heterogeneity was considered when  $I^2 \ge 50\%$ . Upon investigating the sources of heterogeneity, subgroup analyses were performed based on the type of robotic training, which included Lokomat and exoskeleton, and the starting time of gait training after SCI (within 6 months or above). All statistical analyses were carried out using RevMan version 5.3.

## Result

#### Literature search process results

During the database search, a total of 595 articles were identified. After excluding 228 duplicate references, a total of 367 articles remain for further review. To ensure the relevance and appropriateness of the studies, we screened the titles and abstracts, resulting in the exclusion of 345 irrelevant studies. Subsequently, we thoroughly examined the main texts of the remaining articles and engaged in a collaborative effort between two independent reviewers. This led to the discussion of 22 studies. Among these, 7 publications were considered unsuitable and were excluded. Ultimately, a total of 15 studies met the criteria for inclusion in the meta-analysis. For a visual representation of the literature screening process, please refer to Fig. 1.

# **Study characteristics**

The characteristics of the included studies are shown in Table 1. The included studies were conducted between 2011 and 2024 across six countries worldwide. The spinal cord injury levels of participants ranged from ASIA A to D. In these studies, the ages of patients in the combined treatment group varied from 26 to 71 years, with the average time since the onset of spinal cord injury ranging from 2 months to 15 years (Table 1). The treatment frequency varied from 2 to 5 times per week, while the duration of gait training ranged from 3 to 20 weeks, training details shown in the Table 2.

### Risk of bias in the included studies

Figure 2 illustrates the risks of bias encountered in the included studies. It is noteworthy that almost all of the studies in the sample showed minimal bias risk in terms of random sequence generation and allocation concealment, except for Shin et al. [36]. However, all the studies demonstrated a bias risk in relation to participant and personnel blinding. On the other hand, every single study depicted a low or moderate bias risk in terms of outcome assessment blinding, incomplete outcome data, and selective reporting. The evaluation results of the PEDro scale show that the methodological quality of 5 articles is Fair, while the remaining studies are Good (Table 3). Only 2 articles are Level-1 evidence, and the rest are Level-2 evidence. The GRADE evaluation results indicate that the evidence level for the 10 MWT is "Moderate" the evidence level for the 6MWT is "Very Low", and the other outcome indicators are all "Low". (Table S4)

# Results of individual studies 10 MWT meta-analysis results

In the research conducted, a total of 218 participants were involved in nine different studies. The 10 MWT test was examined, and based on the heterogeneity test results ( $I^2=2\%$ , P=0.43), a fixed effect model was used to analyze the collected data. The analysis indicated that there were no significant improvements observed in SCI patients who underwent robotic exoskeleton gait training compared to those who received conventional physiotherapy (CPT). The results can be seen in Fig. 3A, and the analysis outcomes [WMD (95%CI)=-0.03 (-0.06, 0.00) m/s, P=0.08] support this conclusion.

#### 6MWT meta-analysis results

A total of 116 participants were involved in six separate studies examining the 6-min walk test (6MWT). A fixed effect model was used to determine the statistical



Fig. 1 Flow chart showing the study selection process

heterogeneity ( $I^2$ =32%, P=0.18). The analysis findings showed no significant difference in improving walking stamina between REGT and conventional physical therapy (CPT) [WMD (95% CI)=-1.83 (-14.48, 10.83) meters, P=0.78], as shown in Fig. 3B.

For the purpose of exploring more result details, we carried out subgroup analyses considering the duration of injury as well as the type of robotic physical therapy. An examination of the 10 MWT subgroup indicated the following outcomes: ① Within a duration of 6 months, the WMD (95%CI) was 0.07 (- 0.03, 0.17) m/s, P=0.17; ② Beyond 6 months, the WMD (95%CI) was - 0.04 (- 0.07, - 0.01) m/s, P=0.02 (Fig. 4A). Regarding the 6MWT subgroup, we observed: ① Duration less than 6 months, the WMD (95% CI) was 31.8 (- 3.21, 66.81) meters, P=0.08; ② Beyond 6 months, the WMD (95%CI) was - 6.88 (- 20.45, 6.69) meters, P=0.32 (Fig. 4B). These findings demonstrate that

conventional physical therapy(CPT) exhibited a significantly superior impact on improving walking speed (10MWT) for individuals with an injury duration surpassing 6 months when compared to robotic exoskeleton gait training (REGT), as demonstrated in Fig. 4A. The subgroup analysis concerning different types of robotic training is outlined below: 10 MWT exhibited: ① Employment of Lokomat yielded a WMD (95%CI) of -0.04 (-0.07, -0.01) m/s, P=0.02; (2) Employment of exoskeleton resulted in a WMD (95%CI) of 0.05 (-0.06, 0.12) m/s, P=0.25 (Fig. 4C). With respect to 6MWT: ① Utilization of Lokomat produced a WMD (95% CI) of - 9.29 (- 25.16, 6.57) meters, P=0.25; ② Utilization of exoskeleton yielded a WMD (95%CI) of 11.22 (- 9.75, 32.20) meters, P = 0.29 (Fig. 4D). These results indicate that Lokomat robotic training was less effective in enhancing walking speed (10 MWT) compared to CPT, as presented in Fig. 4C.

Table 1 Charact	eristics of	included studie:	S								
Study	Country	Design of Trial	Robotic gait training	AISA classification	Duration of injury	Groups	Sample size for rando- mized	Withdraw, case (%)	Sample size included in the analysis, M/F	Age, years	Outcomes
Alcobendas-Maes- tro, M. 2012	Spain	RCT	Lokomat	C or D	120 (87.5–145) days	REGT	40	3 (7.5) 7 (6)	37, 23/14	45.2 ± 15.5	WISCI-II, 6 MWT, FIM. LEMS
Chang, S. 2018	USA	RCT	Ekso exoskeleton	C or D	15 ± 14 years	REGT	6 4	(c) z	4, 3/1	56±17	10 MWT, 6 MWT,
)					$7 \pm 3$ years	CPT	5	2 (40)	3, 2/1	60±2	TUG, LEMS
Cheung, EYY 2019	China	RCT	Lokomat	B, C or D	17.0 ± 7.01 months 10.4 ± 6.31 months	REGT CPT	∞ ∞	(0) 0	8, 7/1 8, 4/4	55.6 ± 4.98 53.0 ± 12.94	WISCI-II, SCIM-III, FVC, PEF, FEV1
Cinar, C. 2021	Turkey	RCT	Lokomat	A	3.5 ± 2.1 months	REGT	20	3 (15)	17, 7/10	32.9 ± 11.4	WISCI-II, FIM
					3.8 ± 2.6 months	CPT	20	0 (0)	20, 8/12	36.9 ± 12.6	
Edwards, D. 2022	NSA	RCT	Ekso exoskeleton	C or D	1.2-28.5 years	REGT	14	2 (14.3)	12, 5/7	26–58	10 MWT, 6 MWT, THC WISCH
					2.1-14.2 years	CPT	13	1 (7.7)	12,6/6	28-71	100°, VVIDCI-II
Esclarin-Ruz, A. 2014	Spain	RCT	Lokomat	CorD	125.6 ± 65.2 days 140 3 + 45 5 days	REGT (a)	22 77	1 (4.5) 1 (4.5)	21, 15/6 21_13/8	43.6 ± 12 44 q + 7	6 MWT, WISCI-II, LEMS
					117.9 ± 25.6 days	REGT (b)	22	(0.1) - 2 (9.1)	20, 14/6	36.4±12	
					109 ± 50.5 days	CPT (b)	22	1 (4.5)	21, 17/4	42.7 ± 18	
Field-Fote, E. C.	USA	RCT	Lokomat	C or D	≥1 year	REGT	15	1 (6.7)	14, 12/2	45 ± 8.0	10 MWT, LEMS
2011						CPT1	18	3 (16.7)	15, 11/4	42.2 ± 15.7	
						CPT2	22	4 (18.2)	18, 16/2	38.5 ± 12.7	
						CPT3	19	2 (10.5)	17, 14/3	39.3 ± 14.6	
GilAgudo, A. 2023	Spain	RCT	HANK exoskeleton	C or D	4.82 ± 1.3 months	REGT	12	1 (8.3)	11, 7/4	41 ± 12.39	10 MWT, 6 MWT,
					5.55 ± 2.3 months	CPT		1 (9.1)	10, 8/2	51.8± 11.93	TUG, WISCI-II
Midik, M. 2020	Turkey	RCT	Lokomat	C or D	5 (4–30) months	REGT	15	0 (0)	15, 15/0	35.4 ± 12.1	LEMS, WISCI-II,
					27 (17–44) months	CPT	15	0 (0)	15, 15/0	37.9 ± 10.0	SCIM-III
PIIRA, A. 2019	Norway	RCT	Lokomat	C or D	8 (2–54) years	REGT	12	5 (41.7)	7, 4/3	55 土 8	10 MWT, 6 MWT,
					7 (2–48) years	CPT	12	0 (0)	12, 5/7	46 ± 15	LEMS
Shin, J. C. 2014	Korea	RCT	Lokomat	Q	3.33 ± 2.02 months	REGT	30	3 (10)	27, 20/7	43.15 ± 14.37	LEMS, WISCI-II, SCIM-III
					2.73 ± 1.97 months	CPT	30	4 (13.3)	26, 14/12	48.15 ± 11.49	
Tsai, C. 2024	USA	RCT	Ekso exoskeleton	A, B, or C	< 3 months	REGT	20	4 (20)	16, 10/6	$45.8 \pm 18.3$	LEMS
						CPT	12	0 (0)	12, 9/3	$46.8 \pm 18.3$	
Wu, M. 2018	NSA	RCT	Lokomat	C or D	7 (1–8) years	RGT	Ø	1 (12.5)	8, 7/1	45 (26–63)	10 MWT, 6 MWT
					6 (1–24) years	CPT	80	1 (12.5)	8, 5/3	48 (40–54)	

Study	Country	Design of Trial	Robotic gait training	AISA classification	Duration of injury	Groups	Sample size for rando- mized	Withdraw, case (%)	Sample size included in the analysis, M/F	Age, years	Outcomes
Xiang, X 2021	China	RCT	Ekso exoskeleton	A, B, or C	2.0 ± 4.5 months	REGT	6	1 (11.1)	9, 2/7	39.8 ± 12.2	6 MWT, LEMS, PEF,
					2.0 ± 0.5 months	CPT	6	1 (11.1)	9, 1/8	36.6 ± 11.8	FVC, FEV I
Yildirim, M. 2019	Turkey	RCT	Ekso exoskeleton	A, B, C, D	3 ± 2 months	REGT	46	2 (4.3)	44, 17/27	32 ± 23	WISCI-II, FIM
						CPT	47	3 (6.4)	44, 16/28	36.5 ± 24	
Abbreviations: RCT, ra Extremity Motor Score	indomized cc es, LEMS; Spir	ontrol trial; 10-metri nal Cord Independe	e walk test, 10 MWT; 6 ince Measure version	Hinute walk test, 6 M III, FVC; Peak expirator	IWT; Walking Index for Sp y flow, PEF; Forced expira	inal Cord Injury I tory volume in o	, WISCI-II; Tim ne second, FE	ne up to go, TUC EV1; a, patients	G; Functional I with Upper Mo	ndependence M otor Neuron Les	feasure, FIM; Lower ions; b, patients with

Table 1 (continued)

breviations: RCT, randomized control tria; 10-metre walk test, 10 MWT; 6-minute walk test, 6 MWT; Walking Index for Spinal Cord Injury II, WISC-II; Time up to go, TUG; Functional Independence Measure, FIM; Lower
tremity Motor Scores, LEMS; Spinal Cord Independence Measure version III, FVC; Peak expiratory flow, PEF; Forced expiratory volume in one second, FEV1; a, patients with Upper Motor Neuron Lesions; b, patients with
ver Motor Neuron Lesions

# Table 2 Training details of included studies

Study	Groups	Training	Cycle
Alcobendas-Maestro, M. 2012	REGT	60 min/day (30-min overground therapy for walking, 30-min with the Lokomat)	5 days/week for 8 weeks
	CPT	Walking training sessions of 1 hour/day	
Chang, S. 2018	REGT	Included sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit	60 min/day, 5 days/week for 3 weeks
	CPT	Stretching, strengthening, balance training, standing, sit to stand, stair, and gait training	
Cheung, E. Y. Y. 2019	REGT	CPT + Robotic-assisted body weight supported treadmill training, 30 min/day, 3 days/week	8 weeks
	CPT	One hour of standard physiotherapy program, twice per week	
Cinar, C. 2021	REGT	CPT + Robotic therapy training, Twice a week	8 weeks
	CPT	Conventional treatment once a day, 5 days a week	
Edwards, D. 2022	REGT	45 min/day (30 min gait training in the Ekso, followed by 15min per- forming standard overground (OG) gait training outside the Ekso)	3 days/week for 12 weeks
	CPT	45 min of Body Weight Supported (BWS) Treadmill Training, and if possible, OG training without BWS	
Esclarin-Ruz, A. 2014	REGT	60 min/day (30 minutes of conventional mobility training plus 30 minutes of robotic-assisted mobility training),	5 days/week for 8 weeks
	CPT	60 minutes of conventional mobility training	
Field-Fote, E. C. 2011	REGT	Treadmill-based training with robotic assistance	5 days/week, 12 weeks
	CPT1	Overground training with stimulation	
	CPT2	Treadmill based training with stimulation	
	CPT3	Treadmill based training with manual assistance	
GilAgudo, A. 2023	REGT	Robotic ambulatory gait training sessions, 30 min/day	3 days/week for 5 weeks
	CPT	Traditional gait training program (analytical mobilization, strengthen- ing exercises for the lower limbs and gait re-education when possi- bleusing parallels)	
Hu, X. M. 2024	REGT	CPT + 40-50 minutes REGT (including sitting, standing and walking training), once a day, five times a week	8 weeks
	CPT	Routine exercise therapy	
Midik, M. 2020	REGT	CPT + REGT, 30 min/day, 3 days/week	5 weeks
	CPT	Regular physiotherapy for five times a week	
PIIRA, A. 2019	REGT	40-90 min/day (stepping on a treadmill with body-weight support, Overground walking and/or exercises on the treadmill), 3 days/week	20 weeks
	CPT	Low-intensity usual care from their local physical therapist, usually 1-5 times per week	
Shin, J. C. 2014	REGT	REGT (40 min) + regular treatment (30 min), 3 days/week, and 2 days with regular treatment (60 min/day) a week	4 weeks
	CPT	Twice a day in a 30-minute session, 5 times a week	
Tsai, C. 2024	REGT	Overground walking utilizing a powered exoskeleton, 15 hours per week	7 weeks
	CPT	Incorporating walking with the use of parallel bars, a treadmill with an overhead lift, and ceiling track, or a body-weight support device on wheels, 15 hours per week	
Wu, M. 2018	RGT	Robotic treadmill training or Overground walking practice 45 min/day, 3 days/week	6 weeks
	CPT	Treadmill training or Overground walking practice	
Xiang, X. 2021	REGT	Exoskeleton-assisted walking training program (standing, leaning on the wall, or sitting)	50-60 min/day, 4 days/week, 4 weeks
	CPT	Strength training using dumbbell between 5 and 20 kg, aerobic exer- cise, such as walking training with brace as well as static and dynamic balance training in sitting or standing position	
Yildirim, M. 2019	REGT	CPT + Robotic therapy training 30 min/day, 2 days/week	8 weeks
	CPT	Conventional therapy (joint range of motion, stretching, strengthening and gait training), 5 days a week (twice a day)	







Fig. 2 Risk of bias graph and summary

# **TUG meta-analysis results**

The investigation of the Timed Up and Go (TUG) test consists of two separate studies with a total of 28 participants. In order to assess the heterogeneity, a test was conducted which revealed an  $I^2$  value of 0% and a P-value of 0.65. As a result, a fixed effects model was chosen for further analysis. The results of the analysis indicated a statistically significant enhancement in TUG for individuals with SCI who received REGT, with a (WMD) (95%CI) of 6.62 (0.35, 12.88) seconds and a P-value of 0.04. The visualization of these findings can be observed in Fig. 5A.

#### WISCI-II meta-analysis results

Eight studies involving a total of 403 subjects were conducted to examine the effectiveness of the WISCI-II in patients with SCI. To analyze the results, a random effects model was utilized, considering the heterogeneity test ( $I^2$ =58%, P=0.01). The findings indicated that robotic exoskeleton gait training had a significant impact on improving the WISCI-II in SCI patients when compared to CPT. This conclusion was derived from the analysis results [WMD (95%CI)=2.17 (1.05, 3.29), P=0.0001], as shown in Fig. 5B.

# LEMS meta-analysis results

В

In total, 423 subjects participated in 11 separate studies that examined LEMS. When analyzing the data, a fixed effect model was utilized, taking into consideration the heterogeneity test ( $I^2 = 0\%$ , P = 0.59). Findings from the analysis indicated a significant improvement in LEMS among SCI patients who underwent REGT, as compared to those who received CPT. This improvement was statistically significant [WMD (95%CI)=1.33 (0.58, 2.07), P = 0.0005], as demonstrated in Fig. 5C.

A subgroup analysis was conducted in the meta-analysis results of WISCI-II and LEMS, based on the duration of injury and the type of robotic physical therapy. The analysis of the WISCI-II subgroup revealed the following outcomes: ① Within a 6-month period, the weighted mean difference (WMD) (95%CI) was 2.52 (0.89, 4.15), P=0.002; ② Beyond 6 months, the WMD (95%CI) was 1.40 (0.93, 1.88), with statistical significance at P < 0.00001(Fig. 6A). In regard to the LEMS subgroup, the results were as follows: ① For less than 6 months in duration, the WMD (95% CI) was 2.76 (0.66, 4.86), approaching significance at P=0.01; ② Beyond 6 months, the WMD (95%CI) was 1.12 (0.32, 1.92), achieving statistical significance at P=0.006 (Fig. 6B). These subgroup findings demonstrate that REGT can enhance the functional

RCTs
ncluded
of the i
' scores
quality
f PEDro
assessment o
S The
Table 3

Study	Elig ibility criteria	Random allocation	Concealed allocation	Baseline comparability	Blinded subjects	Blinded therapists	Blinded assessors	Adequate follow-up (> 85%)	Intention- to-treat analysis	Between- group comparisons	Point estimates and variability	Total PEDro score	Sample size ≥ 50	Level of evidence
Alcobendas- Maestro, M. 2012	Yes	-	-		0	0	<del></del>	-	<del></del>	-	-	œ	Yes	
Chang, S. 2018	Yes	0	-	<del></del>	0	0	-	<del></del>	0	0	<del>-</del>	Ŋ	No	2
Cheung, EYY 2019	Yes	<del>-</del>	-	<del></del>	0	0	-	<del></del>	<del></del>	<del>-</del>	←	œ	No	2
Cinar, C. 2021	Yes	<del>-</del>	0	<del></del>	0	0	-	<del></del>	0	<del></del>	←	Q	No	2
Edwards, D. 2022	Yes	←	-	<del></del>	0	0	-	0	0	<del></del>	←	9	No	2
Esclarin-Ruz, A. 2014	Yes	<del>-</del>	-	<del></del>	0	0	-	<del></del>	<del></del>	<del></del>	←	œ	Yes	-
Field-Fote, E. C. 2011	Yes	<del></del>	0	<del></del>	0	0	-	<del></del>	0	<del></del>	<del>-</del>	9	Yes	2
GilAgudo, A. 2023	Yes	<del>~~</del>	0	-	0	0	<del></del>	<del></del>	0	<del></del>	<del></del>	9	No	2
Midik, M 2020	Yes	←	0	<del></del>	0	0	-	<del></del>	0	<del></del>	←	9	No	2
PIIRA, A. 2019	Yes	0	-	<del></del>	0	0	-	0	0	<del>-</del>	←	Ŋ	No	2
Shin, J. C. 2014	Yes	0	0	<del></del>	0	0	0	<del></del>	0	<del></del>	←	4	Yes	2
Tsai, C. 2024	Yes	0	0	-	0	0	0	<del>, -</del>	0	1	<del>, -</del>	4	No	2
Wu, M. 2018	Yes		-	<del>,</del>	0	0	0	-	0	-	<del>.                                    </del>	9	No	2
Xiang, X. 2021	Yes	<del>,</del>	←	-	0	0	<del></del>	<del></del>	<del></del>	<del></del>	-	00	No	2
Yildirim, M. 2019	Yes	<del></del>	0	<del>–</del>	0	0	0	<del></del>	0	<del></del>	<del></del>	2	Yes	2



		REGI			CPT			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C		IV, Fixed, 95% CI	
Alcobendas-Maestro, M 2012	68.3	106	14	9	85.58	11	2.8%	59.30 [-15.80, 134.40]			
Chang, S 2018	16.9	15.97	4	7.7	15.02	3	30.0%	9.20 [-13.90, 32.30]			
Esclarin-Ruz, A 2014 (a)	65.18	89.92	5	26.11	77.76	6	1.6%	39.07 [-61.35, 139.49]			
Esclarin-Ruz, A 2014 (b)	74.84	77.52	11	51.32	109.1	9	2.2%	23.52 [-61.21, 108.25]			
Gil-Agudo, A 2023	68.79	67.55	11	48.1	48.58	10	6.4%	20.69 [-29.31, 70.69]			
PIIRA, A 2019	6.6	12	7	23.1	22	9	56.0%	-16.50 [-33.40, 0.40]			
Wu, M 2018	76.1	104.66	8	19.7	160.92	8	0.9%	56.40 [-76.62, 189.42]			
Total (95% CI)			60			56	100.0%	-1.83 [-14.48, 10.83]		•	
Heterogeneity: Chi <sup>2</sup> = 8.81, df =	6 (P = 0	).18); l² =	= 32%								
Test for overall effect: Z = 0.28	(P = 0.7	8)							-200	Favours [CPT] Favours [REGT]	200

Fig. 3 Forest plots for REGT compared with CPT in walking speed assessing the 10 MWT (A), and walking distance using 6 MWT (B)

scores of patients with spinal cord injuries (WISCI-II and LEMS) whether the rehabilitation training starts within 6 months of SCI or more than 6 months. The subgroup analysis for different types of robotic training is outlined below: WISCI-II showed the following results: ① Lokomat exhibited a WMD (95%CI) of 2.05 (0.63, 3.47), with statistical significance at P=0.005; ② Exoskeleton resulted in a WMD (95%CI) of 2.75 (1.19, 4.30), with statistical significance at P = 0.0005 (Fig. 6C). As for LEMS: ① The utilization of Lokomat produced a WMD (95% CI) of 1.22 (0.45, 1.99), with statistical significance at P=0.002; ② The utilization of exoskeleton yielded a WMD (95%CI) of 2.88 (- 0.11, 5.87) meters, with no significant effect at P = 0.06 (Fig. 6D). These results indicate that Lokomat robotic gait training was significantly more effective in enhancing functional scores compared to exoskeleton in WISCI-II and LEMS, although exoskeleton also improved the WISCI-II scores as presented in Fig. 6C.

#### **Respiratory function meta-analysis results**

In two studies examining the effects of gait training assisted by a robotic exoskeleton on respiratory outcomes, including FVC, FEV1, and PEF, a total of 34 patients were analyzed. The fixed effect model was used in all three meta-analyses conducted in Fig. 7. The results indicated that gait training with a robotic exoskeleton significantly increased FEV1, but did not show significant improvements in FVC and PEF. Specifically, the findings revealed that there was a noteworthy increase in FEV1 [WMD (95%CI)=0.60 (0.05, 1.16) L, P=0.03]. However, there was no significant improvement in FVC [WMD (95%CI)=0.52 (- 0.17, 1.21) L, P=0.14] and PEF [WMD (95%CI)=0.82 (- 0.62, 2.26) L, P=0.27]. Therefore, based on the analysis of these studies, it can be concluded that gait training with a robotic exoskeleton has a positive impact on FEV1 but does not significantly affect FVC and PEF.

# **Power analysis**

The power of each included study and effect value for each outcome indicator can be found in Tables S5– S10. For the WISCI II and LEMS outcome measures, the power exceeds 0.80, indicating significant differences between the groups. In contrast, the power for the remaining outcome indicators is relatively low.

		REGT		CPT			Mean Difference		Mean Diffe	erence				REGT			CPT			Mean Difference		Mean Differen	ce	
	Study or Subgroup	Mean SD T	otal N	lean SD	Total	Weight	IV. Fixed, 95% C	3	IV. Fixed.	95% CI		Study or Subaroup	Mean	SD	Total	Mean	SD	Total V	Neiaht	IV. Fixed, 95% C		IV. Fixed, 95%	CI	
۸	2.1.1 <6 months										P	231 c6 months												
А	Alcobendas-Maestro, M 2012	0.1 0.28	14	0 0.24	11	2.2%	0.10 [-0.10, 0.30]		_		D	2.3.1 10 1101015												
	Esclarin-Ruz, A 2014 (a)	0.06 0.28	7	0.03 0.28	6	1.0%	0.03 [-0.28, 0.34]	- 1				Alcobendas-Maestro, M 2012	68.3	106	14	9	85.58	11	2.8%	59.30 [-15.80, 134.40]	]			
	Esclarin-Ruz, A 2014 (b)	0.22 0.22	11	0.17 0.36	10	1.4%	0.05 [-0.21, 0.31]					Esclarin-Ruz, A 2014 (a)	65.18	89.92	5	26.11	77.76	6	1.6%	39.07 [-61.35, 139.49]	]			
	Gil-Agudo, A 2023	0.19 0.16	11	0.12 0.17	10	4.5%	0.07 [-0.07, 0.21]		-	-		Esclarin-Ruz, A 2014 (b)	74.84	77.52	11	51.32	109.1	9	2.2%	23.52 [-61.21, 108.25]	1			
	Subtotal (95% CI)		43		37	9.1%	0.07 [-0.03, 0.17]		1			Gil-Aqudo A 2023	68 79	67.55	11	48.1	48 58	10	6.4%	20 69 629 31 70 69	1		-	
	Heterogeneity: Chi <sup>2</sup> = 0.17, df =	: 3 (P = 0.98); I <sup>2</sup> =	: 0%									Subtotal (95% CI)	00.10	07.00	41	10.1	10.00	36	13 196	31 80 [-3 21 66 81]		-	•	
	Test for overall effect: Z = 1.37	(P = 0.17)																50	19.176	01.00[-0.21, 00.01]		-		
												Heterogeneity: Chi* = 0.76, df =	= 3 (P = 0	086); I* =	0%									
	2.1.2 ≥6 months											Test for overall effect: Z = 1.78	(P = 0.08	3)										
	Chang, S 2018	0.04 0.07	4	0.04 0.08	3	7.1%	0.00 [-0.11, 0.11]		_															
	Cheung, EYY 2019	0.009 0.24	8 0	.042 0.32	8	1.2%	-0.03 [-0.31, 0.24]	. –				2.3.2 ≥6 months												
	Edwards, D 2022	0.18 0.23	9	0.07 0.11	10	3.3%	0.11 [-0.06, 0.28]					Chang S 2018	16.0	15.07	4	77	15.02	3	30.0%	0 20 [.13 00 32 30]	1			
	Field-Fote, EC 2011 (a)	0.01 0.05	4	0.09 0.11	15	16.6%	-0.08 [-0.15, -0.01]					Citalig, 5 2010	10.0	10.01			13.02		50.070	3.20 [-13.30, 32.30]	1	-		
	Field-Fote, EC 2011 (b)	0.01 0.05	5	0.05 0.09	18	24.9%	-0.04 [-0.10, 0.02]					PIIKA, A 2019	6.6	12	(	23.1	22	9	56.0%	-16.50 [-33.40, 0.40]	J	-		
	Field-Fote, EC 2011 (c)	0.01 0.05	5	0.04 0.07	17	30.1%	-0.03 [-0.09, 0.03]					Wu, M 2018	76.1	104.66	8	19.7	160.92	8	0.9%	56.40 [-76.62, 189.42]	]			
	PIIRA, A 2019	0 0.05	7	0.1 0.18	9	6.0%	-0.10 [-0.22, 0.02]					Subtotal (95% CI)			19			20	86.9%	-6.88 [-20.45, 6.69]		•		
	Wu, M 2018	0.12 0.18	8	0.03 0.27	8	1.8%	0.09 [-0.13, 0.31]					Heterogeneity: Chi <sup>2</sup> = 3.97, df =	= 2 (P = 0	(14):   <sup>2</sup> =	50%									
	Subtotal (95% CI)		50		88	90.9%	-0.04 [-0.07, -0.01]		•			Test for overall effect: 7 = 0.99	(P = 0.32	2)										
	Heterogeneity: Chi <sup>2</sup> = 7.05, df =	7 (P = 0.42); I <sup>2</sup> =	: 1%									Test for overall effect. Z = 0.35	(r = 0.52	-/										
	Test for overall effect: Z = 2.27	(P = 0.02)										T-I-LIOCH OD			~~			FC 4	00.00/	4 00 7 44 40 40 001				
	7-1-1/050/ 00				405							Total (95% CI)			60			56 1	100.0%	-1.83 [-14.48, 10.83]		. <b>T</b>		
	Total (95% CI)		93		125	100.0%	-0.03 [-0.06, 0.00]					Heterogeneity: Chi <sup>2</sup> = 8.81, df =	= 6 (P = 0	u18); I² =	32%						200	100 0	100	200
	Heterogeneity: Chi <sup>4</sup> = 11.17, df	= 11 (P = 0.43);	* = 2%					-0.5 -0.	25 0	0.25	0.5	Test for overall effect: Z = 0.28	(P = 0.78	3)							-200		0000	200
	Test for overall effect: 2 = 1.75	(P = 0.08)	-	00. 0. 7	30/			Fa	vours [CPT] F	avours [REGT]		Test for subgroup differences:	Chi <sup>2</sup> = 4.0	)8. df = 1	(P = 0.	04),  ² =	75.5%					ravouis [CPT] ravoi	as [REG1]	
	Test for subgroup differences: 0	Jni* = 3.95, df = 1	I (P = 0	.05), 1* = 74	.7%										ι	.,,,.								
							Mean Difference		Moon Diff.	rence				REGT			CPT			Mean Difference		Mean Differen	Ce .	
		REGT		CPT			mean Difference		mean Dim													mean Differen		
_	Study or Subgroup	REGT Mean SD T	otal N	CPT lean SD	Total	Weight	IV. Fixed, 95% C		IV. Fixed.	95% CI		Study or Subgroup	Mean	SD	Total	Mean	SD	Total \	Weight	IV, Fixed, 95% C	CI	IV, Fixed, 95%	CI	
С	Study or Subgroup 2.2.1 Lokomat	REGT Mean SD T	otal M	CPT lean SD	Total	Weight	IV. Fixed, 95% C	3	IV. Fixed.	95% CI	— п	Study or Subgroup 2.4.1 Lokomat	Mean	SD	Total	Mean	SD	Total \	Weight	IV, Fixed, 95% C	CI	IV, Fixed, 95%	CI	
С	Study or Subgroup 2.2.1 Lokomat Alcobendas-Maestro, M 2012	REGT Mean SD T 0.1 0.28	otal N	CPT lean SD 0 0.24	Total 11	Weight 2.2%	IV. Fixed. 95% C	ы I	IV. Fixed.	95% CI	D	Study or Subgroup 2.4.1 Lokomat	Mean 68.3	SD 106	Total	Mean	SD 85.58	Total \	Weight	IV, Fixed, 95% C		IV, Fixed, 95%	CI	
С	Study or Subgroup 2.2.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019	REGT Mean SD T 0.1 0.28 0.009 0.24	otal M 14 8 0	CPT lean SD 0 0.24 .042 0.32	<u>Total</u> 11 8	Weight 2.2% 1.2%	U. Fixed, 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24]		IV. Fixed.	95% CI	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012	Mean 68.3	106	Total	Mean 9	SD 85.58	<u>Total \</u>	2.8%	IV. Fixed. 95% C	<u>ci</u>	IV, Fixed, 95%		
С	Study or Subgroup 2.2.1 Lokomat Acobendas-Maestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a)	REGT <u>Mean</u> SD T 0.1 0.28 0.009 0.24 0.06 0.28	0tal M 14 8 0 7	CPT lean SD 0 0.24 .042 0.32 0.03 0.28	Total 11 8 6	Weight 2.2% 1.2% 1.0%	0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.03 [-0.28, 0.34]	2   	IV. Fixed.	95% Cl	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a)	Mean 68.3 65.18	106 89.92	<u>Total</u> 14 5	<u>Mean</u> 9 26.11	85.58 77.76	<u>Total 1</u> 11 6	2.8%	IV. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49]	<u>ci</u> 1] 1]	IV. Fixed. 95%		
С	Study or Subgroup 2.2.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b)	REGT <u>Mean</u> SD T 0.1 0.28 0.009 0.24 0.06 0.28 0.22 0.22	0tal N 14 8 0 7 11	CPT 0 0.24 .042 0.32 0.03 0.28 0.17 0.36	Total 11 8 6 10	Weight 2.2% 1.2% 1.0% 1.4%	0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.03 [-0.28, 0.34] 0.05 [-0.21, 0.31]		IV. Fixed.	95% CI	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b)	Mean 68.3 65.18 74.84	5D 106 89.92 77.52	Total 14 5 11	9 26.11 51.32	85.58 77.76 109.1	<u>Total 1</u> 11 6 9	2.8% 1.6% 2.2%	IV. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25]	<u>CI</u>  ]  ]  ]	IV, Fixed, 95%		
С	Study or Subgroup 2.2.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (a)	REGT <u>Mean</u> <u>SD</u> T 0.1 0.28 0.009 0.24 0.06 0.28 0.22 0.22 0.01 0.05 0.01 0.05	0tal M 14 8 0 7 11 4	CPT 0 0.24 .042 0.32 0.03 0.28 0.17 0.36 0.09 0.11	Total 11 8 6 10 15	Weight 2.2% 1.2% 1.0% 1.4% 16.6%	IV. Fixed, 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.03 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01]	CI I I	IV. Fixed.	95% CI	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) PIIRA, A 2019	Mean 68.3 65.18 74.84 6.6	5D 106 89.92 77.52 12	Total 14 5 11 7	9 26.11 51.32 23.1	85.58 77.76 109.1 22	<u>Total 1</u> 11 6 9 9	2.8% 1.6% 2.2% 56.0%	IV. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40]	<u>ci</u> 1] 1] 1]	IV, Fixed, 95%		
С	Study or Subgroup 2.2.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (a) Field-Fote, EC 2011 (b) Field-Fote, EC 2011 (b)	REGT <u>Mean</u> <u>SD</u> T 0.1 0.28 0.009 0.24 0.06 0.28 0.22 0.22 0.01 0.05 0.01 0.05 0.01 0.05	14 80 7 11 4 5	CPT lean SD 0 0.24 0.42 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09	Total 11 8 6 10 15 18	2.2% 1.2% 1.0% 1.4% 16.6% 24.9%	No. 10 1010101000 N. Fixed. 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.03 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02]	CI I I I	IV. Fixed.	95% Cl	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018	Mean 68.3 65.18 74.84 6.6 76.1	106 89.92 77.52 12 104.66	Total 14 5 11 7 8	9 26.11 51.32 23.1 19.7	85.58 77.76 109.1 22 160.92	Total 1 11 6 9 9 8	2.8% 1.6% 2.2% 56.0% 0.9%	IV. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42]	CI 1] 1] 1] 1] 1]	IV, Fixed, 95%		
С	Study or Subgroup 2.2.1 Lokomat Acobendas-Maestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Field-Fote, EC 2011 (a) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c)	REGT Mean SD T 0.1 0.28 0.009 0.24 0.06 0.28 0.22 0.22 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05	14 8 0 7 11 4 5 5 7	CPT lean SD 0 0.24 0.42 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07	Total 11 8 6 10 15 18 17	2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1%	NV. Fixed, 95% G 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.05 [-0.21, 0.31] -0.06 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.09, 0.03]	21       	IV. Fixed.	95% Cl	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018 Subtotal (95% CI)	Mean 68.3 65.18 74.84 6.6 76.1	106 89.92 77.52 12 104.66	Total 14 5 11 7 8 45	9 26.11 51.32 23.1 19.7	85.58 77.76 109.1 22 160.92	Total 1 11 6 9 9 8 43	2.8% 1.6% 2.2% 56.0% 0.9% 63.6%	IV, Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] 9.29 [-25.16, 6.57]	CI 1] 1] 1] 1] 1] 1]	IV, Fixed, 95%		
С	Study or Subgroup 2.2.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EVY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) PIIRA, A 2019	REGT Mean SD T 0.1 0.28 0.009 0.24 0.06 0.28 0.22 0.22 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.05	0tal M 14 8 0 7 11 4 5 5 7 8	CPT 0 0.24 0.42 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18	Total 11 8 6 10 15 18 17 9 8	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0%	NV. Fixed, 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.09, 0.03] -0.10 [-0.22, 0.02]	21     =       	IV. Fixed.	95% Cl	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018 Subtotal (95% CI) Heteropeneity: Ch <sup>2</sup> = 6 31 df	Mean 68.3 65.18 74.84 6.6 76.1	SD 106 89.92 77.52 12 104.66	Total 14 5 11 7 8 45 27%	9 26.11 51.32 23.1 19.7	85.58 77.76 109.1 22 160.92	Total 1 11 6 9 9 8 43	2.8% 1.6% 2.2% 56.0% 0.9% 63.6%	IV. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57]	CI 1) 1) 1) 1) 1) 1)	IV. Fixed, 95%		
С	Study or Subgroup 2.2.1 Lokomat Acobendas-Maestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) PiRA, A 2018 Subtotal (95% C)	Mean         SD         T           0.1         0.28         0.009         0.24           0.06         0.28         0.22         0.22           0.01         0.05         0.01         0.05           0.01         0.05         0.05         0.05           0.12         0.18         0.10         0.10	0tal M 14 8 0 7 11 4 5 5 7 8 69	CPT 0 0.24 .042 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27	Total 11 8 6 10 15 18 17 9 8 102	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1%	IV. Fixed, 95% C 0.10 [-0.10, 0.30] -0.03 [-0.28, 0.34] 0.05 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.09, 0.03] -0.10 [-0.22, 0.02] 0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01]	21 1	IV. Fixed.	95% Cl	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018 Subtotal (95% CI) Heterogeneity: Ch <sup>2</sup> = 6.31, df	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 1)	SD 106 89.92 77.52 12 104.66 0.18);   <sup>2</sup> =	Total 14 5 11 7 8 45 = 37%	9 26.11 51.32 23.1 19.7	85.58 77.76 109.1 22 160.92	Total 1 11 6 9 9 8 8 43	2.8% 1.6% 2.2% 56.0% 0.9% 63.6%	IV. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57]	CI 1] 1] 1] 1] 1]	IV, Fixed, 95%		
С	Study or Subgroup 2.2.1 Lokomat Acobendas-Maestro, M.2012 Acobendas-Maestro, M.2012 Cheung, EYY 2019 Esclarin-Ruz, A.2014 (a) Field-Fote, EC 2011 (a) Field-Fote, EC 2011 (a) Field-Fote, EC 2011 (c) PIIRA, A.2019 Wu, M.2018 Subtotal (55% C)	REGT Mean SD T 0.1 0.28 0.009 0.24 0.06 0.28 0.22 0.22 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.12 0.18 8 (P = 0.66); H = 10000000000000000000000000000000000	otal M 14 8 0 7 11 4 5 5 7 8 69 0%	CPT 0 0.24 .042 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27	Total 11 8 6 10 15 18 17 9 8 102	Weight           2.2%           1.2%           1.0%           1.4%           16.6%           24.9%           30.1%           6.0%           1.8%           85.1%	IV. Fixed. 95% C           0.10 [-0.10, 0.30]           -0.03 [-0.31, 0.24]           0.03 [-0.28, 0.34]           0.05 [-0.21, 0.31]           -0.08 [-0.15, -0.01]           -0.04 [-0.10, 0.02]           -0.03 [-0.02, 0.02]           -0.04 [-0.10, 0.02]           -0.04 [-0.10, 0.02]           -0.04 [-0.07, -0.01]	21	IV. Fixed.	95% CI	D	Study or Subgroup 2.4.1 Lokomat Alcobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018 Subtotal (95% CI) Heterogeneity: Ch <sup>2</sup> = 6.31, df Test for overall effect: Z = 1.1!	Mean 68.3 65.18 74.84 6.6 76.1 = 4 (P = 1) 5 (P = 0.2	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = (5)	Total 14 5 11 7 8 45 = 37%	9 26.11 51.32 23.1 19.7	85.58 77.76 109.1 22 160.92	Total 1 11 6 9 9 8 8 43	2.8% 1.6% 2.2% 56.0% 0.9% 63.6%	IV. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57]	CI 1] 1] 1] 1] 1]			÷
С	Study or Subgroup           2.2.1 Lokomat           Acobendia-Maestro, M2012           Cheung, EYY 2019           Esdatini-Ruz, A 2014 (a)           Esdatini-Ruz, A 2014 (b)           Field-Fole, EC 2011 (a)           Field-Fole, EC 2011 (b)           Field-Fole, EC 2011 (c)           Fie	REGT Mean SD T 0.1 0.28 0.009 0.24 0.06 0.28 0.22 0.22 0.01 0.05 0.01 0.05 0.01 0.05 0.01 0.05 0.12 0.18 18 (P = 0.06); I <sup>2</sup> = (P = 0.02)	0tal M 14 8 0 7 11 4 5 5 7 8 69 69 69	CPT lean SD 0 0.24 0.042 0.32 0.03 0.28 0.07 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27	Total 11 8 6 10 15 18 17 9 8 102	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1%	Mean Jointeence IV. Fixed, 95% C 0.03 [-0.31, 0.24] -0.03 [-0.31, 0.24] -0.08 [-0.15, -0.01] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.09, 0.03] -0.10 [-0.22, 0.02] -0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01]		IV. Fixed.	95% CI	D	Study or Subgroup 2.4.1 Lakomat Alcobendas-Maestro, M 2012 Esclaim-Ruz, A 2014 (a) Esclaim-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018 Subtotal (95% CI) Heterogeneity: Ch <sup>2</sup> = 6.31, df Test for overall effect. Z = 1.19	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 0.2	SD 106 89.92 77.52 12 104.66 0.18);   <sup>2</sup> = (5)	Total 14 5 11 7 8 45 = 37%	9 26.11 51.32 23.1 19.7	<u>SD</u> 85.58 77.76 109.1 22 160.92	Total 1 11 6 9 9 8 8 43	2.8% 1.6% 2.2% 56.0% 0.9% 63.6%	IV, Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 25.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57]	CI 1] 1] 1] 1] 1]	IV. Fixed. 95%	.ci 	
С	Study or Subgroup           2.2.1 Lokomat           Accbandsa-Mastro, M2012           Cheung, EYY 2019           Estatinn-Ruz, A 2014 (a)           Estatinn-Ruz, A 2014 (b)           Field-Fole, EC 2011 (a)           Field-Fole, EC 2011 (a)           Field-Fole, EC 2011 (b)           PIRA, A 2018           Subtotal (B% CI)           Heterogenehy, CH = 502, dT           Test for overail effect: Z = 238	REGT Mean SD T 0.1 0.28 0.009 0.24 0.22 0.22 0.01 0.05 0.01 0.05 0.01 0.05 0.12 0.18 8 (P = 0.66); P = (P = 0.02)	otal M 14 8 0 7 11 4 5 5 7 8 69 69 69	CPT lean SD 0 0.24 0.042 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27	Total 11 8 6 10 15 18 17 9 8 102	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1%	Mean Dintericto IV. Fixed. 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.03 [-0.31, 0.24] 0.03 [-0.28, 0.34] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.03, 0.31] -0.04 [-0.07, -0.01]	21     -             	IV. Fixed.	95% CI	D	Study or Subgroup 2.4.1 Lokomat Accbendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) PIRA, A 2019 Wu, M 2018 Subtotal (85% CI) Heterogeneity: Ch <sup>21</sup> = 6.31, df Test for overall effect. Z = 1.19 2.4.2 Exoskeleton	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = I) 5 (P = 0.2	SD 106 89.92 77.52 12 104.66 0.18);   <sup>2</sup> = (5)	Total 14 5 11 7 8 45 = 37%	9 26.11 51.32 23.1 19.7	<u>SD</u> 85.58 77.76 109.1 22 160.92	<u>Total 1</u> 6 9 9 8 43	2.8% 1.6% 2.2% 56.0% 0.9% 63.6%	IV. Fixed. 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57]	CI 19 19 19 19 19	IV. Fixed, 95%	.cı 	
С	Study or Subgroup           2.2.1 Lokomati           Accbendia-Meastro, M 2012           Cheung, EYY 2019           Esclaimi-Ruz, A 2014 (b)           Esclaimi-Ruz, A 2014 (b)           Field-Fole, EC 2011 (b)           Field-Fole, EC 2011 (c)           S	REGT           Mean         SD         T           0.1         0.28         0.009         0.24           0.06         0.28         0.22         0.22           0.01         0.05         0.01         0.05           0.01         0.05         0.01         0.05           0.12         0.18         8         (P = 0.66); P = (P = 0.02)	otal M 14 8 0 7 11 4 5 7 8 69 69 69	CPT lean SD 0 0.24 0.042 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27	Total 11 8 6 10 15 18 17 9 8 102	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1%	Mean Dimeterice (V. Fixed, 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.05 [-0.21, 0.31] -0.05 [-0.21, 0.31] -0.05 [-0.21, 0.31] -0.04 [-0.15, 0.01] -0.04 [-0.10, 0.02] -0.31 [-0.09, 0.03] -0.10 [-0.22, 0.02] -0.04 [-0.07, -0.01]	21             	IV. Fixed.	95% CI	D	Study of Subgroup 2.4.1 Lokomat Acobendas-Maestro, M. 2012 Esclain-Ruz, A 2014 (a) Esclain-Ruz, A 2014 (b) PIRA, A 2019 Wu, M. 2018 Subtotal (95% CI) Heterogeneity: Ch <sup>2</sup> = 6.31, df Test for overail effect. Z = 1.19 2.4.2 Exoskeleton Chang, S. 2018	Mean 68.3 65.18 74.84 6.6 76.1 = 4 (P = 1) 5 (P = 0.2 16.9	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = (5)	Total 14 5 11 7 8 45 = 37%	Mean 9 26.11 51.32 23.1 19.7 7.7	<u>SD</u> 85.58 77.76 109.1 22 160.92	<u>Total 1</u> 11 6 9 9 8 43 3	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0%	V. Fixed. 95% C 59.30 [-15.80, 134.40] 20.71 [-61.35, 139.49] 20.72 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.20]	CI 1] 1] 1] 1] 1]	V. Fixed, 95%	.cı 	
С	Study or Subgroup           2.2.1 Lokomat           Accoencida-Messito, M 2012           Cheng, EYY 2019           Sciamin-Ruz, A 2014 (b)           Field-Folk, EC 2011 (a)           Field-Folk, EC 2011 (b)           Field-Folk, EC 2011 (c)           Fiel	REGT Mean SD T 0.1 0.28 0.009 0.24 0.22 0.22 0.01 0.05 0.01 0.05 0.01 0.05 0.12 0.18 18 (P = 0.66); P = (P = 0.02) 0.04 0.07	otal M 14 8 0 7 11 4 5 7 8 69 69 69	CPT lean SD 0 0.24 .042 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08	Total 11 8 6 10 15 18 17 9 8 102 3	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 85.1% 7.1%	Mean Dinterence IV. Fixed. 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.09, 0.03] -0.10 [-0.22, 0.02] 0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11]	21 	V. Fixed	95% CI	D	Study or Subgroup 2.4.1 Lokomat Acobendas-Maestro, M 2012 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018 Subtotal (95% C) Heterogeneity-Chi <sup>2</sup> = 6.31, df Test for overall effect. Z = 1.19 2.4.2 Exoskeleton Chang, S 2018 Gil-Aurich A 2023	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 1) 5 (P = 0.2 16.9 68.79	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = (5) 15.97 67.55	Total 14 5 11 7 8 45 = 37%	Mean 9 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 8 43 3 10	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4%	V. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-29.31, 70.69]	CI 1) 1) 1) 2) 2) 2) 2) 3)	N. Fixed. 95%		
С	Study or Subgroup           2.2.1 Lokomat           Accbendia-Meastro, M 2012           Cheung, EYY 2019           Esclamin-Ruz, A 2014 (a)           Esclamin-Ruz, A 2014 (b)           Field-Fole, EC 2011 (a)           Field-Fole, EC 2011 (c)           Zubtodi (255, Cl) = 5.2, df           Heterogeneity, Cl) = 5.2, df           Z-2.2 Excloskelen Cherg, S 2018           Charg, S 2018           Charg, S 2018           Charg, S 2018	REGT           Mean         SD         T           0.1         0.28         0.009         0.24           0.06         0.28         0.22         0.22           0.01         0.05         0.01         0.05           0.12         0.18         8         (P = 0.66); P = (P = 0.02)           0.04         0.07         0.18         0.23	otal N 14 8 0 7 11 4 5 5 7 8 69 69 0% 4 9	CPT lean SD 0 0.24 0.42 0.32 0.03 0.28 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27	Total 11 8 6 10 15 18 17 9 8 102 3 10	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 85.1% 7.1% 3.3%	Mean Dimeterice 10. Fixed, 95% C 0.10 [-0.10, 0.30] -0.03 [-0.31, 0.24] 0.05 [-0.21, 0.31] -0.08 [-0.15, 0.01] -0.04 [-0.15, 0.01] -0.04 [-0.15, 0.01] -0.04 [-0.13, 0.31] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11]	3     -         	•	95% CI	D	Study of Subgroup 2.4.1 Lokomat Acobendas-Maestro, M. 2012 Esclain-Ruz, A 2014 (a) PiRA, A 2019 Wu, M. 2018 Subtotal (95% CI) Heterogeneity: Ch <sup>2</sup> = 6.31, df Test for overail effect. Z = 1.19 2.4.2 Exoskeleton Girl-Agud, A 2023 Subtotal (95% CI)	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 1 5 (P = 0.2 16.9 68.79	<u>50</u> 106 89.92 77.52 12 104.66 0.18);  ² = (5) 15.97 67.55	Total 14 5 11 7 8 45 = 37% 4 11 15	Mean 9 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 8 43 43 3 10 13	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%	V. Fixed, 95% C 59.30 [-15.80, 134.40] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-26.31, 70.69]	CI 1) 1) 1) 1) 1) 1) 1)	N. Fixed. 93%		
С	Study or Subgroup           2.2.1 Lokomat           Accoencia-Meastro, M 2012           Cheung, EYY 2019           Stadamir-Ru, A 2014 (a)           Field-Fohe, EC 2011 (a)           Field-Fohe, EC 2011 (b)           Chang, S 201           Chang, S 201           Chang, S 201           Chang, S 201           Chang, A 2023	REGT           Mean         SD_T           0.11         0.28           0.009         0.24           0.06         0.28           0.22         0.22           0.01         0.05           0.01         0.05           0.01         0.05           0.12         0.18           c8         (P = 0.66); P =           0.04         0.07           0.18         0.23           0.04         0.07           0.18         0.23	otal N 14 8 0 7 11 4 5 5 7 8 69 69 9 0%	CPT lean SD 0 0.24 0.42 0.32 0.03 0.28 0.07 0.11 0.05 0.09 0.14 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.07 0.11 0.12 0.17	Total 11 8 6 10 15 18 17 9 8 102 3 10 10	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 30.1% 6.0% 1.8% 85.1% 7.1% 3.3% 4.5%	Media Dinterence W W. Fixed. 95% C 0.10 [-0.10, 0.30] -0.03 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.22, 0.02] 0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11] 0.11 [-0.60, 0.28]	3     -           	V. Fixed.	95% CI	D	Study of Subgroup 2.4.1 Lokomat Acobendas-Maestro, M 2012 Esclain-Ruz, A 2014 (a) PIIRA, A 2019 Wu, M 2018 Subtotal (95% CI) Heterogeneity: Chi" = 6.31, df rest for overall effect 2: = 1.1! 2.4.2 Exoskeleton Chang, S 2018 Gi-Agudo, A 2023 Subtotal (95% CI)	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = I) 5 (P = 0.2 16.9 68.79	SD 106 89.92 77.52 12 104.66 0.18);   <sup>2</sup> = (5) 15.97 67.55	Total 14 5 11 7 8 45 = 37% 4 11 15	Mean 9 26.11 51.32 23.1 19.7 7.7 48.1	SD 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 8 43 43 10 13	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%	V. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-3.40, 0.40] 65.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-28.31, 70.69] 11.22 [-9.75, 32.20]	CI 19 19 19 19 19 19 19 19	IN Fixed, 95%		
С	Study or Subgroup           2.2.1 Lokomat           Accbendia-Meastro, M 2012           Cheung, EYY 2019           Esclarin-Ruz, A 2014 (b)           Esclarin-Ruz, A 2014 (b)           Field-Fole, EC 2011 (b)           Field-Fole, EC 2011 (c)           Field-Fole, EC 2012 (c)           Chard, B. 2022           Field-Fole, A. 2022           Field-Fole, CA 2022           Field-Fole, CH 2022           Field-Fole, CH 2022	REGT           Mean         SD           0.1         0.28           0.009         0.24           0.6         0.22           0.11         0.05           0.01         0.05           0.01         0.05           0.02         0.22           0.04         0.05           0.02         0.02           0.04         0.07           0.18         0.23           0.04         0.07           0.16         0.23	14 14 8 0 7 11 4 5 5 7 8 69 9 11 24	CPT lean SD 0 0.24 0.42 0.32 0.03 0.28 0.03 0.28 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17	Total 11 8 6 10 15 18 17 9 8 102 3 10 23	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1% 7.1% 3.3% 4.5%	Mean Dimetericle 95% C 10, Fixed, 95% C 0, 10 [-0, 10, 0, 30] -0, 31, 0, 24] 0, 35, 0, 24, 0, 34] 0, 35, 0, 24, 0, 34] -0, 45, -0, 10, -0, 25, 0, 20, -0, -0, -0, -0, -0, -0, -0, -0, -0, -	3       	Wealt Dim	95% CI	D	Study or Subgroup           2.4.1 Lokomat           Alcobendas-Measton, M 2012           Esclain-Ruz, A 2014 (a)           Esclain-Ruz, A 2014 (b)           PIIRA, A 2019           Subtotal (85% CI)           Helerogeneity C. On* 6 - 6.31, df           Test for overall effect. Z = 1.1!           2.4.2 Exoskeleton           Chang, S 2018           Subtotal (85% CI)           Helerogeneity C. Ch" = 0.1, df	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 1 5 (P = 0.2 16.9 68.79	SD 106 89.92 77.52 12 104.66 0.18); l <sup>2</sup> = (5) 15.97 67.55 0.68); l <sup>2</sup> =	<u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0%	Mean 9 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 1 9 9 8 43 3 10 13	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%	V. Fixed, 95% C 59.30 [-15.80, 134.40] 93.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 04.0] -6.640 [-7.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-29.31, 70.69] 11.22 [-9.75, 32.20]	CI 1) 1) 1) 1) 1) 1) 1) 1)	■ cell of lifetime in the second sec		
С	Study or Subgroup           2.2.1 Lokomat           Accoencia-Massim, M 2012           Cheng, EYY 2019           Estadimi-Ruz, A 2014 (a)           Estadimi-Ruz, A 2014 (b)           Estadimi-Ruz, A 2014 (c)           Field-Folo, EC 2011 (a)           Field-Folo, EC 2011 (b)           Gi-Gardo, D 2022           Subtotal (6%)           Subtotal (6%)           Field-Folo, Folo, Folo, 2023           Subtotal (6%)           Field-Folo, Folo, Folo, 212, 214	REGT           Mean         SD         T           0.1         0.28         0.06         0.28           0.00         0.24         0.22         0.22         0.22         0.22         0.22         0.21         0.21         0.22         0.22         0.01         0.05         0.01         0.05         0.01         0.05         0.01         0.05         0.02         0.12         0.18         0.88         (P = 0.02)         0.18         0.20         0.24         0.04         0.07         0.18         0.23         0.19         0.16         0.23         0.19         0.15         0.23         0.19         0.15         0.22         0.22         0.22         0.22         0.24         0.24         0.25         0.12         0.18         0.23         0.19         0.16         0.23         0.19         0.16         0.22         0.22         0.22         0.22         0.24         0.25         0.19         0.16         0.23         0.19         0.16         0.25         0.25         12         (P = 0.52): P = 0.52         P = 0.52 <t< td=""><td>14 14 8 0 7 11 4 5 5 7 8 69 9 11 24 0%</td><td>CPT lean SD 0 0.24 0.42 0.32 0.03 0.28 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17</td><td>Total 11 8 6 10 15 18 10 10 23</td><td>Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1% 7.1% 3.3% 4.5% 14.9%</td><td>Mean Dinteractor W. Fixed. 95% C 0.10 [-0.10, 0.30] -0.03 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.22, 0.02] 0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11] 0.01 [-0.07, 0.21] 0.05 [-0.03, 0.12]</td><td></td><td>V. Fixed.</td><td>95% CI</td><td> D</td><td>Study of Subgroup           2.4.1 Lokomat           Alcobendas-Maestro, M 2012           Esclain-Ruz, A 2014 (a)           Esclain-Ruz, A 2014 (b)           PIIFA, A 2019           Wu, M 2018           Subtotal (95% CI)           Heterogeneity: Chi* = 6.31, df           Chi-Agudo, A 2023           Subtotal (95% CI)           Heterogeneity: Chi* = 6.37, df           Ci-Agudo, A 2023           Subtotal (95% CI)           Heterogeneity: Chi* = 0.17, df           Test for overal effect, 2 = 1.01</td><td>Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 0.2 16.9 68.79 5 (P = 0.2 16.9 5 (P = 0.2) 16.9 16.</td><td>SD 106 89.92 77.52 12 104.66 0.18);  <sup>2</sup> = (5) 15.97 67.55 0.68);  <sup>2</sup> = (9)</td><td><u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0%</td><td><u>Mean</u> 9 26.11 51.32 23.1 19.7 7.7 48.1</td><td><u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58</td><td>Total ) 11 6 9 9 8 43 43 3 10 13</td><td>Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%</td><td>V. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40, 25.40] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-29.31, 70.69] 11.22 [-9.75, 32.20]</td><td>CI 1] 1] 1] 1] 1] 1]</td><td>N. Fixed. 95%</td><td></td><td></td></t<>	14 14 8 0 7 11 4 5 5 7 8 69 9 11 24 0%	CPT lean SD 0 0.24 0.42 0.32 0.03 0.28 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17	Total 11 8 6 10 15 18 10 10 23	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1% 7.1% 3.3% 4.5% 14.9%	Mean Dinteractor W. Fixed. 95% C 0.10 [-0.10, 0.30] -0.03 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.22, 0.02] 0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11] 0.01 [-0.07, 0.21] 0.05 [-0.03, 0.12]		V. Fixed.	95% CI	D	Study of Subgroup           2.4.1 Lokomat           Alcobendas-Maestro, M 2012           Esclain-Ruz, A 2014 (a)           Esclain-Ruz, A 2014 (b)           PIIFA, A 2019           Wu, M 2018           Subtotal (95% CI)           Heterogeneity: Chi* = 6.31, df           Chi-Agudo, A 2023           Subtotal (95% CI)           Heterogeneity: Chi* = 6.37, df           Ci-Agudo, A 2023           Subtotal (95% CI)           Heterogeneity: Chi* = 0.17, df           Test for overal effect, 2 = 1.01	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 0.2 16.9 68.79 5 (P = 0.2 16.9 5 (P = 0.2) 16.9 16.	SD 106 89.92 77.52 12 104.66 0.18);   <sup>2</sup> = (5) 15.97 67.55 0.68);   <sup>2</sup> = (9)	<u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0%	<u>Mean</u> 9 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total ) 11 6 9 9 8 43 43 3 10 13	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%	V. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40, 25.40] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-29.31, 70.69] 11.22 [-9.75, 32.20]	CI 1] 1] 1] 1] 1] 1]	N. Fixed. 95%		
С	Study or Subgroup           2.2.1 Lokomat           Accbendia-Meastro, M 2012           Cheung, EYY 2019           Esclarin-Ruz, A 2014 (b)           Esclarin-Ruz, A 2014 (b)           Field-Fole, EC 2011 (b)           Field-Fole, EC 2011 (c)           Z-2.2 Excloskelen (c)           Chang, S 2018           Chang, S 2018           Calubata (BY, CI)           Heterogeneity: CNF = 1.32, df           Test for overall effect Z = 1.32	REGT           Mean         SD           0.00         0.24           0.00         0.24           0.00         0.22           0.22         0.22           0.01         0.28           0.00         0.24           0.01         0.05           0.01         0.05           0.01         0.05           0.01         0.05           0.12         0.18           0         0.05           0.12         0.18           0.04         0.07           0.16         2.23; P =           (P = 0.25); P =         (P = 0.25); P =	otal         N           14         8         0           7         11         4           5         5         7           8         69         9           11         24         24           9         11         24	CPT lean SD 0 0.24 .042 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17	Total 11 8 6 10 15 18 17 9 8 102 3 10 10 23	Weight 2.2% 1.2% 1.2% 1.4% 16.6% 24.9% 30.1% 6.0% 1.8% 85.1% 7.1% 3.3% 4.5% 14.9%	Mean Dimetericle 20 (1) (Fixed 95% C 0.10 [-0.10, 0.30] -0.33 [-0.28, 0.34] 0.03 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.04 [-0.10, 0.02] -0.03 [-0.08, 0.03] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11] 0.00 [-0.11, 0.11] 0.01 [-0.06, 0.28] 0.07 [-0.07, 0.21] 0.05 [-0.03, 0.12]		N. Fixed	95% CI	D	Study or Subgroup           2.4.1 Lokomat           Alcobendas-Makesto, M 2012           Esclain-Ruz, A 2014 (a)           Esclain-Ruz, A 2014 (b)           PIIRA, A 2019           Wu, M 2018           Subtodal (95% CI)           Helerogeneity: Con* 6 3.1, d1           Test for overall effect. Z = 1.1:           2.4.2 Exoskeleton           Chang, S 2018           Subtodal (95% CI)           Helerogeneity: Con* 6 3.7, d1           Helerogeneity: Con* 6 3.7, d1	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 0.2 16.9 68.79 5 (P = 0.2	<u>SD</u> 106 89.92 77.52 12 104.66 0.18);   <sup>2</sup> = (5) 15.97 67.55 0.68);   <sup>2</sup> = (9)	<u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0%	<u>9</u> 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total ) 11 6 9 9 8 43 43 3 10 13	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%	V. Fixed, 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-29.31, 70.69] 11.22 [-9.75, 32.20]	C1 1) 1) 1) 1) 1) 1) 1) 1) 1)	N. Fixed. 95%		
С	Study or Subgroup           2.2.1 Lokomat           Accoencia-Massim, M 2012           Cheng, EYY 2019           Beadmin-Ruz, A 2014 (a)           Estadimin-Ruz, A 2014 (b)           Evide Fork, EC 2011 (b)           Field-Fork, EC 2011 (b)           Hetrogoneity: Chi <sup>±</sup> = 5.92, df           Extending, A 2023           Subball (95% C1)           Hetrogoneity: Chi <sup>±</sup> = 1.32, df           Test for overait effect: Z = 1.16	REGT           Mean         SD         T           0.009         0.24         0.009         0.24           0.009         0.24         0.005         0.01         0.05           0.01         0.05         0.01         0.05         0.01         0.05         0.12         0.18         0.24         0.07         0.05         0.12         0.18         0.02         0.03         0.018         0.23         0.19         0.16         0.23         0.19         0.16         0.23         0.19         0.16         2.23         19         0.19         0.15         2.02         19         0.15         2.02         10 <td< td=""><td>otal         N           14         8         0           7         11         4           5         7         8           69         0%         4           9         11         24           24         0%         0%</td><td>CPT lean SD 0 0.24 0.02 0.32 0.03 0.28 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17</td><td>Total 11 8 6 10 15 18 17 9 8 102 3 10 10 23</td><td>Weight 2.2% 1.2% 1.4% 16.6% 24.9% 30.1% 6.0% 85.1% 7.1% 3.3% 4.5% 14.9%</td><td>Mean Joneterico W. Fixed, 955: C 0.10 [-0.10, 0.30] -0.33 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.09, 0.03] -0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11] 0.07 [-0.07, 0.21] 0.05 [-0.03, 0.12]</td><td>3                  </td><td>Neit Dim N. Fixed</td><td>995 CI</td><td> D</td><td>Study of Subgroup           2.4.1 Lokomat           Alcobendas-Measto, M 2012           Esclain-Ruz, A 2014 (a)           Esclain-Ruz, A 2014 (b)           PIIFA, A 2019           Subtotal (95% CI)           Heterogeneity: Chi* = 6.31, df           Test for overall effect 2: = 1.1!           2.4.2 Exoskeleton           Charged A 2023           Subtotal (95% CI)           Heterogeneity: Chi* = 0.17, df           Test for overall effect 2: = 1.1!           Test for overall effect 2: = 1.1!</td><td>Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 0.2 16.9 68.79 5 (P = 0.2 16.9 5 (P = 0.2)</td><td>SD 106 89.92 77.52 12 104.66 0.18); I<sup>2</sup> = 5) 15.97 67.55 0.68); I<sup>2</sup> =</td><td><u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0% 60</td><td><u>9</u> 26.11 51.32 23.1 19.7 7.7 48.1</td><td><u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58</td><td>Total 1 11 6 9 9 9 8 8 43 3 10 13 56</td><td>Weight 2.8% 1.6% 2.2% 56.0% 0.3% 63.6% 30.0% 64.4% 100.0%</td><td>IV. Fixed. 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-28.31, 70.69] 11.22 [-9.75, 32.20] -1.83 [-14.48, 10.83]</td><td>C1 1) 1) 1) 1) 1) 1) 1)</td><td>N.Fixed.95%</td><td></td><td></td></td<>	otal         N           14         8         0           7         11         4           5         7         8           69         0%         4           9         11         24           24         0%         0%	CPT lean SD 0 0.24 0.02 0.32 0.03 0.28 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17	Total 11 8 6 10 15 18 17 9 8 102 3 10 10 23	Weight 2.2% 1.2% 1.4% 16.6% 24.9% 30.1% 6.0% 85.1% 7.1% 3.3% 4.5% 14.9%	Mean Joneterico W. Fixed, 955: C 0.10 [-0.10, 0.30] -0.33 [-0.28, 0.34] 0.05 [-0.21, 0.31] -0.08 [-0.15, -0.01] -0.08 [-0.15, -0.01] -0.04 [-0.10, 0.02] -0.03 [-0.09, 0.03] -0.09 [-0.13, 0.31] -0.04 [-0.07, -0.01] 0.00 [-0.11, 0.11] 0.07 [-0.07, 0.21] 0.05 [-0.03, 0.12]	3                 	Neit Dim N. Fixed	995 CI	D	Study of Subgroup           2.4.1 Lokomat           Alcobendas-Measto, M 2012           Esclain-Ruz, A 2014 (a)           Esclain-Ruz, A 2014 (b)           PIIFA, A 2019           Subtotal (95% CI)           Heterogeneity: Chi* = 6.31, df           Test for overall effect 2: = 1.1!           2.4.2 Exoskeleton           Charged A 2023           Subtotal (95% CI)           Heterogeneity: Chi* = 0.17, df           Test for overall effect 2: = 1.1!           Test for overall effect 2: = 1.1!	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 0.2 16.9 68.79 5 (P = 0.2 16.9 5 (P = 0.2)	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = 5) 15.97 67.55 0.68); I <sup>2</sup> =	<u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0% 60	<u>9</u> 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 9 8 8 43 3 10 13 56	Weight 2.8% 1.6% 2.2% 56.0% 0.3% 63.6% 30.0% 64.4% 100.0%	IV. Fixed. 95% C 59.30 [-15.80, 134.40] 39.07 [-61.35, 139.49] 23.52 [-61.21, 108.25] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-28.31, 70.69] 11.22 [-9.75, 32.20] -1.83 [-14.48, 10.83]	C1 1) 1) 1) 1) 1) 1) 1)	N.Fixed.95%		
С	Study or Subgroup           2.2.1 Lokomat           Accbendia-Meastro, M 2012           Cheung, EYY 2019           Esclarin-Ruz, A 2014 (a)           Esclarin-Ruz, A 2014 (b)           Field-Fole, EC 2011 (a)           Field-Fole, EC 2011 (c)           Z-2.5 Coskled (c)           Z-2.5 Coskled (c)           Z-2.5 Coskled (c)           Z-2.2 Exoskled (c)           Chang, S.2018           Caldo, A 2022           Subbta1 (6%, C)           Heterogeneity: CNF = 1.32, dF           Test for overail effect Z = 1.32           Total (6%, C)	NetGT           Mean         SD         T           0.00         0.24         0.26         0.22         0.22         0.22         0.22         0.22         0.22         0.22         0.22         0.22         0.22         0.22         0.21         0.27         0.22         0.11         0.05         0.11         0.05         0.011         0.05         0.011         0.05         0.011         0.05         0.12         0.18         8         (P = 0.02)         0.04         0.07         0.18         0.23         0.19         0.16         2         (P = 0.25); P = (P = 0	otal         N           14         8         0           7         11         4           5         7         8           69         9         11           24         9         11           24         9%         9%           93         93         93	CPT lean SD 0 0.24 .042 0.32 0.03 0.28 0.17 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17	Total 11 8 6 10 15 18 18 17 9 8 102 3 102 3 10 10 23 125	Weight 2.2% 1.2% 1.0% 1.6% 24.9% 30.1% 6.0% 1.8% 85.1% 7.1% 3.3% 4.5% 14.9%	mean Dimension (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)		N Fixed	95% CI	D	Study or Subgroup           2.4.1 Lokomat           Alcobendas-Measto, M 2012           Existan-Ruz, A 2014 (a)           Existan-Ruz, A 2014 (b)           PIIRA, A 2019           Wu, M 2018           Subtotal (95%, CI)           Helerogeneity: Cm <sup>2</sup> 6 3.1, df           Test for overall effect: Z = 1.9:           2.4.2 Exoskeleton           Chi-Agudo, A 2023           Subtotal (95%, CI)           Helerogeneity: Chi <sup>2</sup> 6 8.1, df           Test for overall effect: Z = 1.9:           Total (95%, CI)	Mean 68.3 65.18 74.84 6.6 76.1 5 (P = 0.2 16.9 68.79 5 (P = 0.2 16.9 5 (P = 0.2 16.9 5 (P = 0.2) 5 (P = 0.2) 5 (P = 0.2) 5 (P = 0.2) 6 (P = 0.2) 5 (P = 0.2) 6 (P = 0.2) 7 (P = 0.2)	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = 15.97 67.55 0.68); I <sup>2</sup> = 0.18); I <sup>2</sup> =	<u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0% 60 = 32%	<u>Mean</u> 9 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 8 43 43 10 13 56	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%	IV. Fixed. 95% C 59.30 [-15.80, 134.40] 39.07 [e1.35, 139.44] 39.07 [e1.35, 139.44] -16.50 [-33.40, 0.40] 56.40 [-76.62, 189.42] -9.29 [-25.16, 6.57] 9.20 [-13.90, 32.30] 20.69 [-28.31, 70.69] 11.22 [-9.75, 32.20] -1.83 [-14.48, 10.83]	CI 1] 1] 1] 1] 1] 1] 1] 1] 1] 1]	N. Fixed. 95%		
С	Study or Subgroup           2.2.1 Lokomat           Accoencia-Meastro, M 2012           Cheng, EYY 2019           Estatini-Ruz, A 2014 (a)           Estatini-Ruz, A 2014 (b)           Field-Fole, EC 2011 (b)           Hetrogoneity: Chi <sup>2</sup> = 5.92, df           Hetrogoneity: Chi <sup>2</sup> = 1.32, df           Test for overail effect: Z = 1.15           Total (dSN, Cl)           Heterogoneity: Chi <sup>2</sup> = 1.17, df	REGT           Mean         SD         T           0.009         0.24         0.009         0.24           0.009         0.24         0.005         0.01         0.05           0.01         0.05         0.01         0.05         0.01         0.05           0.01         0.05         0.01         0.05         0.01         0.05         0.02         0.04         0.07         0.18         0.23         0.19         0.16         0.18         0.23         0.19         0.16         0.18         0.23         0.19         0.16         12<(P = 0.22); P = (P = 0.22); P = (P = 0.22); P = (P = 0.25); P = (P = 0.43); P = (1 + (P = 0.43); P = 0.43); P = 11 (P = 0.43); P = 0.43); P = 11 (P = 0.43); P = 0.43;	otal         N           14         8         0           7         11         4           5         5         7           8         69         9           11         24         9           11         24         0%           93         P = 2%         2	CPT lean SD 0 0.24 0.03 0.28 0.03 0.28 0.07 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27	Total 11 8 6 10 15 18 107 9 8 102 3 100 23 125	Weight 2.2% 1.2% 1.0% 1.0% 1.6% 24.9% 6.0% 1.6% 85.1% 7.1% 3.3% 4.5% 14.9%	Mean Jonnet Color 0, 10 [-0, 10, 0, 30] -0.03 [-0.31, 0.24] 0.05 [-0.27, 0.31] -0.04 [-0, 10, 0.20] -0.04 [-0, 10, 0.21] -0.04 [-0, 10, 0.22] -0.04 [-0, 10, 0.22] -0.04 [-0, 0.01] -0.04 [-0, 0.02] -0.04 [-0, 0.01] -0.04 [-0, 0.02] -0.04 [-0, 0.02] -0.04 [-0, 0.02] -0.04 [-0, 0.02] -0.04 [-0, 0.02] -0.03 [-0.06, 0.00]		W.Fixed	995 Cl	D	Study of Subgroup 2.4.1 Lokomat Acobendas-Measto, M 2012 Esclain-Ruz, A 2014 (a) Esclain-Ruz, A 2014 (b) PIIRA, A 2019 Wu, M 2018 Subtotal (95% CI) Heterogeneity: Ch <sup>a</sup> = 6.31, df Test for overall effect 2 = 1.11 2.4.2 Exoskeleton Chang, S 2018 Gir-Agudo, A 2023 Subtotal (95% CI) Heterogeneity: Ch <sup>a</sup> = 8.1, df Heterogeneity: Ch <sup>a</sup> = 8.1, df	Mean 68.3 65.18 74.84 6.6 76.1 1 = 4 (P = 1 16.9 68.79 1 = 1 (P = 0.2 16.9 68.79 1 = 0 (P = 0.2) 1 = 0 (P = 0.2)	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = 15.97 67.55 0.68); I <sup>2</sup> = 0.18); I <sup>2</sup> =	<u>Total</u> 14 5 11 7 8 45 = 37% 4 11 15 = 0% 60 = 32%	Mean 9 26.11 51.32 23.1 19.7 7.7 48.1	<u>SD</u> 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 9 8 43 43 10 13 56	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 6.4% 36.4%	M. Fixed 35% C 59.30 [-15.80, 134.40] 30.07 [-15.8], 139.40] 30.07 [-15.8], 139.40] 32.52 [-12.1, 108.25] -15.55 [-3.30, 0.01; 56.40 [-76.52, 189.42] 4.29 [-15.93, 32, 30] 20.65 [-28.31, 70.66] 11.22 [-9.75, 32, 20] -1.83 [-14.48, 10.83]	CI 19 19 19 19 19 1 1 -200	NV. Fixed. 95%		
С	Study or Subgroup           2.2.1 Lokomati           Ackobendas-Meastro, M 2012           Cheung, EYY 2019           Esclamin-Ruz, A 2014 (a)           Esclamin-Ruz, A 2014 (b)           Field-Fole, EC 2011 (a)           Field-Fole, EC 2011 (c)           Charg, S 2018           Charg, S 2018           External effect: 2 1.2, dT           Test for overall effect: 2 1.75           Total (05% C)           Heterogeneity: Chi <sup>2</sup> = 11.17, dT           Fest for overall effect: 2 1.75	$\begin{array}{c} \mbox{REGT} \\ \mbox{Rem}  {\rm SD} \ {\rm T} \\ 0.1 \ 0.28 \ 0.009 \ 0.24 \\ 0.009 \ 0.24 \ 0.06 \ 0.28 \\ 0.22 \ 0.22 \ 0.22 \ 0.01 \ 0.05 \\ 0.01 \ 0.05 \ 0.01 \ 0.05 \\ 0.01 \ 0.05 \ 0.01 \ 0.05 \\ 0.12 \ 0.18 \ 0.05 \ 0.12 \ 0.18 \\ 0.12 \ 0.18 \ 0.05 \ 0.12 \ 0.18 \\ 0.12 \ 0.18 \ 0.05 \ 0.05 \ 0.12 \ 0.18 \ 0.05 \ 0.12 \ 0.18 \\ 0.12 \ 0.18 \ 0.05 \ 0.12 \ 0.18 \ 0.23 \ 0.19 \ 0.05 \ 0.12 \ 0.18 \ 0.23 \ 0.19 \ 0.05 \ 0.18 \ 0.23 \ 0.19 \ 0.18 \ 0.23 \ 0.19 \ 0.18 \ 0.23 \ 0.19 \ 0.18 \ 0.23 \ 0.19 \ 0.18 \ 0.23 \ 0.19 \ 0.18 \ 0.25 \ 0.18 \ 0.18 \ 0.18 \ 0.25 \ 0.18 \ 0.18 \ 0.25 \ 0.18 \$	total         N           14         8         0           7         11         4           5         7         8           69         0%         9           11         24         0%           93         P = 2%         24	CPT Isan SD 0 0.24 0.02 0.32 0.03 0.28 0.07 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17	Total 11 8 6 10 15 18 17 9 8 102 10 23 125	Weight 2.2% 1.2% 1.0% 1.4% 16.6% 30.1% 6.0% 30.1% 6.0% 30.1% 6.0% 1.8% 85.1%	mean University of the second	-0.5 -0.	V. Fixed	95% Cl	D	Study or Subgroup           2.4.1 Lokomat           Accoendas-Measto, M 2012           Esclain-Ruz, A 2014 (a)           Esclain-Ruz, A 2014 (b)           PIIRA, A 2019           Wu, M 2018           Subtodal (95% CI)           Helerogenety: Cm <sup>2</sup> = 0.81, df           Test for overall effect: Z = 1.91           Peterogenety: Cm <sup>2</sup> = 0.17, df           Test for overall effect: Z = 1.92           Total (95% CI)           Test for overall effect: Z = 0.21	Mean 4. 68.3 65.18 74.84 6.6.6 76.1 74.84 6.6.7 76.1 16.9 68.79 16.9 68.79 15.5 (P = 0.2) 16.9 68.79 15.5 (P = 0.2) 16.9 68.79 15.5 (P = 0.2) 16.9 1	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = 15.97 67.55 0.68); I <sup>2</sup> = 15.97 0.18); I <sup>2</sup> = 15.97 67.55 0.68); I <sup>2</sup> = 15.97 67.55 15.97	Total 14 5 11 7 8 45 = 37% 4 11 15 = 0% 60 = 32% 4 (1) 	Mean 9 26.11 51.32 23.1 19.7 7.7 48.1	SD 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 8 43 43 10 13 56	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 64.4% 36.4%	M. Fund. 35% C 59.30 (-15.80, 134.40) 39.07 (-16.35, 139.40) 39.07 (-16.35, 139.40) 39.07 (-16.35, 139.40) 49.23 (-16.10, 125.25) 49.20 (-13.90, 52.50) 20.66 (-28.31, 70.66) 11.22 (-8.75, 32.20) -1.83 (-14.48, 10.83)	CI 1 1 1 1 1 1 1 1 1 1 1 1 1	N. Fied 253	CI	
С	Study or Subgroup           2.2.1 Lokomat           Accoencia-Meastro, M 2012           Cheng, EYY 2019           Exademix-Ruz, A 2014 (a)           Exademix-Ruz, A 2014 (b)           Exademix-Ruz, A 2014 (c)           Field-Fole, EC 2011 (b)           Hetrogeneity: CA 2013           Subtoal (1954; C)           Hetrogeneity: CAP = 132, df =           Test for overall differences: (C)           Field for ubgroup differences: (C)           Field for ubgroup differences: (C)	REGT           Mean         SD           0.009         0.24           0.009         0.24           0.009         0.24           0.010         0.05           0.02         0.22           0.011         0.05           0.012         0.011           0.011         0.05           0.02         0.02           0.04         0.05           0.05         0.12           0.04         0.07           0.18         0.23           0.04         0.07           0.18         0.23           0.19         0.16           12         (P = 0.52); P =           11 (P = 0.43); (P = 0.43);           12 (P = 0.43); M = = 3.44, df = 1	interference         interference           14         8         0           7         11         4           5         5         7           8         69         9           11         24         0%           93         P = 2%         1           I (P = 0)         I         I	CPT (san SD 0 0.24 0.03 0.28 0.07 0.36 0.09 0.11 0.05 0.09 0.04 0.07 0.1 0.18 0.03 0.27 0.04 0.08 0.03 0.27 0.04 0.08 0.07 0.11 0.12 0.17 0.05, F = 74	Total 11 8 6 10 15 18 17 9 8 102 3 102 3 102 125 .6%	Weight 2.2% 1.2% 1.2% 24.9% 30.1% 6.0% 85.1% 7.1% 3.3% 4.5% 14.9%	Mean United Tele (14, 14, 14, 14, 14, 14, 14, 14, 14, 14,	21 	V. Fixed	95% Cl	D	Study of Subgroup 2.4.1 Lokomat Acobendas-Maestro, M 2012 Esclaim-Ruz, A 2014 (a) Esclaim-Ruz, A 2019 (b) PIIRA, A 2019 Subtotal (95% CI) Heterogeneity: Chi <sup>+</sup> = 6.31, df Test for overall effect 2 = 1.1! 2.4.2 Exoskeleton Chang, S 2018 Gi-Agudo, A 2023 Subtotal (95% CI) Heterogeneity: Chi <sup>+</sup> = 0.17, df Test for overall effect 2 = 0.2! Total (95% CI)	Mean 68.3 65.18 74.84 6.6 76.1 74.84 6.6 76.1 75.1 76.1 76.1 76.1 76.1 76.1 76.1 76.1 76.1 76.2	SD 106 89.92 77.52 12 104.66 0.18); I <sup>2</sup> = 15.97 67.55 0.68); I <sup>2</sup> = 15.97 80, 15 0.18); I <sup>2</sup> = 15.97 15.97 15.97 15.97 15.97 15.97 15.97 15.99 15.97 15.97 15.97 15.97 15.99 15.97	Total           14           5           11           7           8           45           937%           4           11           15           90%           60           32%           1 (P = 0)	Mean 9 26.11 51.32 23.1 19.7 7.7 48.1	SD 85.58 77.76 109.1 22 160.92 15.02 48.58	Total 1 11 6 9 9 8 43 3 10 13 56	Weight 2.8% 1.6% 2.2% 56.0% 0.9% 63.6% 30.0% 64.6% 36.4%	M. Fund. 35% C 59.30 [-15.80, 134.40] 30.07 [-15.3, 138.48] 30.07 [-15.3, 138.48] 30.07 [-15.20, 135.138.40] 50.40 [-75.62, 148.40] 9.20 [-13.90, 32.30] 20.69 [-23.17, 00] 9.20 [-13.90, 32.30] 20.69 [-23.17, 00] 11.22 [-4.75, 32.20] -1.83 [-14.48, 10.83]	CI 1) 1) 1) 1) 1) 1) -200	V. Fred. 955	CI	

Fig. 4 Subgroup analysis of 10 MWT and 6 MWT. SCI patients were treated by REGT compared with CPT starting at the early stage or above 6 months after SCI assessing 10 MWT (**A**) and 6 MWT (**B**); utilizing different kind of robotic exoskeleton, Lokomat or exoskeleton assessing 10 MWT (**C**) and 6 MWT (**D**)

# Discussion

This meta-analysis aims to explore the effectiveness of lower limb robotic exoskeletons in rehabilitation training for patients with SCI. Our meta-analysis results indicate that REGT intervention can better regulate the balance of patients with spinal cord injury compared to CPT. The post-injury walking motor function scores of patients, including TUG, WISCI-II and LEMS, showed significant improvement, and the FEV1 index of respiratory function was significantly enhanced. When analyzing the walking speed (10 MWT) and walking distance (6 MWT) results of rehabilitation training for patients with spinal cord injury, there was no significant difference between the REGT and CPT groups, indicating that the results were equivalent. In subgroup analysis, it was found that patients who began robotic exoskeleton gait training within 6 months after spinal cord injury did not show a significant difference in walking speed and distance compared to those who underwent traditional physical therapy. However, for patients with chronic spinal cord injury who started rehabilitation training after 6 months, conventional physical therapy was found to be more beneficial in improving walking speed. These results suggests that REGT can enhance the recovery of walking balance, muscle strength of lower limbs, and pulmonary function in patients with spinal cord injury. In terms of motor function recovery of SCI patients, robotic exoskeletonassisted training may be considered, while we recommend combining REGT with CPT to better improve the walking speed recovery in patients with spinal cord injuries in the medium to long term.

Through the results of meta-analysis, we have found that REGT does not have a significant effect on improving patients' walking speed compared to CPT. What is even more surprising is that CPT has greater advantages for patients' walking speed with spinal cord injuries over 6 months. However, for patients injured within 6 months, REGT has the same effect as CPT. Combining the improvement results of REGT on gait and SCI-related scores, we conclude that for patients with diagnosis of SCI (Injury within 6 months), both REGT and CPT can improve the patient's walking speed and distance. Moreover, REGT can also enhance strength of lower limbs and walking balance. For the length of complication duration above 6 months after SCI, it is recommended to consider traditional treatment methods or a combination of robotic exoskeletons and traditional rehabilitation approaches. The 10-m walk test (10MWT) is primarily used to measure the fastest speed at which a 10-m walk can be completed. A result of less than 0.94m/s often indicates a lack of walking ability [37]. Traditional upright walking transfer training poses significant challenges for



Fig. 5 Forest plots for REGT compared with CPT in walking stability assessing TUG (A) and functional scores using the WISCI-II (B) and LEMS (C)

both patients and therapists in the early stages of spinal cord injury. In order to maintain an upright position, it usually requires the assistance of at least two therapists and sometimes the cooperation of family members, making the training inconvenient. The emergence of REGT addresses these limitations. REGT simulates the physiological walking mode and provides body weight support, freeing the therapist's hands. This makes early upright walking transfer training for spinal cord injuries easier to implement. Existing research suggests that nerves exhibit stronger self-repair ability and plasticity in the early stages of injury [38–40], allowing patients to receive more physiological walking transfer training during this period. This may enable nerve remodeling according to our expectations of the desired pattern. For patients with spinal cord injuries lasting longer than 6 months, additional physical stimulation and training may be necessary.

According to the results of a meta-analysis, REGT has been found to improve the walking balance of patients with spinal cord injury. The Timed Up and Go (TUG) test is commonly used to evaluate the overall multi-task mobility score [41]. The analysis revealed that REGT had a significantly higher score than CPT in this test, indicating that REGT improves the patient's center of gravity shift and overall balance after robotic exoskeleton training, leading to improved walking balance. Recent research [42] also suggests that actively controlling the abnormal swing of the trunk core can effectively enhance the movement balance of patients with spinal cord injuries, who often face difficulties in walking. Patients with SCI face difficulties in controlling sideways movement during walking, which makes it challenging to position the foot in the mediolateral direction [43]. Additionally, they experience limitations in expanding their stability boundaries after being disturbed, and it requires significant metabolic energy to stabilize sideways motion while walking [44]. In comparison to adults of the same age without spinal cord injury, patients who do not use assistive devices exhibit greater lateral deflection of the center of mass when walking at higher speeds [45]. In the field of training using robotic exoskeletons, patients with spinal cord injuries can reduce the abnormal swing of the body's trunk, thereby providing a more stable foothold for walking [46]. This helps in reducing the swing of the trunk core in the sagittal plane and lessens the need for patients to exert energy and psychological stress in

		F	REGT		CPT		Mean	Difference	Mean	Difference			R	EGT		CPI	r -		Mean Difference		Mean D	interence		
	Study or Subgroup	Mean	SD To	tal Mean	SD	Total We	inht IV Ra	indom 95% Cl	IV Ran	dom 95% Cl		Study or Subgroup	Mean	SD To	tal Me	an S	SD Tota	I Weight	IV. Fixed, 95% C		IV. Fixe	d. 95% CI		_
•	2 E 4 dC mantha	moun	00 13	in in con		10101 110					D	2.7.1 <6 months												
А	2.5.1 ×6 monuts										D	Alcohendas-Maestro M 2012	7	9.56	37	5 8.	47 3	R 3.3%	2 00 [-2 09 6 09]	1	-	·		
	Alcobendas-Maestro, M 2012	12	6.74	37 5	5.14	38 9	9.9% 7.0	00 [4.28, 9.72]				Esclario Ruz A 2014 (a)	9 22	10.5	21 5	28 10	07 2	1 1 29/	3 05 [ 3 44 9 54]		_		_	
	Cinar, C 2021	2.6	3.4	17 1.6	1.8	20 14	1.8% 1.0	0 [-0.80, 2.80]		+		Esclarin Ruz, A 2014 (a)	0.00	10.5	20 0.	E7 10.	20 2	4 4 90/	3.00[-0.44, 0.04]		_			
	Esclarin-Ruz A 2014 (a)	7.57	5 17	21 6 14	4.62	21 8	14	3 [-1 54 4 40]				Cil Asuda A 2002	0.15	6.97	20 23	3/ 10.	00 Z	1 1.3%	3.56 [-2.66, 10.04]		_	<b></b>		
	Esclarin Duz A 2014 (b)	0 45	2 70	20 50	4.10	24 4	1.00 0.0	5 [ 1.04, 4.40]	-	<b></b>		GII-Agudo, A 2023	4.45	5.37	11	3 23	00 1	J 4.4%	1.45 [-2.13, 5.03]				_	
	Escialin-Ruz, A 2014 (0)	0.43	3.70	20 5.0	4.10	21 1	1.2% 0.0	io [-1.79, 5.09]				Shin, JC 2014	0	3.33	2/	4 13.	33 2	5 1.1%	2.00 [-5.18, 9.18]					
	Gil-Agudo, A 2023	3.54	2.65	11 0.7	1.49	10 14	1.7% 2.8	84 [1.02, 4.66]				Tsai, C 2024	15.4	11.9	16 e	5.3 E	5.2 1	2 1.2%	9.10 [2.30, 15.90]	1				
	Shin, JC 2014	8	12.59	27 5	14.81	26 2	2.1% 3.00	[-4.41, 10.41]				Subtotal (95% CI)		1	32		120	5 12.6%	2.76 [0.66, 4.86]			-		
	Yildirim, M 2019	4	8.19	44 1.5	6.03	44 8	3.8% 2.5	0 [-0.51, 5.51]		+		Heterogeneity: Chi <sup>2</sup> = 4.10, df =	= 5 (P = 0.	54); l² = 0	%									
	Subtotal (95% CI)		1	77		180 7	14% 2.5	52 [0 89 4 15]		•		Test for overall effect: Z = 2.58	(P = 0.01)	))										
	U				001/			Terest unel		-														
	Heterogeneity: Tau* = 2.78; Ch	I <sup>*</sup> = 15.97	, at = ь (P	= 0.01); I*	= 62%							2.7.2 ≥6 months												
	Test for overall effect: Z = 3.03	(P = 0.00	2)									Cheung, EYY 2019	1	5.52	8 0	0.6 8.	79 ;	B 1.1%	0.40 [-6.79, 7.59]	1				
												Field-Fote, EC 2011 (a)	2.5	4.2	4 2	2.8 3	3.3 1	5 2.8%	-0.30 [-4.74, 4.14]			-		
	2.5.2 ≥6 months											Field-Fote EC 2011 (b)	2.5	42	5 3	31 4	1 1	8 3.3%	-0.60 [-4.74 3.54]			+-		
	Chauna EVV 2010	47	4.05	0 0 1	2.60		00 10	01040 500	-			Field-Fote EC 2011 (c)	2.5	4.2	5 1	12 3	1	7 3 5%	-0 70 [-4 72 3 32]		_	<u> </u>		
	Cileuly, ETT 2019	1.7	4.00	0 0.1	2.09	0 0	3.0% 1.0	0 [-2.12, 0.32]				Meder M 2020	1.0	1 66	15 0		77 1	5 70 70/	1 20 10 22 2 001					
	Midik, M 2020	3.9	0.8	15 2.5	0.5	15 23	3.0% 1.4	40 [0.92, 1.88]				MIGIK, M 2020	1.0	1.55	7 0	.0 0.		0 0 000	1.20 [0.32, 2.00]				_	
	Subtotal (95% CI)			23		23 2	9.6% 1.4	10 [0.93, 1.88]		•		PIIRA, A 2019	5.4	5		J.Z 4	1.0 1.	2 2.8%	5.20 [0.71, 9.69]				_	
	Heterogeneity: Tau <sup>2</sup> = 0.00: Ch	i <sup>2</sup> = 0.01.	df = 1 (P =	: 0.92); l <sup>2</sup> :	= 0%							Wu, M 2018	-0.4	13.17	8 -0	).7 4.9	99	8 0.6%	0.30 [-9.46, 10.06]					
	Test for overall effect: 7 = 5.81	(P < 0.00	001)									Xiang, X 2021	1	11.34	9	0 8.	15	9 0.7%	1.00 [-8.12, 10.12]					
		(1 - 0.00	001)									Subtotal (95% CI)			61		102	2 87.4%	1.12 [0.32, 1.92]			•		
												Heterogeneity: Chi <sup>2</sup> = 5.11, df =	= 7 (P = 0)	35); I² = 0	%									
	Total (95% CI)		2	00		203 10	0.0% 2.1	7 [1.05, 3.29]		<b>•</b>		Test for overall effect: Z = 2.74	(P = 0.000	5)										
	Heterogeneity: Tau <sup>2</sup> = 1.35; Ch	i <sup>2</sup> = 19.13	, df = 8 (P	= 0.01); l <sup>2</sup>	= 58%			-			_													
	Test for overall effect: 7 = 3.81	(P = 0.00)	01)						-10 -5	0 5 10		Total (95% CI)		1	93		23	0 100.0%	1.33 [0.58, 2.07]			•		
	Tast for subarous differences	Chil = 1.6	6 df = 1 ()	P = 0.20)	12 - 30 79	Ĺ			Favours [CP	T] Favours [REGT]		Heterogeneity: Chi2 = 11.26, df	= 13 (P =	0.59); l <sup>2</sup> =	= 0%							-	-	-
	reactor aubgroup differences.	0111 - 1.0	0, 01 - 1 (	- 0.20),	- 33.17	•						Test for overall effect: Z = 3.48	(P = 0.00)	)5)						-20	-10	0	10 2	20
																					Favours [CP1]	Favours	[REGT]	
												Test for subgroup differences: (	Chi <sup>z</sup> = 2.08	5 df = 1 ()	P = 0.15	$1^2 = 5^2$	1.4%							
												Test for subgroup differences: 0	Chi <sup>2</sup> = 2.0	5, df = 1 (l	P = 0.15	), l² = 5 <sup>.</sup>	1.4%							
		F	EGT		СРТ		Mean	Difference	Mean	Difference		Test for subgroup differences: 0	Chi <sup>2</sup> = 2.0	5, df = 1 (l EGT	P = 0.15	), I <sup>2</sup> = 5 <sup>.</sup> CPT	1.4%		Mean Difference		Mean Di	fference		
	Study or Subgroup	Maan	EGT	tal Moan	CPT	Total We	Mean	Difference	Mean	Difference		Test for subgroup differences: 0	Chi <sup>z</sup> = 2.0i R Mean	5, df = 1 (l EGT SD To	P = 0.15	), I <sup>2</sup> = 5 <sup>-</sup> CPT an S	1.4% D Tota	Weight	Mean Difference IV. Fixed, 95% C		Mean Di IV. Fixed	fference 1. 95% Cl		_
	Study or Subgroup	F Mean	EGT SD To	tal Mean	CPT SD	Total We	Mean right IV, Ra	Difference Indom, 95% Cl	Mean IV. Ran	Difference Idom. 95% Cl		Test for subgroup differences: 0 <u>Study or Subgroup</u> 2.8.1 Lokomat	Chi <sup>z</sup> = 2.0i R Mean	5, df = 1 (l EGT <u>SD To</u>	P = 0.15 tal_Mea	), I <sup>2</sup> = 5 <sup>-</sup> CPT an S	1.4% 5 5D Tota	Weight	Mean Difference IV. Fixed. 95% C	1	Mean Di IV. Fixed	fference 1.95% Cl		_
C	<u>Study or Subgroup</u> 2.6.1 Lokomat	F Mean	EGT SD To	ital Mean	CPT SD	Total We	Mean hight IV. Ra	Difference Indom, 95% Cl	Mean IV. Ran	Difference dom, 95% Cl	— r	Test for subgroup differences: 0	R R Mean 7	5, df = 1 (l EGT <u>SD To</u> 9.56	P = 0.15 tal_Mea 37	), I <sup>2</sup> = 5 <sup>-</sup> CPT an S 5 8.4	1.4% 5 <u>D Tota</u> 47 38	Weight 3.3%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09]	1	Mean Di IV. Fixed	fference 1.95% CI		_
С	<u>Study or Subgroup</u> 2.6.1 Lokomat Alcobendas-Maestro, M 2012	F Mean 12	EGT SD To 6.74	<u>ital Mean</u> 37 5	CPT SD 5.14	Total We	Mean Hight IV. Ra	Difference Indom, 95% Cl 00 [4.28, 9.72]	Mean IV. Ran	Difference dom. 95% Cl	— c	Test for subgroup differences: ( 	Chi <sup>2</sup> = 2.0 R <u>Mean</u> 7 1	5, df = 1 (l EGT <u>SD To</u> 9.56 5.52	P = 0.15 tal Mea 37 8 0	), I <sup>2</sup> = 5 <sup>-</sup> CPT an S 5 8.4 1.6 8.7	1.4% 5 <u>D Tota</u> 47 38 79 8	Weight 3.3% 3.1.1%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59]	1	Mean Di IV. Fixer	fference 1.95% Cl		_
С	Study or Subgroup 2.6.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019	F Mean 12 1.7	EGT SD To 6.74 4.65	<u>tal Mean</u> 37 5 8 0.1	CPT SD 5.14 2.69	<u>Total We</u> 38 9 8 6	Mean hight IV. Ra 9.9% 7.0 5.6% 1.6	Difference indom, 95% Cl 00 [4.28, 9.72] i0 [-2.12, 5.32]	Mean IV. Ran	Difference dom. 95% Cl	C	Test for subgroup differences: ( 	R Mean 7 1 8.33	5, df = 1 (l EGT <u>SD To</u> 9.56 5.52 10.5	P = 0.15 tal Mea 37 8 0 21 5.2	), I <sup>2</sup> = 5 <sup>-</sup> CPT an S 5 8.4 1.6 8.7 28 10.9	1.4% 5 <u>D Tota</u> 47 38 79 8 97 21	3.3% 3.1.1% 1.3%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54]	1	Mean Di IV. Fixer	fference 1.95% Cl		_
С	Study or Subgroup 2.6.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021	Mean 12 1.7 2.6	6.74 4.65	tal Mean 37 5 8 0.1	CPT SD 5.14 2.69	<u>Total We</u> 38 9 8 6	Mean hight IV. Ra 9.9% 7.0 5.6% 1.6 1.8% 1.0	Difference indom, 95% Cl 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.80, 2.80]	Mean IV. Ran	Difference dom. 95% Cl	C	Test for subgroup differences: ( 	Chi <sup>2</sup> = 2.0 R <u>Mean</u> 7 1 8.33 6.15	5, df = 1 (l EGT <u>SD To</u> 9.56 5.52 10.5 0.72	P = 0.15 tal Mea 37 8 0 21 5.1 20 2.5	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3	1.4% 5 <u>D Tota</u> 47 38 79 8 97 21 38 21	Weight 3.3% 1.1% 1.3% 1.3%	Mean Difference IV, Fixed, 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04]	1	Mean Di IV. Fixer	fference 1. 95% Cl		_
С	Study or Subgroup 2.6.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Erelerie Pur & 2014 (a)	Mean 12 1.7 2.6 7.67	6.74 4.65 3.4	tal Mean 37 5 8 0.1 17 1.6	CPT SD 5.14 2.69 1.8	Total We 38 9 8 6 20 14	Mean <u>iight IV. Ra</u> 9.9% 7.0 3.6% 1.6 4.8% 1.0 9.9% 1.4	Difference indom, 95% Cl 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.80, 2.80] 2 14 54 400	Mean IV. Ran 	Difference dom. 95% Cl	C	Test for subgroup differences: ( 	Chi <sup>2</sup> = 2.0 R <u>Mean</u> 7 1 8.33 6.15 2.5	5, df = 1 (l EGT <u>SD To</u> 9.56 5.52 10.5 10.72 4.2	P = 0.15 tal Mea 37 8 0 21 5.1 20 2.5 4 2	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3	1.4% 5D Tota 47 38 79 8 97 21 38 21 38 21	Weight 3.3% 1.1% 1.3% 1.3% 5.2.8%	Mean Difference <u>IV. Fixed. 95% C</u> 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 4.14]	1	Mean Di IV. Fixer	fference 1. 95% Cl		_
С	Study or Subgroup 2.6.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a)	Mean 12 1.7 2.6 7.57	6.74 4.65 3.4 5.17	tal Mean 37 5 8 0.1 17 1.6 21 6.14	CPT SD 5.14 2.69 1.8 4.62	Total We 38 9 8 6 20 14 21 8	Mean ight IV. Ra 9.9% 7.0 3.6% 1.6 4.8% 1.0 3.9% 1.4	Difference indom, 95% Cl 00 [4.28, 9.72] 00 [-2.12, 5.32] 00 [-0.80, 2.80] 33 [-1.54, 4.40]	Mean IV. Ran -	Difference dom, 95% Cl	C	Test for subgroup differences: 0 <u>Study or Subgroup</u> 2.8.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (a) Field-Fote, EC 2011 (b)	R Mean 7 1 8.33 6.15 2.5 2.5	5, df = 1 (l EGT <u>SD To</u> 9.56 5.52 10.5 10.72 4.2 4.2	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3 1.1 4	1.4% D Tota 47 38 79 8 97 21 38 21 38 21 3 15 1 18	Weight 3.3% 1.1% 1.3% 1.3% 5.2.8% 3.3%	Mean Difference <u>IV. Fixed. 95% C</u> 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 3.54]	1	Mean Di IV. Fixe	fference 1. 95% Cl 		_
С	Study or Subgroup 26.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b)	Mean 12 1.7 2.6 7.57 6.45	6.74 4.65 3.4 5.17 3.78	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8	CPT SD 5.14 2.69 1.8 4.62 4.18	Total We 38 9 20 14 21 8 21 1	Mean ight IV. Ra 9.9% 7.0 9.9% 7.0 9.9% 7.0 1.6% 1.0 1.8% 1.0 3.9% 1.4 1.2% 0.6	Difference indom, 95% Cl 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.80, 2.80] 3 [-1.54, 4.40] 5 [-1.79, 3.09]	Mean IV. Rar -	Difference	C	Test for subgroup differences: ( <u>Study or Subgroup</u> 2.8.1 Lokomat ) Acobendas-Meestro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (a) Field-Fote, EC 2011 (b) Field-Fote, EC 2011 (c)	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5	5, df = 1 (l EGT <u>SD To</u> 9.56 5.52 10.5 10.72 4.2 4.2 4.2	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 5 3	), I <sup>2</sup> = 5' CPT 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3 1.1 4 1.2 3	1.4% 5D Tota 5D Tota 579 8 597 21 38 21 38 21 38 315 1 18 4 17 4 17	Weight 3 3.3% 3 1.1% 1.3% 1.3% 5 2.8% 5 3.3% 7 3.5%	Mean Difference <u>IV. Fixed. 95% C</u> 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 4.14] -0.60 [-4.74, 3.54] -0.70 [-4.72, 3.32]	1	Mean Di IV. Fixer	fference d. 95% Cl		_
С	Study or Subgroup 2.6.1 Lokomat Acobendas-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (b) Midik, M 2020	Mean 12 1.7 2.6 7.57 6.45 3.9	EGT 5D Tc 6.74 4.65 3.4 5.17 3.78 0.8	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5	CPT 5.14 2.69 1.8 4.62 4.18 0.5	Total We 38 9 20 14 21 8 21 11 15 23	Mean ight IV. Ra 9.9% 7.0 9.9% 7.0 9.9% 1.6 1.8% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4	Difference indom, 95% CI 00 [4.28, 9.72] 00 [-2.12, 5.32] 00 [-0.80, 2.80] 3 [-1.54, 4.40] 5 [-1.79, 3.09] 40 [0.92, 1.88]	Mean IV. Rar - -	Difference dom. 95% Cl	C	Test for subgroup differences: 0 <u>Study or Subgroup</u> 2.8.1 Lokomat D. Acobendas-Maestro, M. 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c)	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 1.8	6, df = 1 (l EGT 9.56 5.52 10.5 10.5 10.72 4.2 4.2 4.2 4.2 1.55	P = 0.15 tal Mer 37 8 0 21 5.3 20 2.8 4 2 5 3 15 0	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3 1.1 4 1.2 3 1.6 0.7 1.6 0.7	1.4% 5 <u>D Tota</u> 47 38 79 8 97 21 38 21 38 21 38 21 38 15 4 1 18 4 1 77 15	Weight 3 3.3% 3 1.1% 1.3% 1.3% 5 2.8% 3 3.5% 5 72.7%	Mean Difference <u>IV. Fixed. 95% C</u> 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 4.14] -0.70 [-4.72, 3.32] 1.20 [0.32, 2.08]	1	Mean Di IV. Fixer 	fference d. 95% Cl		_
С	Study or Subgroup 2.6.1 Lokomat Alcobendas-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Midik, M 2020 Shin, JC 2014	12 1.7 2.6 7.57 6.45 3.9 8	EGT 5D Tc 6.74 4.65 3.4 5.17 3.78 0.8 12.59	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81	Total We 38 9 20 14 21 8 21 1 15 23 26 2	Mean ight IV. Ra 3.9% 7.0 3.6% 1.6 8.8% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4 2.1% 3.00	Difference indom. 95% Cl 00 [4.28, 9.72] 00 [-2.12, 5.32] 00 [-0.80, 2.80] 33 [-1.54, 4.40] 15 [-1.79, 3.09] 40 [0.92, 1.88] [-4.41, 10.41]	Mean IV. Ran - - -	Difference dom. 95% Cl	C	Test for subgroup differences: ( <u>Study or Subgroup</u> 2.8.1 Lokomat Acobendas-Mesetro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Midik, M 2020 PIRA, A 2019	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 1.8 5.4	6, df = 1 (f EGT 9.56 5.52 10.5 10.7 4.2 4.2 4.2 4.2 1.55 5	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 15 0 7 0	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.5 57 10.3 1.8 3 1.1 4 1.2 3 1.6 0.7 1.2 4	1.4% 5 <u>D Tota</u> 47 38 79 8 97 21 38 21 38 21 38 21 38 21 38 1 4 37 18 5 5 12	Weight 3 3.3% 3 1.1% 1.3% 1.3% 4 2.8% 3 .3% 5 72.7% 2.8%	Mean Difference IV. Fixed, 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 3.54] -0.60 [-4.72, 3.32] 1.20 [0.32, 2.08] 5.20 [0.71, 9.69]	1	Mean Di IV. Fixer 	fference <u>J. 95% Cl</u> 		
С	Study or Subgroup 2.6.1 Lokomat Acobendas-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Midik, M 2020 Shin, JC 2014 Subtotal (95% CI)	12 1.7 2.6 7.57 6.45 3.9 8	EGT 5D To 6.74 4.65 3.4 5.17 3.78 0.8 12.59	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81	Total         We           38         9           8         6           20         14           21         8           21         11           15         22           149         7	Mean ight IV. Ra 3.9% 7.0 3.6% 1.6 3.6% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4 2.1% 3.00 2.1% 3.00	Difference Indom. 95% Cl. 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.80, 2.80] 3 [-1.54, 4.40] 5 [-1.79, 3.09] 40 [0.92, 1.88] 1 [-4.41, 10.41] 1 [-4.41, 10.41]	Mean IV. Ran - - -	Difference dom. 95% Cl	C	Test for subgroup differences: ( <u>Study or Subgroup</u> 2.8:1 Lokomat Acobends-Matrio, M. 2012 Generative Ray, A 2014 (a) Exclamine, Ray, A 2014 (b) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Mids, M. 2020 PIRA, A 2019	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 1.8 5.4 6	6, df = 1 (f EGT 9.56 5.52 10.5 10.72 4.2 4.2 4.2 1.55 5 3.33	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 15 0 7 0 27	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.5 57 10.3 1.8 3 1.1 4 1.2 3 1.6 0.7 1.2 4 4 13.3	1.4% 50 Tota 50 Tota 50 Tota 50 Tota 50 Tota 50 Tota 50 Tota 51 Tota 52 Tota 53 Tot	Weight 3 3.3% 4 1.1% 1.3% 5 2.8% 3 3.3% 5 2.8% 5 1.1% 5 1.3% 5 1.1% 5 1.3% 5 1.1% 5 1.3% 5 1.3%	Mean Difference <u>IV. Fixed. 95% C</u> 2.00 [-2.09, 6.09] 0.40 (-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 (-4.74, 3.54] -0.60 [-4.74, 3.54] 1.20 [0.32, 2.08] 5.20 [0.71, 9.69] 5.20 [0.71, 9.69]	1	Mean Di 	fference J. 95% Cl		
С	Study or Subgroup 2.6.1 Lokomat Alcobendas-Maestro, M 2012 Cheng, EY 2019 Char, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Midik, M 2020 Shih, JC 2014 Subtotal (6%); Cl)	F Mean 12 1.7 2.6 7.57 6.45 3.9 8	EGT <u>SD</u> To 6.74 4.65 3.4 5.17 3.78 0.8 12.59 1 df = 6 (B)	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 - 0.010	CPT SD 5.14 2.69 1.8 4.62 4.18 0.5 14.81 R = 64%	Total         We           38         5           8         6           20         14           21         8           21         17           15         23           26         2           149         7	Mean ight IV. Ra 3.9% 7.0 3.6% 1.6 4.8% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4 2.1% 3.00 5.5% 2.0	Difference Indom, 95% C1 00 [4.28, 9, 72] 10 [-2.12, 5.32] 10 [-0.80, 2.80] 3 [-1.54, 4.40] 15 [-1.79, 3.09] 40 [0.92, 1.88] 1 [-4.41, 10.41] 15 [0.63, 3.47]	Mean IV. Ran - - -	Difference dom. 95% Cl	C	Test for subgroup differences: ( <u>Study or Subgroup</u> 2.8.1 Lokomat Acobendas-Mesetro, M 2012 Cheung, EYY 2019 Esclarin-Ruz, A 2014 (b) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Field-Fote, EC 2011 (c) Midik, M 2020 Shin, JC 2014 Wu, M 2018	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4	6, df = 1 (l EGT 9.56 5.52 10.5 10.5 10.72 4.2 4.2 4.2 1.55 5 3.33 3.17	P = 0.15 tal Mer 37 8 0 21 5.3 20 2.4 4 2 5 3 5 3 15 0 7 0 27 8 -0	),   <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3 1.1 4 1.2 3 1.6 0.7 1.2 4 4 13.3 1.7 4.9	1.4% 50 Tota 47 38 79 8 97 21 38 21 38 21 38 21 1 18 1 18 1 18 1 18 1 18 1 19 1 2 3 26 99 8	Weight 3 3.3% 5 1.1% 1.3% 5 2.8% 5 3.3% 7 3.5% 5 72.7% 2 2.8% 5 1.1% 8 0.6%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 4.14] -0.30 [-4.74, 3.54] -0.70 [-4.72, 3.32] 1.20 [0.32, 9.64] 5.20 [0.71, 9.69] 2.00 [-5.18, 9.18] 5.20 [-5.18, 9.18]	1	Mean Di 	fference 1.95% Cl		
С	Study or Subgroup 2.6.1 Lokomat Alcobendiar-Maetro, M 2012 Chang, EYY 2019 Chang, 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Midik, M 2020 Shin, J.C 2014 Subtotal (95% CI) Heterogeneity, Tau <sup>2</sup> = 1,91; Ci	Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>2</sup> = 16.82	EGT <u>SD</u> To 6.74 4.65 3.4 5.17 3.78 0.8 12.59 1 off = 6 (P	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010);	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 P = 64%	Total         We           38         9           20         14           21         8           21         11           15         22           26         2           149         70	Mean i ight IV. Ra 3.9% 7.0 3.6% 1.6 4.8% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4 2.1% 3.00 5.5% 2.0	Difference Indom, 95% CI 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.80, 2.80] 3 [-1.54, 4.40] 5 [-1.79, 3.09] 40 [0.92, 1.88] 40 [0.92, 1.88] 10 [-4.41, 10.41] 15 [0.63, 3.47]	Mean IV. Rar - - -	Difference dom. 95% Cl	C	Test for subgroup differences: C <u>Study or Subgroup</u> 2.8.1 Lokomat Accoendia-Massio, M 2012 Cheng, EY 2019 Eclamon-Rux, 2014 (b) Friek-Foh, EC 2011 (c) Friek-Foh, EC 2	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4	6, df = 1 (l EGT 9.56 5.52 10.5 10.5 10.5 10.5 10.5 1.55 5 3.33 3.17 1	P = 0.15 tal Mor 37 8 0 21 5.3 20 2.4 4 2 5 3 15 0 7 0 27 8 -0 57	),   <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 2.8 3 1.1 4 1.2 3 1.6 0.7 1.2 4 1.2 3 1.6 0.7 1.2 4 1.3 3 1.1 4 1.2 3 1.6 0.7 1.2 4 1.2 3 1.6 0.7 1.2 4 1.2 3 1.1 4 1.2 3 1.1 4 1.2 3 1.1 4 1.2 3 1.1 4 1.2 4	1.4% 5D Tota 5D Tota 579 6 579 21 58 21 538 21 53 15 51 12 55 12 53 26 599 6 199 199	Weight           3         3.3%           1.1%         1.3%           1.3%         3.3%           3.3%         3.3%           3.3%         3.5%           7         2.8%           5         1.1%           6         0.6%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] 0.30 [-4.74, 3.54] 1.20 [0.32, 2.08] 5.20 [0.71, 9.69] 5.20 [0.71, 9.69] 5.20 [0.71, 9.69] 5.20 [0.74, 9.14] 1.22 [0.45, 1.99]	1	Mean Di IV. Fixer	fference 1.95% Cl 		
С	Study or Subgroup 2.6.1 Lokomat Accberidas-Maestro, M2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Midik, M 2020 Shin, J.C 2014 Subical (495K CI) Helerogeneity, Tau' = 1.91; CT rest for overall effect. Z = 2.83	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>2</sup> = 16.82 (P = 0.00	EGT 6.74 4.65 3.4 5.17 3.78 0.8 12.59 1 , df = 6 (P 5)	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010);	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 I <sup>2</sup> = 64%	Total         We           38         8           20         14           21         8           21         17           15         23           26         2           149         70	Mean iight IV. Ra 3.9% 7.0 3.6% 1.6 3.8% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4 2.1% 3.00 5.5% 2.0	Difference Indom, 95% Cl 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.80, 2.80] 3 [-1.54, 4.40] 5 [-1.79, 3.09] 40 [0.92, 1.88] 1 [-4.41, 10.41] 15 [0.63, 3.47]	Mean IV. Ran - - -	Difference dom. 95% Cl	[	Test for slugaroup differences: C <u>Study or Subgroup</u> 2.8.1 Lekomat Accobendas-Massitor, M.2012 Exclarin-Ruz, A 2014 (a) Exclarin-Ruz, A 2014 (a) Exclarin-Ruz, A 2014 (a) Friek-Febe, EC 2011 (a) Friek-Febe, EC 2011 (b) Friek-Febe, EC 2011 (c) Friek-Febe, EC 2011 (c) Friek-Feb, EC 2011 (c) Frie	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 * 1.0 (P = 0	6, df = 1 (l EGT 9.56 5.52 10.5 10.72 4.2 4.2 4.2 1.55 5 3.33 3.17 1 .80);   <sup>2</sup> = 1	P = 0.15 tal Mor 37 8 0 21 5.3 20 2.4 4 2 5 3 15 0 7 0 27 8 -0 57 0%	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3 1.1 4 1.2 3 1.6 0.7 1.2 4 4 13.3 1.7 4.9	1.4% 5D Tota 5D Tota 579 8 797 21 38 21 39 21 39 21 39 21 39 21 30 21	Weight 3 3.3% 3 1.1% 1.3% 5 2.8% 3.3% 5 2.8% 5 72.7% 5 72.7% 5 72.7% 5 72.7% 5 0.6% 9 3.8%	Mean Difference IV. Fixed, 95% C 2.00 [-2.09, 6.09] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 4.14] -0.30 [-4.74, 3.54] -0.70 [-4.74, 3.54] -0.70 [-4.74, 3.54] -0.70 [-9.78, 9.18] 5.20 [0.71, 9.69] 5.20 [0.71, 9.69] 0.30 [-9.46, 10.06] 1.22 [0.45, 1.99]	1	Mean Di IV. Fixer 	fference 1.95% Cl 		
С	Study or Subaroup 2.6.1 Lokomat Accoendia-Maestro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Micki, M 2020 Shih, JC 2014 Subtotal (8% C1) Heterogeneity: Tau <sup>2</sup> = 1.91; C1 Test for overall effect: Z = 2.83	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 8 I <sup>P</sup> = 16.82 (P = 0.00	SD         Tc           6.74         4.65           3.4         5.17           3.78         0.8           12.59         1           , df = 6 (P           5)	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010);	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81   <sup>2</sup> = 64%	Total         We           38         8           20         14           21         8           21         15           21         12           15         23           16         2           149         7	Mean ight IV. Ra 3.9% 7.0 3.6% 1.6 8.8% 1.0 9.9% 1.4 1.2% 0.6 3.0% 1.4 1.2% 0.6 3.00 5.5% 2.0	Difference (ndom, 95% Cl 00 [4.28, 9.72] 00 [-2.2, 5.32] 00 [-0.80, 2.80] 3 [-1.54, 4.40] 5 [-1.79, 3.09] 40 [0.92, 1.88] 40 [0.92, 1.88] 15 [0.63, 3.47]	Mean IV. Ran - - -	Difference dom, 95% Cl	C	Test for subgroup differences: C <u>Study or Subgroup</u> <u>2.8.1 Lokoma</u> <u>Alcobendas-Maseto</u> , M. 2012 <u>Esclaten-Ruz</u> , A 2014 (a) <u>Esclaten-Ruz</u> , A 2014 (b) <u>Field-Fola</u> , EC 2011 (b) <u>Field-Fola</u> , EC 2011 (c) <u>Mick</u> , M. 2020 <u>Field-Fola</u> , EC 2011 (c) <u>Mick</u> , M. 2020 <u>Stim</u> , J. 2019 <u>Stim</u>	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 * 10 (P = 0.000 (P = 0.000)	6, df = 1 (l EGT 9.56 5.52 10.5 10.72 4.2 4.2 4.2 1.55 5 3.33 3.17 1 .80); l <sup>2</sup> = l	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 15 0 7 0 27 8 -0 57 0%	), I <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3 1.1 4 1.2 3 1.6 0.7 1.2 4 4 13.3 1.7 4.9	1.4% 5D Tota 5D Tota 47 38 79 8 97 21 38 21 38 21 38 21 38 21 38 21 38 21 38 21 38 21 5 12 39 8 199	Weight 3.3% 1.1% 1.3% 1.3% 3.3% 3.5% 7.2.7% 2.8% 5.1.1% 5.0.6% 93.8%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [6.79, 7.59] 3.05 [-3.44, 9.54] 3.05 [-3.44, 9.54] 0.30 [4.74, 4.14] 0.30 [4.74, 2, 3.32] 1.20 [0.32, 2.08] 2.20 [-5.18, 9.18] 0.30 [-9.46, 10.06] 1.22 [0.45, 1.99]	1	Mean Di IV. Fixe, 	fference <u>4.95% Cl.</u> 		
С	Study or Subgroup 2.6.1 Lokomat Accbendis-Mastrin, M2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) MdL, M 2020 Shin, J.C 2024 Subtrati (195% CI) Heterogeneity: Tau <sup>2</sup> = 1.91; CT rest for overall effect Z = 2.83 2.6.2 Excekeleton	Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>2</sup> = 16.82 (P = 0.00	6.74 6.74 4.65 3.4 5.17 3.78 0.8 12.59 1 , df = 6 (P 5)	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010);	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81   <sup>2</sup> = 64%	Total         We           38         8           20         14           21         8           21         1           15         23           149         71	Mean ight IV. Ra 2.9% 7.0 5.6% 1.6.6 1.0% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4 1.2% 0.6 3.0% 1.4 1.2% 2.0 5.5% 2.0	Difference Indom, 95% Cl 00 [4.28, 9.72] 01 [-2.12, 5.32] 01 (-0.80, 2.80] 13 [-1.54, 4.40] 15 [-1.79, 3.09] 40 [0.92, 1.88] 14 [-4.41, 10.41] 15 [0.63, 3.47]	Mean IV. Ran - - -	Difference dom. 95% Cl	C	Test for subgroup differences: C - <u>Study or Subgroup</u> . 2.8.1 Lokoma Accoberdia-Massito, M. 2012 Chernig, E.Y. 2016 (a) Ecdain-Nuz, A 2014 (b) Friek-Fole, EC 2011 (c) Friek-Fole, EC 2011 (c) Friek-Fole, EC 2011 (c) Friek-Fole, CO11 (c) Friek-Fole, CO11 (c) Subjects (d) FOL Subjects (d) FOL Subjects (d) FOL Fole, CO11 (c) Friek-Fole, CO11 (c) Friek-Fole, CO11 (c) File, A 2019 Subjects (d) FOL Fole, CO11 (c) Fole, Fole, CO11 (c) Fol	R Mean 7 1 8.33 6.15 2.5 2.5 2.5 1.8 5.4 6 -0.4 1 (P = 0 (P = 0.002)	6, df = 1 (l EGT 9.56 5.52 10.5 10.5 10.72 4.2 4.2 4.2 4.2 1.55 5 3.33 3.17 1 .80);   <sup>2</sup> = 1	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 15 0 7 0 27 8 -0 57 0%	), I <sup>2</sup> = 5 <sup>+</sup> CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 1.8 3 1.6 0.7 1.2 4 4 13.3 1.7 4.9	1.4% 5D Tota 5D Tota 50 Tota 50 Tota 50 Tota 50 Tota 50 Tota 51 Tot	Weight 3 3.3% 1.1% 1.3% 1.3% 5 2.8% 5 3.3% 7 3.5% 5 72.7% 2 2.8% 5 1.1% 9 3.8%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.06 [-3.44, 9.54] 0.30 [-4.74, 4.14] -0.70 [-4.74, 3.54] -0.70 [-4.74, 3.54] -0.70 [-4.72, 3.32] -0.70 [-4.72, 3.32] 2.00 [-5.18, 9.18] 2.00 [-5.18, 9.18] 2.00 [-5.18, 9.18] 1.22 [0.45, 1.99]	1	Mean Di IV. Fixe. 	fference d. 95% Cl.		
С	Study or Subgroup 2.6.1 Lokomat Accoenda-Meastro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Midik, M 2020 Shih, JC 2014 Subtotal (8% CI) Heterogeneity-Tau <sup>2</sup> = 1.91; Cf Test for overail effect: Z = 2.83 2.6.2 Exoskeleton Gi-Auxida A 2023	Mean 12 1.7 2.6 7.57 6.45 3.9 8 P = 16.82 (P = 0.00 3.54	EGT <u>SD Tr</u> 6.74 4.65 3.4 5.17 3.78 0.8 12.59 1 , df = 6 (P 5) 2.65	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010); 11 0.7	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 P = 64% 1.49	Total We 38 8 20 14 21 1 15 22 26 2 149 70 10 14	Mean ight IV. Ra 3.9% 7.0 3.6% 1.6 8.8% 1.0 3.9% 1.4 1.2% 0.6 3.0% 1.4 2.1% 3.00 5.5% 2.0 4.7% 2.6 4.7% 2.6	Difference indom. 95% C1 00 [4.28, 9.72] 01 [-2.12, 5.32] 00 [-8.02, 280] 33 [-1.54, 4.40] 55 [-1.79, 3.09] 40 [0.92, 1.88] 40 [0.92, 1.88] 15 [0.63, 3.47] 84 [1.02, 4.66]	Mean IV. Ran - - -	Difference dom. 95% Cl	C	Test for subgroup differences: C -Study or Subgroup. 2.8.1 Lokomat Accoundus-Messito, M 2012 Chang, EY2019 Esclarin-Ruz, A 2014 (a) Faid-Fois, EC 2011 (a) Faid-Fois, EC 2011 (a) Faid-Fois, EC 2011 (a) Faid-Fois, EC 2011 (b) Mick, M 2020 Faid-Fois, EC 2011 Subtact (PSH-C1) Faid-Fois, E	Chi <sup>2</sup> = 2.04 R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 2 10 (P = 0 (P = 0.002)	6, df = 1 (l EGT 9.56 5.52 10.5 10.5 10.72 4.2 4.2 4.2 1.55 5 3.33 3.17 1.800);   <sup>2</sup> = 1 2)	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 5 3 15 0 7 0 27 8 -0 57 0%	), I <sup>2</sup> = 5 <sup>+</sup> CPT an S 5 8.4 1.6 8.7 28 10.9 57 10.3 8.8 3 1.1 4 1.2 3 1.1 4 1.2 3 1.6 0.7 1.2 4 4 13.3 1.7 4.9	1.4% 5D Tota 5D Tota 47 38 79 8 97 21 38 21 1.3 15 1.1 18 1.4 17 77 15 1.5 12 33 26 99 8 199	Weight 3.3% 1.1% 1.3% 5.2.8% 3.3% 5.2.8%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 3.54] -0.30 [-4.74, 3.54] -0.30 [-4.74, 3.54] -0.30 [-4.74, 3.54] 1.20 [0.32, 2.06] 5.20 [0.71, 9.69] 0.30 [-9.46, 10.06] 1.22 [0.45, 1.99]	1	Mean Di IV. Fixe	fference 1.95% Cl	-	
С	Study or Subgroup 2.6.1 Lokomat Accoentide-Massim, M 2012 Chean, C 2021 Estatini-Ruz, A 2014 (a) Estatini-Ruz, A 2014 (b) Midik, M 2020 Sub-2019/SF 401 Helerogeneity, Tau <sup>2</sup> = 191; Ch Test for overall effect. Z = 28.4 2.6.4 Excession de Company Catégoria, A 2020 Grégoria, A 2020	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 iP = 16.82 (P = 0.00 3.54	SD         Tc           6.74         4.65           3.4         5.17           3.78         0.8           12.59         1           , df = 6 (P         5)           2.65         8.19	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010); 11 0.7 44 15	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 I <sup>2</sup> = 64%	Total         We           38         8           20         14           21         8           21         17           15         26           26         2           149         71           10         14	Mean ight IV. Ra 9.9% 7.( 6.6% 1.6 1.8% 1.0 9.9% 1.4 1.2% 0.6 0.0% 1.4 2.1% 3.00 5.5% 2.0 4.7% 2.6 4.7% 2	Difference indom. 95% C1 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.80, 2.80] 3 [-1.54, 4.40] i5 [-1.79, 3.09] 40 [0.92, 1.88] [-4.41, 10.41] 15 [0.63, 3.47] 84 [1.02, 4.66] 0 [-0.51] 5.51]	Mean IV. Ran - - -	Difference dom 95% C1		Test for subgroup differences: C - <u>Study or Subgroup</u> 2.8.1 Lokomat Accobendas-Messelo, M 2012 Cheng, EYY 2019 () Esclain-Ruz, A 2014 (b) Field-Fole, EC 2011 (e) Field-Fole, EC 2011 (e) Malk, M 2020 Malk, M 2020 Subtratil (9%-C) Heterogeneity: CM <sup>2</sup> = 6.17, df = 1.8.5 Coversid (EZ 2 - 3.11) 2.8.2 Exoskeleton (G-Agudo, Azoz)	Rean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 2 5 (P = 0.002 4.45	6, df = 1 (l EGT 9.56 5.52 10.5 10.72 4.2 4.2 4.2 1.55 5 3.33 3.17 1 .80);   <sup>2</sup> = 1 () 5.37	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 5 3 15 0 7 0 27 8 -0 57 0% 11	<ol> <li>j), l<sup>2</sup> = 5"</li> <li>CPT</li> <li>an</li> <li>S</li> <li>8.4</li> <li>8.7</li> <li>28</li> <li>10.9</li> <li>57</li> <li>10.3</li> <li>1.4</li> <li>1.2</li> <li>3.6</li> <li>0.7</li> <li>4.9</li> <li>1.7</li> <li>4.9</li> <li>3</li> <li>2.6</li> </ol>	1.4% 50 Tota 50 Tota 50 Tota 579 & 57 2 1 58 21 53 22 51 18 51 18 51 18 52 12 53 22 59 & 199 56 10	Use of the second secon	Mean Difference V. Fixed. 95% C 2.00 (-2.09, 6.09) 0.40 (-6.79, 7.59) 3.05 (-3.44, 9.54) 0.30 (-4.74, 4.14) 0.30 (-4.74, 4.14) 0.70 (-4.72, 3.32) 0.71 (-4.72, 3.32) 1.20 [0.32, 2.08] 5.20 [0.71, 9.69] 1.22 [0.45, 1.99] 1.45 [-2.13, 5.03]	1	Mean Di IV. Fixe 	fference 1.95% C1 	-	
С	Study or Subgroup 2.6.1 Lokomat Accobendas-Meastro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Midik, M 2020 Shih, JC 2014 Subtotal (95% CI) Test for overall effect. Z = 2.83 2.6.2 Exoskeleton Gi-Agudo, A 2023 Yidim, M 2019 m	Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>2</sup> = 16.82 (P = 0.00 3.54 4	SD         Tc           6.74         4.65           3.4         5.17           3.78         0.8           12.59         1           , df = 6 (P           5)         2.65           8.19	tal Mean 37 5 8 0.1 17 1.6 21 6.14 21 6.14 25 5.5 27 5 45 = 0.010); 11 0.7 44 1.5 55	CPT SD 5.14 2.69 1.8 4.62 4.18 0.5 14.81 I <sup>2</sup> = 64% 1.49 6.03	Total         We           38         6           20         14           21         11           15         23           149         70           10         14           64         8	Mean Mean 10,9% 1,6%	Difference indom. 95% CI 00 [4.28, 9.72] 00 [-2.12, 5.32] 00 [-2.12, 5.32] 00 [-2.12, 5.32] 10 [-0.80, 2.80] 13 [-1.54, 4.40] 15 [-1.79, 3.09] 40 [0.92, 1.88] 14 [-1.02, 1.86] 15 [-1.02, 4.66] 00 [-0.51, 5.51] 84 [1.02, 4.66]	Mean  V. Rar - - -	Difference dom. 95% Cl	C	Test for subgroup differences: C - Study or Subgroup. 2.8.1 Lokomat Account of Subgroup. 2.8.1 Lokomat Account of Subgroup. Ecidatin-Ruz, A 2014 (a) Ecidatin-Ruz, A 2014 (a) Frield-Free, EC 2011 (a) Fried-Free, EC 2011 (a) Fried-Free, EC 2011 (b) Mick, M 2020 Shin, J.C 2014 Wu, M 2019 Substatl (9%)-Cl) Heterogenetic, Ch <sup>2</sup> = 6.17, d1 = Test for overall effect. Z = 3.11 Cl 2.8.2 Exclusive (a), A 2023 Cl 3.4.2.2.4.2.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1	Rean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 -10 (P = 0 (P = 0.002 4.45 15.4	5, df = 1 (l EGT <u>SD To</u> 9.56 5.52 10.5 10.5 10.5 4.2 4.2 4.2 1.55 (3.33) 3.17 1 .80);   <sup>2</sup> = 1 5 5.37 11.9	P = 0.15 tal Mea 37 8 0 21 5.3 20 2.4 4 2 5 3 5 3 15 0 7 0 27 8 -0 57 0% 11 16 6	),   <sup>2</sup> = 5' CPT an S 5 8.4 1.6 8.7 28 10.5 57 10.3 1.8 3 1.1 4 4.2 3 1.6 0.7 1.2 4 4 13.3 1.7 4.9 3 2.6 3 2.6 3 6	1.4% 50 Tota 50 Tota 50 Tota 57 2 1 58 21 53 25 51 12 53 26 59 8 199 56 10 56 10 56 10 56 10 56 10 56 10 57 12 58 21 59 5 50 10 50 10	<ul> <li>Weight</li> <li>3.3%</li> <li>1.1%</li> <li>1.3%</li> <li>2.8%</li> <li>3.3%</li> <li>2.8%</li> <li>3.3%</li> <li>2.8%</li> <li>1.1%</li> <li>0.8%</li> <li>93.8%</li> <li>4.4%</li> <li>1.2%</li> </ul>	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 3.05 [-3.44, 9.54] 3.58 [-2.88, 10.04] -0.30 [-4.74, 3.54] -0.30 [-4.74, 3.54] -0.30 [-4.74, 3.54] -0.30 [-4.74, 3.54] 0.30 [-2.48, 10.06] 1.22 [0.45, 1.99] 1.45 [-2.13, 5.03] 9.10 [2.30, 15.90]	1	Mean Di IV. Fixe 	fference 1.95% Cl 		
С	Study or Subgroup 2.6.1 Lokomat Accoentida-Meastro, M 2012 Cheng, EYY 2019 Chinar, C 2021 Esclaini-Ruz, A 2014 (a) Esclaini-Ruz, A 2014 (b) Midik, M 2020 Shin, J.C 2014 (b) Midik, M 2020 Shin, J.C 2014 (c) Helerogeneity, Tau <sup>2</sup> = 1.91; Cr Test for overall effect. Z = 2.83 2.6.2 Exoskeleton Gl:Aquido, A 2023 Yildirm, M 2019 Subtolati (d%, Cr)	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>2</sup> = 16.82 (P = 0.00 3.54 4	SD         Tc $6.74$ $4.65$ $3.4$ $5.17$ $3.78$ $0.8$ $12.59$ $1$ $.df = 6$ (P $5$ ) $2.65$ $8.19$	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010); 11 0.7 44 1.5 55	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81   <sup>2</sup> = 64%	Total         We           38         3           8         6           20         14           21         1           21         1           15         2           149         7           10         14           54         2	Mean ight IV. Ra 3.9% 7.(. 6.6% 1.6 1.8% 1.0 1.8% 1.0 1.9% 1.4 1.2% 0.6 5.5% 2.0 1.7% 2.6 3.5% 2.7	Difference indom. 95% CI 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-0.40, 2.80] 1 [-1.79, 3.09] 1 [-4.41, 10.41] 15 [0.63, 3.47] 84 [1.02, 4.66] 0 [-0.51, 5.51] 75 [1.19, 4.30]	Mean  V. Ran - - -	Difference dom 95% C1	C	Test for subgroup differences: C <u>Study or Subgroup</u> 2.8.1 Lokomat Akobendas-Massito, M.2012 Chenng, EYY 2019 Esclarin-Ruz, A 2014 (a) Field-Fok, EC 2011 (a) Field-Fok, EC 2011 (a) Field-Fok, EC 2011 (a) Mick, M. 2020 PilRA, A 2019 Substant (GYS, C) Heterogenehy: CA <sup>2</sup> = 6.7, dF Heterogenehy: CA <sup>2</sup> = 6.7 Heterogenehy: CA <sup>2</sup> = 6.7 Heterogenehy: CA <sup>2</sup> = 6.7 Heterogenehy: CA <sup>2</sup> = 6.7 Heterogenehy: CA <sup>2</sup> = 6.	Rean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.	5, df = 1 (l EGT 9.56 5.52 10.5 10.72 4.2 4.2 4.2 1.55 5 3.33 3.17 1 .800); l <sup>2</sup> = l 5.37 11.9 11.34	P = 0.15 tal Mor 37 8 0 21 5.1 20 2.1 4 2 5 3 15 0 7 0 27 8 -0 57 0% 11 16 6 9	), P = 5' CPT 5 8.4 1.6 8.7 1.6 8.7 1.6 8.7 1.6 8.7 1.7 10.3 1.8 3 1.1 4 1.2 3 1.1 4 1.2 3 1.1 4 1.2 4 4 13.3 3 2.6 3 2.6 3 2.6 3 3 6 0 8.1 1.3 6 0 8.1 1.5 8 1.5 8 1.	1.4% 50 Tota 50 Tot	Weight           3         3.3%           1.1%         1.3%           1.3%         2.8%           3.5%         3.5%           7         2.8%           1.1%         0.6%           93.8%         4.4%           2         1.2%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 0.30 [-3.44, 9.54] 3.58 [-2.88, 10.04] 0.30 [-4.74, 3.54] 1.20 [0.32, 2.08] 1.20 [0.32, 2.08] 1.20 [0.32, 2.08] 1.22 [0.45, 1.99] 1.45 [-2.13, 5.03] 9.10 [2.30, 15.90]	1	Mean Di N. Fixe 	fference 1,95% Cl		
С	Study or Subgroup           2.6.1 Lokomat           Alcobardiar-Masetro, M. 2012           Alcobardiar-Masetro, M. 2013           Chair, C. 2021           Esclarin-Ruz, A 2014 (a)           Esclarin-Ruz, A 2014 (b)           Shitu, J. 2020           Shitu, J. 2020           Shitu, C. 2014           Subtotal (B% C1)           Heterogeneity: Tau <sup>2</sup> = 1.91;C1           Reference           Subtotal (B% C1)           Heterogeneity: Tau <sup>2</sup> = 0.00;C1	F Mean 12 1.7 2.6 6.7 57 6.45 3.9 8 i <sup>2</sup> = 16.82 (P = 0.00 3.54 4 i <sup>2</sup> = 0.04,	SD Tc           6.74           4.65           3.4           5.17           3.78           0.8           12.59           1           df = 6 (P           5)           2.65           8.19           df = 1 (P =	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010); 11 0.7 44 1.5 55 = 0.85);   <sup>2</sup> =	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 P = 64% 1.49 6.03 = 0%	Total         Ws           38         6           20         14           21         8           20         14           21         8           20         14           21         8           20         14           15         26           149         70           10         14           44         8           54         22	Mean iight IV. Ra 9.9% 7.( 3.6% 1.6 8.8% 1.0. 3.9% 1.4 2.1% 3.00 5.5% 2.0 4.7% 2.6 8.8% 2.5 3.5% 2.7	Difference indom, <u>95% C1</u> 00 (4.28, 9.72) 0 (-0.20, 2.80) 3 (-1.54, 4.40) 5 (-1.79, 3.09) 40 (0.92, 1.88) (-4.41, 10.41) 15 (0.63, 3.47) 84 (1.02, 4.66) 0 (-0.51, 5.51) 75 (1.19, 4.30)	Mean IV. Rari - - -	Difference dom 95% Cl	C	Test for subgroup differences ( <u>Study or Subgroup</u> , <u>2.8.1 Lokoma</u> <u>Accobencias-Massito</u> , M 2012 <u>Cherning</u> , ErY, 2016 (a) Ecclaim-Ruz, A 2014 (b) Freids-Fole, EC 2011 (a) Freids-Fole, EC 2011	R Rean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.	5, df = 1 (l EGT 9,56 5,52 10,5 10,72 4,2 4,2 4,2 4,2 4,2 3,33 3,17 1.800); l <sup>2</sup> = 1 5,37 11,9 1,34	P = 0.15 tal Mez 37 8 0 21 5,3 15 0 7 0 27 8 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0	), P = 5 CPT 5 8.4. 6 8.7 10.6 8.7 10.6 8.7 10.6 8.7 10.6 8.7 10.6 8.7 10.2 4 4 13.3 1.6 0.7 1.2 4 4 13.3 6 0.7 1.7 4.5 3 2.6 0 8.1	1.4% 50 Tota 47 38 79 8 97 21 38 21 33 26 199 199 56 10 12 12 33 36 10 15 \$ 31 31 31 31 31 31 31 31 31 31	Weight           3.3%           1.1%           1.3%           2.8%           3.3%           72.7%           2.8%           3.3%           1.1%           93.8%           4.4%           1.2%           0.7%           6.2%	Mean Difference IV. Fixed. 95% C 2.00 [-2.09, 6.09] 0.40 [-6.79, 7.59] 0.50 [-3.44, 9.54] 0.50 [-4.74, 8.14] 0.50 [-4.74, 8.14] 0.50 [-4.74, 8.14] 0.50 [-9.46, 10.06] 1.22 [0.45, 1.99] 1.45 [-2.13, 5.03] 1.00 [-3.28 [-0.11, 5.87]	1	Mean Di IV. Fixe	fference 1,95% CI 	- - - - -	
С	Study or Subgroup 2.6.1 Lokomat Accoendia-Meastro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Mick, M 2020 Shin, J.C 2014 Subtotal (8% CI) Heterogeneity: Tau <sup>2</sup> = 1.91; CI Test for overall effect. Z = 3.48 26.2 Excoskeleton Gl-Agudo, A 2023 Yldirim, M 2019 Subtotal (8% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; CI	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>P</sup> = 16.82 (P = 0.00 3.54 4 i <sup>P</sup> = 0.04, (P = 0.00	SD Tc           6.74           4.65           3.4           5.17           3.78           0.8           12.59           1           , df = 6 (P           5)           2.65           8.19           df = 1 (P = 05)	tal         Mean           37         5           8         0.1           17         1.6           21         6.14           20         5.8           15         2.5           45         =           11         0.7           44         1.5           55         =           6.0.85); I <sup>2</sup> =	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 P = 64% 1.49 6.03 = 0%	Total         We           38         8           20         14           21         8           21         11           15         22           149         71           10         14           54         22	Mean ight IV. Ra 1.0 1.6% 1.6 1.8% 1.0 1.8% 1.0 1.8% 0.6 3.0% 1.4 1.2% 0.6 3.0% 1.4 1.2% 0.6 3.0% 2.6 3.5% 2.7 3.5% 2.7	Difference indian, 35% CI 00 [4.28, 9,72] 0 [-2.12, 5.32] 0 [-2.12, 5.32] 0 [-3.0, 2.80] 3 [-1.54, 4.40] 5 [-1.79, 3.09] 40 [0.22, 1.88] [-4.41, 10.41] 95 [0.63, 3.47] 95 [0.63, 3.47] 95 [0.61, 5.61] 9 [0.19, 4.30]	Mean IV. Rar - - -	Difference dom, 95% Cl	C	Test for subgroup differences: C <u>Sturk or Subgroup</u> . <u>2.8.1 Lokoma</u> . <u>Alcobendas-Maseto</u> , M.2012 <u>Charga, EYY 2019</u> <u>Esclatin-Ruz</u> , A2014 (a) <u>Esclatin-Ruz</u> , A2014 (b) <u>Field-Field</u> , EC2011 (b) <u>Field-Field</u> , EC2011 (c) <u>Midik</u> , M.2020 <u>Field-Field</u> , EC2011 (c) <u>Midik</u> , M.2020 <u>Midik</u> , M.2020 <u>Field-Field</u> , EC2011 (c) <u>Midik</u> , M.2020 <u>Field-Field</u> , C.2014 <u>Midik</u> , M.2020 <u>Midik</u> , M.2020 <u>Field-Field</u> , C.2014 <u>Midik</u> , M.2020 <u>Field-Field</u> , C.2014 <u>Midik</u> , M.2020 <u>Field-Field</u> , C.2014 <u>Midik</u> , M.2020 <u>Field-Field</u> , C.2014 <u>Midik</u> , M.2020 <u>Midik</u> , M.2020 <u>Midik</u> , M.2020 <u>Field-Field</u> , C.2014 <u>Midik</u> , M.2020 <u>Midik</u> , M.2020	Rean 7 1 8.33 6.15 2.5 2.5 2.5 1.8 5.4 6 -0.4 * 10 (P = 0 (P = 0.002 4.45 15.4 1 * 2 * 2 * 2 * 2 * 2 * 3 * 4 * 5 * 2 * 5 * * 5 * 5	5, df = 1 (l EGT 9.56 5.52 10.5 10.72 4.2 4.2 1.55 5.3 3.33 3.17 1.80); l <sup>2</sup> = 1 5.37 11.9 1.34 (4); l <sup>2</sup> = 55	P = 0.15 tal Mer 37 8 0 21 5.2 20 2.4 4 2 5 3 15 0 27 8 -0 57 7 11 16 6 9 36 15%	), P = 5' CPT 5 8.4 16 8.7 28 10.5 57 10.3 1.1 4 1.2 3 1.1 4 1.2 4 1.3 6 0 8.1 1.1 4 1.2 4 1.3 6 0 8.1 1.1 4 1.2 4 1.3 6 1.1 4 1.1 4 1.2 4 1.3 6 1.1 4 1.2 4 1.3 6 1.1 4 1.1 4 1.2 4 1.3 6 1.1 4 1.1 4 1.2 4 1.3 6 1.1 4 1.1 4 1.2 4 1.3 6 1.1 4 1.1 4 1.1 4 1.2 4 1.3 6 1.1 7 1.1 4 1.1 4 1.	1.4% 5D Tota 5D Tota 47 3& 79 & & 80 21 207 21 88 21 21 21 33 2& 199 8 199 8 199 8 199 199 199	Weight           3         3.3%           5         1.1%           1         1.3%           5         2.8%           5         72.7%           2         2.8%           5         1.1%           6         2.8%           5         1.1%           6         2.8%           6         1.2%           0         4.4%           1         1.2%           0         4.4%           2         2.8%	Man Difference IV. Fixed. 35% C 200 [+2.09, 6.09] 0.40 [-679, 7.59] 3.56 [-244, 9.26] 3.56 [-244, 9.26] 0.30 [+74, 4.354] 0.30 [+74, 4.354] 0.30 [+74, 4.354] 0.20 [-71, 98] 1.20 [3.22 [0.45, 1.99] 1.45 [+2.13, 5.03] 9.10 [+2.30, 15.90] 1.06 [+4.1, 15.87]	1	Mean Di N. Fixe 	fference 1, 95% Cl 	- - - -	
С	Study or Subgroup 2.6.1 Lokomat Accoentide-Meastin, M 2012 Chean, C 2021 Estatini-Ruz, A2014 (e) Estatini-Ruz, A2014 (e) Mathewatin, M 2020 Shin, Jo 2014 Subtotal (95% C1) Heterogeneity: Tau'= 1 91:C1 2.6.2 Excessible Gir4-Qudo, A 2023 Yidirim, M 2019 Subtotal (95% C1) Heterogeneity: Tau'= 0.00;CCh Test for overall effect. Z = 3.46	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>2</sup> = 16.82 (P = 0.00 3.54 4 i <sup>2</sup> = 0.04, (P = 0.00	SD Tc           6.74           4.65           3.4           5.17           3.78           0.8           12.59           1           df = 6 (P           5)           2.65           8.19           df = 1 (P = 05)	tal Mean 37 5 8 0.1 17 1.6 21 6.14 20 5.8 15 2.5 27 5 45 = 0.010); 11 0.7 44 1.5 55 = 0.85); I <sup>2</sup> =	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 1 <sup>2</sup> = 64% 1.49 6.03 = 0%	Total         We           38         8           20         14           21         8           21         15           26         2           149         70           10         14           54         2	Mean iight IV. Ra 9.9% 7.( 3.6% 1.6 1.8% 1.0 9.8% 1.4 1.8% 1.0 0.6 3.0% 1.4 1.8% 2.0 1.6% 2.6 3.0% 2.6 3.5% 2.7	Difference indom, 95% C1 0 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-2.02, 2.80] 3 [-1.54, 4.40 5 [-1.79, 3.09] 0 (0.22, 1.88] [-4.41, 10.41] 15 [0.63, 3.47] 84 [1.02, 4.66] 0 [-0.51, 5.51] 5 [1.19, 4.30]	Mean IV. Rat - - -	Difference dom, 95% Cl	C	Test for subgroup differences ( <u>Study or Subgroup</u> <u>2.8.1 Lokoma</u> <u>Accobendia-Messito</u> , M. 2012 <u>Coheng, EYY</u> 2019 (a) <u>Esclain-Ruz</u> , A.2014 (b) <u>Field-Fole</u> , EC 2011 (a) <u>Field-Fole</u> , EC 2011 (a) <u>Field-Fole</u> , EC 2011 (a) <u>Mick</u> , M. 2001 <u>Mick</u> , M.	Rean 7 1 3.3 6.15 2.5 2.5 2.5 1.8 5.4 6 -0.4 2.5 2.5 2.5 1.8 6 -0.4 2.5 2.5 2.5 1.8 6 -0.4 2.5 2.5 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5	5, df = 1 (0 EGT 9.56 5.52 4.2 4.2 4.2 1.55 1.333 3.17 1.80); l <sup>2</sup> = 1 5.37 11.9 1.34 (4); l <sup>2</sup> = 50	P = 0.15 tal Mer 37 8 0 21 5.2 20 2.1 4 2 20 2.2 4 2 2.2 2.2 2.2 2.2 2.2 2.	), l <sup>2</sup> = 5' CPT 28 10.5 57 10.3 18 3 1.2 4 1.2 4 1.2 4 3 2.6 0 8.1 3 2.6 0 8.1	1.4% 5D Tota 5D Tota 5D Tota 77 38 77 21 283 21 14 15 12 199 56 10 199 56 10 199 56 10 199 56 10 199 56 10 199 56 10 57 19 57 1	Weight 3.3% 1.1% 1.3% 5.2.8% 3.3% 5.2.8%	Mean Difference IV. Fixed. 35% C 0 200 [-2.09, 6.09] 0.40 [-677, 759] 3.56 [-2.48, 10.04] 0.56 [-3.44, 326] 0.30 [-74, 43, 351] 0.30 [-74, 43, 351] 0.30 [-74, 65] 0.30 [-9.46, 10.06] 1.22 [0.45, 1.99] 1.45 [-2.13, 5.03] 1.45 [-2.13, 5.03] 1.00 [-3.4, 10.12]	1	Mean Di IV. Fixe	fference 1, 95% GI	- - - - -	
С	Study or Subgroup 2.6.1 Lokomat Accoenda-Meastro, M 2012 Cheung, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Midik, M 2020 Shih, JC 2014 Subtotal (8% CI) Heterogeneity: Tau <sup>2</sup> = 1.91; CI Test for overail effect. Z = 2.83 2.6.2 Exoskeleton Gi-Agudo, A 2023 Yidirim, M 2019 Subtotal (8% CI) Heterogeneity: CI O: Heterogeneity: CI	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 i <sup>2</sup> = 16.82 (P = 0.00 3.54 4 i <sup>2</sup> = 0.04, (P = 0.00	SD Tc           6.74           4.65           3.4           5.17           3.78           0.8           12.59           1           , df = 6 (P           2.65           8.19           df = 1 (P = 05)	tal         Mean           37         5           8         0.1           17         1.6           21         6.14           20         5.8           15         2.5           45         =           10.010);         1           11         0.7           55         =           • 0.85);   <sup>2</sup> =         00	CPT 5.14 2.69 1.8 4.62 4.18 0.5 14.81 P = 64% 1.49 6.03 = 0%	Total         We           38         8           20         14           21         15           26         2           149         70           10         14           54         2:           203         100	Mean iight IV. Ra 9.9% 7.0 6.0% 1.6 1.0% 1.0 1.0% 1.4 1.2% 0.6 3.0% 1.4 1.2% 0.6 3.5% 2.0 1.4% 0.6 3.5% 2.0 1.4% 0.6 3.5% 2.7 1.4% 0.6 3.5% 2.7 1.4% 0.6 3.5% 2.7 1.4% 0.6 3.5% 2.7 1.4% 0.6 3.5% 2.7 1.4% 0.6 3.5% 2.7 1.4% 0.6 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0.6\\ 1.4% 0	Difference Indom, 95% CI 00 [4.28, 9,72] 0 [-2.12, 5.22] 0 [-2.02, 5.20] 0 [-3, 0.40] 15 [-1.54, 4.40] 10 (0.32, 1.88] [-4.41, 10.41] 15 [0.63, 3.47] 15 [1.02, 4.66] 0 [-0.51, 5.51] 15 [1.19, 4.30] 17 [1.05, 3.29]	Mean IV. Rar - - -	Difference dom, 95% Cl	c	Test for subgroup differences: C -Sturk or Subgroup. 2.8.1 Lokomat Accounting-Hussel, M. 2012 Charang, EYY 2019 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (a) Field-Fola, EC 2011 (b) Field-Fola, EC 2011 (b) Field-Fola, EC 2011 (c) Midik, M 2020 PIIRA, A 2019 Shin, JC 2014 Wu, M 2019 Shin, JC 2014 Shin, JC 20	Chi <sup>2</sup> = 2.01 R Mean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 = 10 (P = 0.002 4.45 15.4 1 = 2 (P = 0.06) (P = 0.06)	s, df = 1 (i <u>SD To</u> 9.56 5.52 10.5 1	P = 0.15           tal         Mer           37         8         0           21         5.1         5         2           220         2.4         2         2         3           5         3         1         5         3           15         3         1         7         0           227         -0         -0         5         7           00%         11         6         9         3         36           01%         336         0         3%         3         3	), l <sup>2</sup> = 5' CPT 5 8.4 16 8.7 28 10.9 57 10.2 57 10.2 57 10.2 57 10.2 57 10.2 57 10.2 57 10.2 1.1 4 1.2 3 1.1 4 1.2 3 1.1 4 1.2 3 1.2 4 4 13.3 6 0.7 1.3 6 0 8.1 1.3 6 0 8.1 1.3 6 1.3 7 1.3 7 1	1.4% FD Tota FD Tot	Weight 3.3% 1.1% 1.3% 1.3% 5.2.8% 3.3% 72.7% 0.6% 9.3.8% 0.6% 9.3.8% 0.6% 0.7% 6.2%	Mean Difference IV. Fixed. 35% C 400 [200 8.60] 400 [870 7.80] 305 [344 9.54] 305 [344 9.54] 305 [344 9.54] 305 [344 9.54] 305 [344 9.54] 305 [344 9.54] 305 [347 4.54] 407 [472, 3.32] 120 [322, 200 [53, 80] 520 [071, 9.69] 520 [071, 9.69]	1	Mean Di IV. Fixe 	fference 1, 95% Cl		
С	Study or Subgroup 2.6.1 Lokomat Accoendia-Meastin, M 2012 Chean, C 2021 Esclaint-Ruz, A 2014 (a) Esclaint-Ruz, A 2014 (b) Mdisk, M 2020 Shih, J, C 2014 Subtolat (89% C1) Heterogeneity: Tau" = 1.91; C1 Test for overall effect. Z = 2.83 2.6.2 Escoketard, M 2019 Viddim, M 2019 Subtolat (89% C1) Heterogeneity: Tau" = 0.00; C1 Test for overall effect. Z = 3.46 Test (89% C1)	F Mean 12 1.7 2.6 6.45 3.9 8 i <sup>2</sup> = 16.82 4 i <sup>2</sup> = 16.82 4 i <sup>2</sup> = 0.00 3.54 4 i <sup>2</sup> = 0.04, 0 4	SD Tc           SD Tc           6.74           4.65           3.4           5.17           3.78           0.8           12.59           1	tal         Mean           37         5           8         0.1           17         1.6           21         6.14           20         5.8           15         2.5           27         5           45         =           10         0.7           44         1.5           55         =           0.045); I <sup>2</sup> =         00	CPT SD 2.69 1.8 4.62 4.18 0.5 1.4481 1.49 6.03 = 0%	Total         We           38         6           20         12           21         12           21         15           26         2           149         71           10         14           54         22           203         100	Mean iight IV. Ra 3.9% 7.0 3.6% 1.6 3.6% 1.6 3.6% 1.6 3.6% 1.6 3.6% 2.0 3.0% 1.4 1.2% 0.6 3.0% 1.4 1.2% 0.6 3.0% 1.4 3.00 1.4 3.00 2.0 3.0% 2.1 3.0% 2.1	Difference indom, 95% C1 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-2.02, 2.80] 3 [-1.54, 4.40 5 [-1.79, 3.09] 40 (0.22, 1.88] 1 [-4.41, 10.41] 15 [0.63, 3.47] 84 [1.02, 4.66] 0 [-0.51, 5.51] 5 [1.19, 4.30] 77 [1.05, 3.29]	Mean IV. Ran - - - -	Difference dom. 95% Cl		Test for subgroup differences ( <u>-Study or Subgroup</u> 2.8.1 Lekomat Akobendas-Messito, M. 2012 Cheng, E.YY 2019 Ecelario-Neur, A.2014 (0) Field-Fole, E.C. 2011 (a) Field-Fole, E.C. 2011 (a) Field-Fole, E.C. 2011 (a) Field-Fole, E.C. 2011 (a) Matik, M. 2020 (Field-Fole, E.C. 2011 (a) Matik, M. 2020 (Field-Fole, E.C. 2011 (a) Matik, M. 2020 Field-Fole, E.C. 2011 (a) Matik, M. 2020 Field-Fole, E.C. 2011 (a) Matik, M. 2020 (a) Califormia Subtotal (6%) (C) Heterogeneity, CIP <sup>™</sup> = 0.39, df = Test for overall effect. Z = 1.19 Subtotal (6%) (C) Fold (6%) (C) Fold (6%) (C)	Chi <sup>2</sup> = 2.01 Rean 7 1 8.33 6.15 2.5 2.5 2.5 2.5 2.5 1.8 5.4 6 -0.4 1 (P = 0.002 4.45 15 .2 .5 2.5 2.5 2.5 2.5 2.5 2.5	s, df = 1 (l <u>SD</u> To 9.56 5.52 10.5 1	P = 0.15 tal Mer 37 8 0 21 5.3 15 0 7 0 27 8 -0 7 0% 11 16 6 9 9 33 15 0% 9 9 9 9 9 9 9 9 9 9 9 9 9	), I <sup>2</sup> = 5' CPT 5 8.4. 6 8.7. 28 10.9. 57 10.3. 8 3 3. 1.1 4 4. 1.2 3. 1.6 0.7. 1.2 4. 4 4 13.3. 3 2.6. 0 8.1	1.4% FD Tota FD Tota F	Weight 3.3% 1.1% 1.3% 5.28% 3.3% 5.28%	Maan Difference IV. Fixed, 35% C 2001/200, 606) 0040 [679, 728] 305 [344, 954] 305 [344, 954] 305 [344, 954] 305 [344, 954] 305 [344, 954] 305 [344, 954] 305 [347, 414] 0.30 [477, 432] 0.30 [477, 432] 1.30 [58, 207] 1.33 [0.58, 207] 1.33 [0.58, 207]	1	Mean Di IV. Fixe	fforence 1, 95% Cl 		
С	Study or Subgroup           2.6.1 Lokomat           Alcoberdia-Masetro, M.2012           Chang, EYZ 2021           Esclaint-Ruz, A2014 (a)           Esclaint-Ruz, A2014 (b)           Esclaint-Ruz, A2014 (c)           Shin, U.2 2014           Subtotal (6% C1)           Heterogeneity: Tau <sup>2</sup> = 1.91; C1           Heterogeneity: Tau <sup>2</sup> = 0.00; C1           Heterogeneity: Tau <sup>2</sup> = 0.00; C1           Test for overail effect: Z = 3.46           Total (6% C1)           Heterogeneity: Tau <sup>2</sup> = 0.00; C1           Heterogeneity: Tau <sup>2</sup> = 1.35; C1	F Mean 12 1.7 2.6 7.57 6.45 3.9 8 $i^2 = 16.82$ (P = 0.00 3.54 4 $i^2 = 0.04$ , (P = 0.00 $i^2 = 0.04$ , (P = 0.00	SD Ts           5.74           4.65           3.4           5.17           3.78           12.59           1	tal         Mean           37         5           8         0.1           17         1.6           21         6.14           20         5.8           215         2.5           27         5           45         5           55         :           55         :           600         = 0.01); I <sup>2</sup>	CPT 5.14 2.69 1.8 4.62 4.18 5.14 1.49 5.03 5.05 1.49 5	Total         We           38         8           20         14           21         17           15         22           26         2           149         71           10         14           54         22           203         101	Mean iight IV. Ra 0.9% 7.0. 6% 1.6. 1.0% 1.0. 1.0% 1.4. 1.2% 0.6. 3.0% 1.4. 1.2% 0.6. 1.2% 0.6. 1.4%	Difference ndom, 95% C1 00 [4.28, 9.72] 01 [2.12, 5.32] 01 (-21, 25, 5.32] 01 (-20, 25, 6.32) 32 [-1.54, 4.40] 32 [-1.54, 4.40] 32 [-1.54, 4.40] 15 [0.63, 3.47] 84 [1.02, 4.66] 0 [-0.51, 5.51] 15 [1.19, 4.30] 71 [1.05, 3.29]	Mean IV. Rar - - - - - - - - - - - - -	Difference dom, 95% Cl		Test for subgroup differences ( <u>Study or Subgroup</u> <u>2.8.1 Lokoma</u> <u>Accobencias-Massito</u> , M. 2012 <u>Corong, EFX - 2014</u> (a) <u>Ecclarin-Res</u> , 2014 (a) <u>Ecclarin-Res</u> , 2014 (b) <u>Field-Fols</u> , EC 2011 (a) <u>Field-Fols</u> , EC 2011 (a) <u>Field-Fols</u> , EC 2011 (a) <u>Field-Fols</u> , 2011 (c) <u>Field-Fols</u> , 2011 (c) <u>Field-Fo</u>	$\begin{array}{c} R\\ Mean\\ \hline\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ $	6, df = 1 (l EGT <u>SD</u> To 9,56 5,52 10,5 5,52 10,5 5,52 4,2 4,2 4,2 4,2 4,2 1,55 5,33 3,317 1,155 5,37 11,9 5,37 11,34 (4); l <sup>2</sup> = 5 1,134 (4); l <sup>2</sup> = 5 1,134 (4); l <sup>2</sup> = 5 1,134 (4); l <sup>2</sup> = 5 1,134 (4); l <sup>2</sup> = 5 (4); l <sup>2</sup> = 1 (4); l <sup>2</sup> = 5 (4); l <sup>2</sup> = 5 (4)	P = 0.15 tall Meri 37 8 0,21 20 2.4 20 2.4 4 2 5 3 5 3 5 3 5 3 5 3 5 3 5 3 5 3	), P = 5 CPT 5 8.4 1.6 8.7 28 10.5 1.2 3 1.1 4 1.2 3 1.2 4 4 13.3 1.2 4 1.3 6 0 8.1 3 2.6 0 8.1	1.4% SD Tota 47 3& 50 Tota 47 3& 50 Tota 50 Tota 5	Weight 3.3% 1.1% 1.3% 2.8% 3.5% 72.7% 0.6% 9.3.8% 0.6% 9.3.8% 0.6% 0.7% 6.2% 1100.0%	Mean Difference IV. Fixed. 35% C 400 [200 6.09] 400 [377 40] 305 [344 9.54] 305 [345 9.54] 305 [345 9.54] 305 [345 9.54] 305 [345 9.54] 305 [345 9.54] 305 [345 9.55] 305 [	1	Mean Di IV. Fixe 	fference 1.95% Cl.	- - - -	
С	Study or Subgroup 2.6.1 Lokomat Accoentida-Meastro, M 2012 Cheang, EYY 2019 Cinar, C 2021 Esclarin-Ruz, A 2014 (a) Esclarin-Ruz, A 2014 (b) Midik, M 2020 Shin, J.C 2014 Subtotal (8%): C1) Heterogeneity, Tau <sup>2</sup> = 1.91; CF Test for overall effect. Z = 2.83 2.6.2 Exoskeleton Gli Agudo, A 2023 Yidirim, M 2019 Subtotal (8%): C1) Heterogeneity, Tau <sup>2</sup> = 0.00; CT Test for overall effect. Z = 3.81 Tosta (8%): C1) Heterogeneity, Tau <sup>2</sup> = 1.35; CT Test for overall effect. Z = 3.81	$\begin{array}{c} & \\ \hline Mean \\ 12 \\ 1.7 \\ 2.6 \\ 7.57 \\ 6.45 \\ 3.9 \\ 8 \\ i^2 = 16.82 \\ (P = 0.00 \\ 4 \\ i^2 = 0.04 , \\ i^2 = 0.04 \\ (P = 0.00 \\ i^2 = 19.13 \\ (P = 0.00 \\ i^2 = 19.13 \\ (P = 0.00 \\ i^2 = 19.13 \\ i$	SD         Tc           6.74         4.65           3.4         5.17           3.78         0.8           12.59         1           df = 6 (P           5)         2.65           8.19         df = 1 (P = 1           df = 1 (P = 2         2.65           0.05)         2           df = 8 (P         001)	tal         Mean           37         5           8         0.1           17         1.6           21         6.14           15         2.5           45         5           55         0.010);           11         0.7, 24           55         0.85);           9         0.010;	CPT SD 5.14 2.69 1.82 4.62 4.18 4.18 5.14 1.49 6.03 = 0%	Total         We           38         8           20         14           21         15           26         2           149         71           10         14           54         22           203         100	Mean iight IV. Ra 3.9% 7. (. 5.6% 1.6. 8.8% 1.0. 3.9% 1.4 1.2% 0.6. 3.9% 1.4 1.2% 0.6. 5.5% 2.0 5.5% 2.0 5.5% 2.7 3.5% 2.7 3.5% 2.1	Difference ndom, 95% C1 00 [4.28, 9.72] 0 [-2.12, 5.32] 0 [-2.12, 5.32] 0 [-2.02, 5.32] 1 [-3, 4.40] 5 [-1.73, 3.09] 1 [-4.41, 10.41] 15 [0.63, 3.47] 84 [1.02, 4.66] 0 [-0.51, 5.51] 75 [1.19, 4.30] 77 [1.05, 3.29]	Maan IV. Rar 	Difference dom. 95% Cl	C	Test for subgroup differences ( Study or Subgroup) 2.8.1 Lokomat Akobendas-Massto, M.2012 Chenng, EYY 2019 Esclarin-Ruz, A2014 (a) Friek-Fok, EC 2011 (a) Friek-Fok, EC 2011 (a) Friek-Fok, EC 2011 (a) Mick, M. 2020 PilKA, A2019 Substant (9% C) Heterogeneity: Ch <sup>2</sup> = 6.7, di Heterogeneity: Ch <sup>2</sup> = 6.3, di Substant (9% C) Heterogeneity: Ch <sup>2</sup> = 3.99, di Test for overall diffect Z = 3.10 Coal (9% C) Heterogeneity: Ch <sup>2</sup> = 1.39, di Test for overall diffect Z = 1.10 Coal (9% C) Heterogeneity: Ch <sup>2</sup> = 1.12, di Heterogeneity: Ch <sup>2</sup> = 1.12, di	R Mean 7 1 8.33 6.15 2.5 2.5 5.4 6 5.4 6 5.4 6 5.4 6 7 0.4 1 1 8.33 6.15 7 2.5 2.5 5.1.8 5.4 6 7 0.4 1 2.5 2.5 5.1.8 1.5.4 1.1 2.5 2.5 5.2.5 1.8 1.5.4 2.5 2.5 2.5 1.8 1.5.4 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5	s, df = 1 (l EGT <u>SD To</u> 9.56 5.52 10.5 5.52 1.55 5 3.33 3.17 1 1.34 4.2 4.2 4.2 4.2 5 5 3.33 7 1 1.34 4.3; P = 5i 0.59; P = 5i 1.54 1.55 5 5 5 5 5 5 5 5 5 5 5 5	P = 0.15 tal Mez 37 8 00 21 5.2 5 3 15 0 27 8 -00 57 7 00 8 -00 57 11 9 36 10% 33 0%	), P = 5 CPT 5 8.4 6 8.7 28 10.5 28 10.5 2	1.4% PD Tota 47 38 47 38 47 38 47 38 47 38 21 38 21 38 21 38 21 1 18 44 17 17 18 44 17 19 8 56 10 199 8 199 8 56 10 230 230	Weight 3 3.3% 3 1.1% 1.3% 2.8% 3 .5% 5 72.7% 5 2.8% 5 1.1% 5 2.8% 9 3.8% 9 3.8% 9 4.4% 6 .2% 100.0%	Mean Difference IV. Fixed, 395 C 200 [200 6,00] 0.40 [679, 728] 3.05 [3.44, 9.54] 3.05 [3.44, 9.54] 3.05 [3.44, 9.54] 3.05 [3.44, 9.54] 0.30 [474, 4.14] 0.30 [477, 3.32] 1.20 [5.32, 105] 1.20 [5.32, 105] 1.45 [2.13, 5.03] 9.10 [2.30, 15.30] 1.05 [4.21, 15.87] 1.33 [0.58, 2.07]	-20	Mean Di N. Fixe 	fforence 1.95% CI		

Fig. 6 Subgroup analysis of WISCI-II and LEMS. SCI patients were treated by REGT compared with CPT starting at the early stage or 6 months after SCI assessing WISCI-II (**A**) and LEMS (**B**); utilizing different kind of robotic exoskeleton, Lokomat or exoskeleton assessing WISCI-II (**C**) and LEMS (**D**)

		R	EGT			СРТ			Mean Difference	Mean Difference	
-	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	I IV, Fixed, 95% Cl	
	Cheung, EYY 2019	0	1.28	8	0	0.85	8	42.1%	0.00 [-1.06, 1.06]		
A	Xiang, X 2021	0.7	1.1	9	-0.2	0.85	9	57.9%	0.90 [-0.01, 1.81]		
	Total (95% CI)			17			17	100.0%	0.52 [-0.17, 1.21]		
	Heterogeneity: Chi <sup>2</sup> = 1	.59, df =	: 1 (P :	= 0.21)	; l² = 37	%					$\rightarrow$
	Test for overall effect: 2	Z = 1.48	(P = 0	.14)						Favours [CPT] Favours [REGT]	4
		1	REGT			СРТ			Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% Cl	I IV, Fixed, 95% CI	
Б	Cheung, EYY 2019	0.2	0.88	8	0	0.86	8	42.6%	0.20 [-0.65, 1.05]		
В	Xiang, X 2021	0.8	0.95	9	-0.1	0.6	9	57.4%	0.90 [0.17, 1.63]	<b>−</b> ∎−	
	Total (95% CI)			17			17	100.0%	0 60 [0 05 1 16]		
		4 40 -4	_ 4 (D	- 0.00	. 12 - 01	20/	17	100.070	0.00 [0.03, 1.10]		
	Heterogeneity: Chi-=	1.49, df	= 1 (P	= 0.22	); 1- = 33	5%				-4 -2 0 2	4
	lest for overall effect:	Z = 2.12	: (P = (	J.U3)						Favours [CPT] Favours [REGT]	
			REGT			СРТ			Mean Difference	Mean Difference	
	Study or Subgroup	Mean	SD	Tota	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI	
~	Cheung, EYY 2019	0.7	2.3	8	0	2.34	8	40.3%	0.70 [-1.57, 2.97]		
C	Xiang, X 2021	1.8	1.83	9	0.9	2.2	9	59.7%	0.90 [-0.97, 2.77]		
	Total (95% CI)			17			17	100.0%	0 82 [-0 62 2 26]		
	Hotorogonoity: Chi2 -	0.02 4	- 1 (	11 0 - 0 90	·) · 12 − 0	0/	17	100.070	0.02 [-0.02, 2.20]		
	Telefogeneity: Chi	0.02, ui	- I (P 1 /D -	· - 0.08	ı), I <sup>_</sup> – U	70				-4 -2 0 2 4	
	rest for overall effect	. ∠ - 1.1	г (Р =	0.27)						Favours [CPT] Favours [REGT]	

Fig. 7 Forest plots for REGT compared with CPT in respiratory function assessing the FVC (A), FEV1 (B) and PEF (C)

controlling their body posture [47]. By undergoing walking training under physiological conditions that can be repeated, patients are able to activate their trunk muscles more effectively, allowing them to adapt to postural control and maintenance while in motion. This, in turn, significantly improves their weight transfer and balance skills [48]. Similarly, our meta-analysis results indicate that patients undergoing robotic exoskeleton gait training exhibited significant improvements in the Timed Up and Go (TUG) test, the Walking Index for Spinal Cord Injury II (WISCI-II), and the Lower Extremity Motor Score (LEMS). Notably, the enhancement of trunk core stability emerged as a critical factor contributing to TUG improvements. The TUG indicator focuses on overall activity ability and dynamic balance. It reflects the comprehensive improvement of muscle strength and balance ability [49]. The use of robotic exoskeletons enables paralyzed spinal cord injury patients to walk and transfer independently, closely resembling their natural physiological state [50]. By utilizing exoskeleton robots as assistive devices, patients with spinal cord injuries can walk safely and independently, while experiencing the positive effects of rehabilitation training.

In this study, the comparison of walking function score results in patients after spinal cord injury was conducted. The meta-analysis included two important indicators: WISCI-II (Walking Index for Spinal Cord Injury) and LEMS (Low Extremity Motor Score). The internationally accepted indicator for evaluating lower limb motor function is the Lower Extremity Motor Score (LEMS), which is a standard for neurological classification of spinal cord injury developed by the American Spinal Injury Association (ASIA). LEMS is a critical evaluation metric utilized to ascertain the ASIA classification of spinal cord injury, with its effectiveness acknowledged both nationally and internationally [51]. WISCI II is frequently employed in rehabilitation facilities to assess the ambulation capabilities of SCI patients. Research has demonstrated that it exhibits consistent validity with the ASIA classification. The results of meta-analyses indicate that robotic exoskeleton gait training significantly enhances patients' WISCI-II and LEMS scores. This study aims to investigate the effects of repeated standing and walking exercises within REGT training on the strength and tension of lower limb muscles. Trainers aspire to preserve lower limb muscle strength to the fullest extent possible, even in the aftermath of nerve damage. It is common for patients with spinal cord injuries to experience prolonged periods of bed rest due to mobility challenges. Numerous studies have documented the detrimental effects of prolonged bed rest on the body, including decreased bone mass, muscle fiber atrophy, and muscle steatosis [52–55]. The use of lower limb robotic devices mitigates patients' bed rest duration, thereby indirectly alleviating the aforementioned adverse effects [52]. These enhancements consisted of a rise in the mass of the lower limb and appendages while observing a reduction in the total, lower limb, and appendicular adipose tissue [53, 54]. Moreover, the intervention also resulted in a substantial augmentation in the cross-sectional dimensions of the calf muscle and a growth of 14.5% in the bone mineral density of the tibia [55]. In addition, there was a decrease exceeding 5% in both subcutaneous adipose tissue and intramuscular adipose tissue [54, 55].

In our meta-analysis, we found that patients who underwent Lokomat robotic-assisted gait training therapy showed greater improvement in strength of lower limbs (LEMS) compared to patients who underwent CPT; however, patients who received robotic exoskeleton gait training rehabilitation did not show significant statistical differences compared to CPT. Both the WISCI-II and LEMS indicators significantly improved in the Lokomat group, while only the WISCI-II improved in the robotic exoskeleton group. This suggests that Lokomat therapy may be more effective in improving strength of lower limbs. However, it is important to note that our study did not directly compare Lokomat and exoskeleton for gait rehabilitation training in patients with spinal cord injury. Instead, we compared the Lokomat group to a conventional physical rehabilitation therapy (CPT) group, and the exoskeleton group to the CPT group. We found that the Lokomat group performed worse than the CPT group in terms of walking speed recovery, while the exoskeleton group performed similarly to the CPT group. These findings are consistent with a recent network meta-analysis that directly compared Lokomat and exoskeleton and found that exoskeletons may lead to better outcomes in walking speed [56]. However, it is important to consider the possibility of patient data publication bias, as Lokomat has been widely used clinically and has more available patient case data. Additionally, the high cost and technical limitations of robotic exoskeletons may limit their practical use in rehabilitation centers. Future studies should focus on conducting relevant clinical randomized controlled experiments to further analyze and compare the effectiveness of Lokomat and exoskeleton therapy in spinal cord injury rehabilitation.

Our study also found that REGT improves pulmonary function to some extent and may be more effective than traditional rehabilitation, particularly in terms of the indicator FEV1 (forced expiratory volume in one second). FEV1 is an evaluation index for assessing pulmonary reserve function. In patients with spinal cord injury, especially those with injuries above the thoracic 6 segment of spinal cord, the likelihood of pulmonary dysfunction increases. Although there are few studies on

cardiac function in the RCT literature we included, there is substantial evidence that REGT has a positive promoting effect on cardiac function in patients with spinal cord injury. Robert et al. [57] discovered that the upright heart rate of patients in the REGT group was significantly lower than that of the CPT group, and this effect was even more pronounced during long-term intervention training (24 weeks). Peter et al. [58] confirmed that REGT training has a similar effect to water exercise training in terms of increasing peak oxygen consumption (VO<sub>2</sub>) and improving patients' pulmonary function and cardiovascular neuroadaptation. Orthostatic hypotension with tachycardia is a typical symptom in patients with spinal cord injury who are unable to promptly raise blood pressure due to associated autonomic dysfunction. REGT training provides external support, reduces the risk of falls for patients with spinal cord injuries, and makes them more psychologically and physically receptive to early standing and walking training. This maximizes the preservation and exercise of cardiopulmonary function and autonomic nervous system regulation. In addition, REGT induces a unique walking physiological rhythm. This change in posture activates intravascular baroreceptors, leading to a series of neural adjustments in the body [47, 59]. It may provide different stimulation to the sympathetic and parasympathetic nervous systems, thereby driving overall improvement in cardiopulmonary function [60, 61]. Furthermore, lower limb exoskeleton training can also offer various other health benefits, including improved bowel and bladder function, reduced muscle atrophy and spasm, and relief from neuropathic pain [62, 63]. These benefits contribute to a better quality of life and prognosis for patients.

# Limitation

The studies included in the review had varying designs (2-, 3-, and 4-arm designs), durations, and types of robotic exoskeleton devices used. Additionally, the participants in each study had different characteristics. According to our quality assessment results of the RCTs, among the 15 included RCT articles, one-third of the RCTs (5 articles) had an average quality, while the remaining two-thirds had a good quality (Table 3). Although we obtained some results from the metaanalysis following data aggregation, the presence of various biases diminishes the certainty of the evidence presented in our final meta-analysis results (Table S4). The mode, intensity, and frequency of REGT varied across different rehabilitation centers. The duration of the rehabilitation training ranged from 4 to 8 weeks. The shortest training time per day reported was 30 min [64], while the longest training time was 90 min [65]. This variation in training duration may introduce some bias in the rehabilitation effect data.Furthermore, the degree and level of spinal cord injury among the patients included in each study are inconsistent. This means that the functional status of the lower limbs before the start of rehabilitation training varies greatly among patients. In three of the documents, the level of spinal cord injury reached ASIA level A [66-68], indicating complete paralysis of both lower limbs after surgery. This difference in patient data may result in some deviation in the data related to postoperative gait training and improvement in functional scores. Unfortunately, the included literature does not currently provide sufficient data to conduct subgroup analysis based on ASIA grading levels. It is recommended that future studies include more randomized controlled trials with larger sample sizes to address these issues more comprehensively and minimize any offset.

# Conclusion

Robotic exoskeleton gait training is an effective method for improving walking balance and strength of lower limbs in patients with spinal cord injury compared to conventional physical gait training programs. REGT has shown significant improvements in walking balance, spinal cord recovery function scores, and to some extent, breathing and ventilation functions. However, there is no significant difference between the two programs in terms of lower limb walking speed and distance during the early post-injury period. After 6 months of injury, the conventional physical gait training becomes more advantageous in walking speed. However, further high-quality randomized controlled trials are needed to fully understand the effectiveness of robotic exoskeleton gait training on lower limb function, walking and cardio-pulmonary function for individuals with spinal cord injury.

# Abbreviations

SCI	Spinal cord injury
REGT	Robotic exoskeleton gait training
CPT	Conventional physical training
10 MWT	10-M walk test
6 MWT	6-Min walk test
TUG	Time up to go
WISCI-II	Walking Index for Spinal Cord Injury II
LEMS	Lower Extremity Motor Scores
FFV1	Forced expiratory volume in one second

#### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12984-025-01649-1.

```
Additional file1 (DOCX 18 KB)
Additional file2 (DOCX 17 KB)
Additional file3 (DOCX 16 KB)
```

#### Author contributions

Liu SY, Chen FY and Yang LY contributed to methodology, design, and development of the study. Liu SY, Chen FY and Yin JQ share first authorship and equally contributed to data curation, acquisition, formal analysis and the writing of the manuscript. Yang LY and Wang GQ contributed to supervision, review and edit the manuscript. All authors read and approved the final manuscript.

#### Funding

This research was supported by Liaoning Province Science and Technology Plan Joint Program (Natural Science Foundation-General Project) (2024-MSLH-559 & 2024-MSLH-579), Collaborative Research Project of China Medical University, as well as the 345 Talent Project of Shengjing Hospital (30C&30D).

#### Availability of data and materials

No datasets were generated or analysed during the current study.

#### Declarations

**Ethics approval and consent to participate** Not applicable.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

#### Author details

<sup>1</sup>Department of Orthopedics, Shengjing Hospital of China Medical University, Sanhao Street 36, Shenyang, Liaoning, People's Republic of China. <sup>2</sup>Department of Rehabilitation, Shengjing Hospital of China Medical University, Puhe Road 16, Shenyang, Liaoning, People's Republic of China. <sup>3</sup>Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.

#### Received: 25 August 2024 Accepted: 13 May 2025 Published online: 29 May 2025

#### References

- Bárbara-Bataller E, Méndez-Suárez JL, Alemán-Sánchez C, Sánchez-Enríquez J, Sosa-Henríquez M. Change in the profile of traumatic spinal cord injury over 15 years in Spain. Scandinavian J Trauma Resuscitation Emergency Med. 2018;26:27.
- Xie J, Flack J, Sharma K. Delving into the recent advancements of spinal cord injury treatment: a review of recent progress. Neural Regen Res. 2022;17:283–91.
- Jonathan A, Williams CH, Mikael J, Turunen, et al. Time course changes to structural, mechanical and material properties of bone in rats after complete spinal cord injury. J Musculoskelet Neuronal Interact. 2022;22:212–34.
- Budd MA, Gater DR, Channell I. Psychosocial consequences of spinal cord injury: a narrative review. J Personalized Med. 2022;12:1178.
- Kuzu D, Kim S, Kratz AL. Active or passive pain coping: which predicts daily physical and psychosocial functioning in people with chronic pain and spinal cord injury? Rehabil Psychol. 2022;67:304–14.
- Kopiczko A, Cieplińska J. Forearm bone mineral density in adult men after spinal cord injuries: impact of physical activity level, smoking status, body composition, and muscle strength. BMC Musculoskelet Disord. 2022;23:81.
- Gedde MH, Lilleberg HS, Aßmus J, Gilhus NE, Rekand T. Traumatic vs non-traumatic spinal cord injury: a comparison of primary rehabilitation outcomes and complications during hospitalization. J Spinal Cord Med. 2019;42:695–701.
- Tweedy SM, Beckman EM, Geraghty TJ, et al. Exercise and sports science Australia (ESSA) position statement on exercise and spinal cord injury. J Sci Med Sport. 2017;20:108–15.

- Kang D, Park J, Eun S-D. A preliminary study on the feasibility of community game-based respiratory muscle training for individuals with high cervical spinal cord injury levels: a novel approach. BMC Sports Sci Med Rehabil. 2022;14:137.
- Khan AS, Livingstone DC, Hurd CL, et al. Retraining walking over ground in a powered exoskeleton after spinal cord injury: a prospective cohort study to examine functional gains and neuroplasticity. J Neuroeng Rehabil. 2019;16:145.
- Formento E, Minassian K, Wagner F, et al. Electrical spinal cord stimulation must preserve proprioception to enable locomotion in humans with spinal cord injury. Nat Neurosci. 2018;21:1728–41.
- Capogrosso M, Milekovic T, Borton D, et al. A brain–spine interface alleviating gait deficits after spinal cord injury in primates. Nature. 2016;539:284–8.
- Wagner FB, Mignardot J-B, Le Goff-Mignardot CG, et al. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018;563:65–71.
- Angeli CA, Boakye M, Morton RA, et al. Recovery of over-ground walking after chronic motor complete spinal cord injury. N Engl J Med. 2018;379:1244–50.
- Dongnan S, Zhigang H, Jipeng W, Peng S, Zhaohui L. Review of adaptive control for stroke lower limb exoskeleton rehabilitation robot based on motion intention recognition. Front Neurorobot. 2023;17:1186175.
- Xianlian Zhou LZ. Model-based comparison of passive and active assistance designs in an occupational upper limb exoskeleton for overhead lifting. IISE Trans Occup Ergon Hum Factors. 2021;9:167–85.
- Goffredo M, Guanziroli E, Pournajaf S, et al. Overground wearable powered exoskeleton for gait training in subacute stroke subjects: clinical and gait assessments. Eur J Phys Rehabil Med. 2020;55:710–21.
- 18. Cunjin Wang LD, Shen D, et al. Design of an Ankle Exoskeleton that recycles energy to assist propulsion during human walking. IEEE Trans Biomed Eng. 2022;69:1212–24.
- Bao G, Pan L, Fang H, et al. Academic review and perspectives on robotic exoskeletons. IEEE Trans Neural Syst Rehabil Eng. 2019;27:2294–304.
- Thomassen G-KK, Jørgensen V, Normann B. "Back at the same level as everyone else"—user perspectives on walking with an exoskeleton, a qualitative study. Spinal Cord Series Cases 2019;5:103.
- Yoshikawa K, Mutsuzaki H, Sano A, et al. Training with hybrid assistive limb for walking function after total knee arthroplasty. J Orthopaedic Surgery Res. 2018;13.
- Giulia Barbareschi RR, Thornton M, et al. Statically vs dynamically balanced gait: analysis of a robotic exoskeleton compared with a human. Annu Int Conf IEEE Eng Med Biol Soc. 2015:6728–31.
- Ho JS, Ko KS, Law SW, Man GC. The effectiveness of robotic-assisted upper limb rehabilitation to improve upper limb function in patients with cervical spinal cord injuries: a systematic literature review. Front Neurol. 2023;14:1126755.
- 24. Niu Huiqi ZB, Liu Ligang, et al. Human muscle fatigue monitoring method and its application for exoskeleton interactive control. J Biomed Eng. 2023;40:654–62.
- Duojin Wang XG, Hongliu Yu. Sensors and algorithms for locomotion intention detection of lower limb exoskeletons. Med Eng Phys. 2023;113:103960.
- Jiting Li RZ, Zhang Y. iHandRehab: an interactive hand exoskeleton for active and passive rehabilitation. IEEE Int Conf Rehabil Robot. 2011;2011:5975387.
- 27. Alashram AR, Annino G, Padua E. Robot-assisted gait training in individuals with spinal cord injury: a systematic review for the clinical effectiveness of Lokomat. J Clin Neurosci. 2021;91:260–9.
- Gonzalo Rodriguez Tapia ID, Lejeune T, Previnaire J-G. Wearable powered exoskeletons for gait training in tetraplegia: a systematic review on feasibility, safety and potential health benefits. Acta Neurol Belg. 2022;122:1149–62.
- Minassian K, Hofstoetter US, Dzeladini F, Guertin PA, Ijspeert A. The human central pattern generator for locomotion: does it exist and contribute to walking? Neuroscientist. 2017;23:649–63.
- Anatol G Feldman MFL, Garofolini A, Piscitelli D, Zhang L. Central pattern generator and human locomotion in the context of referent control of motor actions. Clin Neurophysiol. 2021;132:2870–89.
- Gosgnach S. Synaptic connectivity amongst components of the locomotor central pattern generator. Front Neural Circuits. 2022;16:1076766.

- Fu Q, Luo T, Pan C, Wu G. Central pattern generator–based coupling control method for synchronously controlling the two-degrees-of-freedom robot. Sci Prog. 2019;103:36850419877731.
- Northcutt AJ, Schulz DJ. Molecular mechanisms of homeostatic plasticity in central pattern generator networks. Dev Neurobiol. 2019;80:58–69.
- Kathrin L Engisch XW, Rich MM. Homeostatic plasticity of the mammalian neuromuscular junction. Adv Neurobiol. 2022;28:111–30.
- Emiliano A, Lukas B, Susan A-O, Christine H, Matthias E. Construct validity of the physiotherapy evidence database (PEDro) quality scale for randomized trials: item response theory and factor analyses. Res Synth Methods. 2019;11:227–36.
- Shin JC, Kim JY, Park HK, Kim NY. Effect of robotic-assisted gait training in patients with incomplete spinal cord injury. Ann Rehabil Med. 2014;38:719–25.
- Isabel S-A, Ángel G-A, Roberto C-I-C, Antonio JD-A. Walking ability outcome measures in individuals with spinal cord injury: a systematic review. Int J Environ Res Public Health. 2021;18:9517.
- Lynskey JV. Activity-dependent plasticity in spinal cord injury. J Rehabil Res Dev. 2008;45:229–40.
- Wai G, Zdunowski S, Zhong H, et al. Emergence of functionally aberrant and subsequent reduction of neuromuscular connectivity and improved motor performance after cervical spinal cord injury in Rhesus. Front Rehabil Sci. 2023;4:1205456.
- Bertuzzi M, Chang W, Ampatzis K. Adult spinal motoneurons change their neurotransmitter phenotype to control locomotion. Proc Natl Acad Sci. 2018;115:E9926–33.
- Diane Podsiadlo B, Richardson S. The timed "up & go": a test of basic functional mobility for frail elderly persons. 1991;39:142–8.
- Dusane S, Shafer A, Ochs WL, et al. Control of center of mass motion during walking correlates with gait and balance in people with incomplete spinal cord injury. Front Neurol. 2023;14:1146094.
- Ochs WL, Woodward J, Cornwell T, Gordon KE. Meaningful measurements of maneuvers: people with incomplete spinal cord injury 'step up' to the challenges of altered stability requirements. J Neuroeng Rehabil. 2021;18:46.
- 44. Zwijgers E, van Asseldonk EHF, Vos-van der Hulst M, Geurts ACH, Keijsers NLW. Impaired foot placement strategy during walking in people with incomplete spinal cord injury. J NeuroEng Rehabil. 2022;19:134.
- Cornwell T, Woodward J, Ochs W, Gordon KE. Stabilization strategies for fast walking in challenging environments with incomplete spinal cord injury. Front Rehabil Sci. 2021;2: 709420.
- Wei Y, Jiyu Z, Sheng Z, Canjun Y. Lower limb exoskeleton gait planning based on crutch and human-machine foot combined center of pressure. Sensors (Basel). 2020;20:7216.
- Chad S, Molly T, Monica B, et al. The utilization of an overground robotic exoskeleton for gait training during inpatient rehabilitation-single-center retrospective findings. Int J Rehabil Res. 2020;43:206–13.
- Raed AA, Amanda EC, Alison MMW, Mark GC, Tania L. Overground walking with a robotic exoskeleton elicits trunk muscle activity in people with high-thoracic motor-complete spinal cord injury. J Neuroeng Rehabil. 2018;15:109.
- Hélio José C-J, Bruno R, Ivan de Oliveira G, Ricardo Yukio A, Marco Carlos U, Emanuele M. The physical capabilities underlying timed "up and go" test are time-dependent in community-dwelling older women. Exp Gerontol. 2018;104:138–46.
- Dennis RL, Janice JE, Tania L. Gait speed using powered robotic exoskeletons after spinal cord injury: a systematic review and correlational study. J Neuroeng Rehabil. 2015;12:82.
- Ditunno JF, Ditunno PL, Scivoletto G, et al. The walking index for spinal cord injury (WISCI/WISCI II): nature, metric properties, use and misuse. Spinal Cord. 2013;51:346–55.
- Smith É, Carroll Á. Bone mineral density in adults disabled through acquired neurological conditions: a review. J Clin Densitom. 2011;14:85–94.
- Suparna Rajan MJM, Catherine Warms, et al. Clinical assessment and management of obesity in individuals with spinal cord injury: a review. J Spinal Cord Med. 2008;31:361–72.
- Gorgey AS, Dudley GA. Skeletal muscle atrophy and increased intramuscular fat after incomplete spinal cord injury. Spinal Cord. 2006;45:304–9.
- 55. Karelis A, Carvalho L, Castillo M, Gagnon D, Aubertin-Leheudre M. Effect on body composition and bone mineral density of walking with a robotic

exoskeleton in adults with chronic spinal cord injury. J Rehabil Med. 2017;49:84–7.

- Zhang L, Lin F, Sun L, Chen C. Comparison of efficacy of Lokomat and wearable exoskeleton-assisted gait training in people with spinal cord injury: a systematic review and network meta-analysis. Front Neurol. 2022;13: 772660.
- Evans RW, Shackleton CL, West S, et al. Robotic locomotor training leads to cardiovascular changes in individuals with incomplete spinal cord injury over a 24-week rehabilitation period: a randomized controlled pilot study. Arch Phys Med Rehabil. 2021;102:1447–56.
- Gorman PH, Scott W, VanHiel L, Tansey KE, Sweatman WM, Geigle PR. Comparison of peak oxygen consumption response to aquatic and robotic therapy in individuals with chronic motor incomplete spinal cord injury: a randomized controlled trial. Spinal Cord. 2019;57:471–81.
- Karen JN, Kiran KK, Kathleen C, et al. Robotic exoskeleton gait training during acute stroke inpatient rehabilitation. Front Neurorobot. 2020;14: 581815.
- 60. Bryce TN, Dijkers MP, Kozlowski AJ. Framework for assessment of the usability of lower-extremity robotic exoskeletal orthoses. Am J Phys Med Rehabil. 2015;94:1000–14.
- Leung AKL, Wong AFY, Wong ECW, Hutchins SW. The physiological cost index of walking with an isocentric reciprocating gait orthosis among patients with T12–L1 spinal cord injury. Prosthet Orthot Int. 2009;33:61–8.
- Atif SK, Donna CL, Caitlin LH, et al. Retraining walking over ground in a powered exoskeleton after spinal cord injury: a prospective cohort study to examine functional gains and neuroplasticity. J Neuroeng Rehabil. 2019;16:145.
- Federica T, Matteo L, Marco T, Silvia F, Marcella M, Giorgio S. Overground robotic training effects on walking and secondary health conditions in individuals with spinal cord injury: systematic review. J Neuroeng Rehabil. 2022;19:27.
- Midik M. Effects of robot-assisted gait training on lower extremity strength, functional independence, and walking function in men with incomplete traumatic spinal cord injury. Turkish J Phys Med Rehabil. 2020;66:54–9.
- Piira A, Lannem A, Sørensen M, et al. Robot-assisted locomotor training did not improve walking function in patients with chronic incomplete spinal cord injury: a randomized clinical trial. J Rehabil Med. 2019;51:385–9.
- Yildirim MA, Öneş K, Gökşenoğlu G. Early term effects of robotic assisted gait training on ambulation and functional capacity in patients with spinal cord injury. Turkish J Med Sci. 2019;49:838–43.
- Xiang X-N, Zong H-Y, Ou Y, et al. Exoskeleton-assisted walking improves pulmonary function and walking parameters among individuals with spinal cord injury: a randomized controlled pilot study. J Neuroeng Rehabil. 2021;18:86.
- Çiğdem Çinar MAY, Öneş K, Gökşenoğlu G. Effect of robotic-assisted gait training on functional status, walking and quality of life in complete spinal cord injury. Int J Rehabil Res. 2021;44:262–8.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.